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c Stellingen behorende bij het proefschrift 
't-le ron-Glia interactions in the CNS; implication of CXCR3-signaling 
in excitotoxicity-induced neurodegeneration 
Hilmar R.J. van Wearing 
1. De rol van microglia bij - door excitotoxiciteit ge'induceerde - neuronale celdood 
is primair van een neuroprotectieve aard. Echter, het klassieke 'geactiveerde' 
microglia fenotype is niet noodzakelijk voor de bijdrage van deze cellen in de 
bescherming van neuronen in dit paradigms (dit proefschrift). 
2. Gezien de beperkingen van het gebruik van ge'isoleerde microglia als model 
voor het bestuderen van microglia functies in vitro, zou het gebruik van het 
·organotypische slice culture model", waarin de fysiologische neuron- en/of gila 
interacties bewaard blijven, de voorkeur moeten hebben (dit proefschrift). 
3. De communicatie tussen neuronen en/of gila cellen via chemokine­
signaaltransductie, waaronder CXCL 10/CXCR3 en CCL21/CXCR3, be'invloedt in 
sterke mate het overleven van neuronen onder excitotoxische omstandigheden. 
Echter, het verschil in zowel het expressiepatroon als het effect van 
bovengenoemde liganden suggereert dat deze twee vormen van communicatie 
via verschillende signaalsystemen verlopen (dit proefschrift). 
4. Het begrip "kamertemperatuur" in experimentele protocollen dient voorzichtig 
gehanteerd le worden, gezien deze gevoelsmatig vele graden lager ligt bij 
mannen dan bij vrouwen. 
5. De observatie dat CCL21 effecten induceert in CXCR3-deficiente astrocy1en 
suggereert de aanwezigheid van een additionele (nag onbekende) receptor voor 
dit ligand in het brein (dit proefschrift). 
6. Voor een "immune-privileged" orgaanstelsel bevat het CZS verdacht veel 
componenten van het afweersysteem. 
7. Het huidige beleid van het openbaar vervoer in Noord-Nederland doet de slogan 
"Er gaat niets boven Groningen• eer aan. 
8. Alhoewel af en toe "de zinnen verzetten" een promotietraject vele malen 
draaglijker maakt, kan dit in letterlijke zin desastreuze gevolgen hebben voor de 
uiteindelijke lay-out van een proefschrift. 
9. Mochten Pasen en Pinksteren ooit op een dag vallen, dan zou daze feestdag 
"Sint Juttemis" moeten heten. 
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1.1 INTRODUCTION 
The primary units of the central nervous system (CNS) are the neurons, which are highly 
specialized in the processing and transmission of electrochemical signals from the brain 
to the periphery and vice versa. Neurons are post-mitotic (non-dividing) cells and are 
highly vulnerable to changes or disturbances in their environment. Subsequently, their 
proper functioning and survival depends on the support of glia cells, the most abundant 
cell population within the CNS. Three glia cell-types have been identified: 
oligodendrocytes, astrocytes and microglia. Each of these glia cell-types has distinct 
functions, ranging from metabolic and trophic support (CNS homeostasis) to neuronal 
signal propagation, providing a stable environment for neurons to function properly under 
physiological conditions (Fig. 1.1 ). 
The CNS as an "immune-privileged" organ 
Due to its limited regenerative capacity the CNS is particularly sensitive to injury. Any 
type of inflammatory- or immune response within the CNS is a potential threat to 
neuronal survival if this response is not tightly controlled. In the early 1950s, it was 
already appreciated that the CNS responds differentially to immune-related threats when 
compared to the periphery (Barker and Billingham, 1977; Billingham and Boswell, 1953; 
Medawar, 1948). Early transplantation experiments with allogeneous (non-self) skin 
grafts directly in the brain or retina revealed that an immune response in the CNS would 
only occur when a similar graft was simultaneously transplanted into the skin (Medawar, 
1948). Normally, foreign tissue grafts are directly recognized and attacked ("rejected") by 
the peripheral immune system. Based on the unusual tolerance to foreign transplants, it 
was concluded that the CNS could only submit to, but not induce, an immune response 
(Medawar, 1948). For a long time, this immune-tolerant or "immunologically-privileged" 
state (Barker and Billingham, 1977; Billingham and Boswell, 1953) of the CNS was 
considered to be a passive state, contributed to an apparent lack of lymphatic vessels in 
the CNS and the existence of the blood-brain barrier (BBB), an anatomic barrier between 
neural tissue and the blood-stream which limits/prevents the entry of potentially harmful 
blood-derived factors (e.g. antigens, immune cells and pathogens), while still allowing 
exchange of metabolic factors essential for CNS homeostasis (Abbott, 2002; Becher et 
al., 2006; Carson et al., 2006; Galea et al., 2007). Therefore, an immune response within 
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Figure 1.1 Glia cells in the healthy CNS. Oligodendrocytes support and enhance neuronal 
transmission by forming myelin sheaths around neuronal axons, allowing fast propagation of signals 
along the neuronal fibre. Microglia continuously monitor their environment for irregularities and are 
considered as the endogenous immune cells of the CNS. Astrocytes are essential for brain 
homeostasis and neuronal function as they provide metabolic- and trophic support to neurons, 
regulate extracellular ion- and water levels, and are actively involved in neurotransmitter uptake and 
release from neuronal synaptic clefts. Moreover, astrocytes provide structural support to the BBB as 
they make close contact with the cerebro-microvasculature and regulate tight junction formation 
between vascular endothelial cells. 
the CNS was thought only to occur in case of BBB-disruption caused by severe 
inflammation. Although the concept of immune-privilege still holds true today, its 
definition has changed radically in recent years. First of all, it is now recognized that 
antigens from the CNS are drained to the cervical lymph nodes and that lymphocytes 
(peripheral immune cells) readily monitor and infiltrate the CNS, irrespective of an intact 
BBB (Cserr and Knopf, 1992; Hickey, 2001). Furthermore, the immune-privileged state of 











maintain an immune-suppressive environment (Galea et al., 2007). Moreover, being 
immune-privileged does not imply that immune responses cannot be facilitated within the 
CNS. On the contrary, several immune-regulatory defence mechanisms exist within the 
CNS parenchyma, which can initiate and regulate a direct response (innate immune 
response) against "foreign" disturbances, including neuronal injury and infiltration of 
microbial pathogens or blood-derived components (Dong and Benveniste, 2001; Farina 
et al., 2007; Hanisch, 2002; Streit, 2002). In addition, it is becoming clear that CNS­
residing cells may also be critically involved in the regulation of adaptive (antigen­
specific) immune responses by effective presentation of captured antigens and secretion 
of (anti-) inflammatory factors to infiltrating lymphocytes (Aloisi et al., 2000; Becher et al., 
2000; Tian et al., 2009). The view of glia cells being mere homeostatic, supportive cells 
has changed radically in recent years and it is now generally accepted that both 
microglia and astrocytes (and also neurons) are prominent players in the initiation and 
regulation of both innate and adaptive immune responses. 
MICROGLIA 
Microglia: sentinels and immune-effector cells of the CNS 
Microglia comprise approximately 10-20% of the total glia population and are considered 
the primary endogenous immune-effector cells of the CNS (Aloisi, 2001; Hanisch, 2002; 
Hanisch and Kettenmann, 2007; Kreutzberg, 1 996; Streit, 2002; van Rossum and 
Hanisch, 2004). Unlike other glia cell-types, microglia are derived from the 
haematopoietic (monocytic) lineage and share similarities in function and phenotype with 
peripheral monocytes, such as macrophages and dendritic cells (Cuadros and 
Navascues, 2001 ;  Sou let and Rivest, 2008). Early during development, microglia 
precursors infiltrate and populate the CNS, where they adapt a typical ramified 
morphology, characterized by a small cell body with elongated secondary- and tertiary 
processes (Cuadros and Navascues, 2001; Sou let and Rivest, 2008). 
Little is known about the function of microglia under physiological conditions, although 
recent findings indicate that ramified microglia directly monitor the functional state of 
neurons (Davalos et al., 2005; Nimmerjahn et al., 2005; Wake et al., 2009). Indeed, it 
has been shown in vivo that ramified microglia continuously scan their environment by 
dynamic extension and retraction of their dendritic processes (Davalos et al., 2005; 
Nimmerjahn et al., 2005). Moreover, recent findings suggest that ramified microglia 
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directly monitor the functional state of neuronal synapses by brief and direct, one-hour 
interval contacts (Wake et al., 2009). In response to ischemia, the frequency and 
duration of these contacts were markedly increased, often followed by breakdown of the 
presynaptic terminal (Wake et al., 2009). These results suggest that, next to their 
monitoring function, microglia actively contribute to the increased turn-over of neuronal 
synapses in response to injury. 
Microglia play a key role in the early innate immune response and are considered as the 
first line of defence against potential threats to normal CNS homeostasis (Kreutzberg, 
1996; Streit, 2002; van Rossum and Hanisch, 2004). Accordingly, microglia express a 
battery of surface receptors which can detect even the smallest changes in their 
environment. These receptors include several types of pattern recognition receptors, 
such as mannose- and Toll-like receptors (which recognize bacterial, viral and fungal 
components) and complement receptors (which recognize various pathogens and serum 
components) (Aloisi, 2001 ). Upon any type of disturbance, ranging from impaired 
neuronal activity to full-blown pathological conditions, microglia become rapidly activated 
and change their phenotype from a "surveillance" state to a "reactive" profile. This 
phenotypic shift involves drastic changes in morphology and function. Upon activation, 
microglia retract their processes and transform into amoeboid, macrophage-like cells 
with phagocytic properties. Subsequently, these activated microglia migrate to the site of 
injury where they remove pathogens and cellular debris by phagocytosis and excrete 
(anti-) inflammatory and/or neurotrophic factors, all in order to limit neuronal damage and 
to facilitate recovery (Hanisch, 2002; Kreutzberg, 1996; Streit, 2002; van Rossum and 
Hanisch, 2004). 
Furthermore, activated microglia may also participate in the regulation of adaptive 
immune responses as professional antigen-presenting cells (APCs) (Aloisi, 2001). Upon 
activation, microglia rapidly express major histocompatibility complex (MHC) class I I  
receptors and various adhesion- and co-stimulatory molecules, which are required for 
proper antigen presentation to CD4+ T-cells (Aloisi et al., 2000; Aloisi, 2001; Becher et 
al., 2000). Indeed, several in vitro studies have shown that microglia are able to take up, 
process and present antigens to T-cells, leading to T-cell proliferation and/or T-cell 
effector functions (Aloisi et al., 2000; Becher et al., 2000). Even though the antigen­
presenting capacity of microglia might be less pronounced than that of their peripheral 
counterparts due to the immune-tolerant environment of the CNS, the contribution of 
activated microglia in the re-stimulation of infiltrating T-cells in the CNS might be 
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significant (Aloisi et al., 2000; Aloisi, 2001; Becher et al., 2000; van Rossum and 
Hanisch, 2004). 
Activation of microglia: "ON"- and "OFF"-signals 
The course and outcome of microglia activation depends on the type of injury and 
signals involved. Accordingly, microglia responses are highly variable and adaptive as 
these cells are capable of integrating multifarious inputs and respond accordingly 
(Hanisch, 2002; Hanisch and Kettenmann, 2007; Schwartz et al., 2006). Two types of 
signal principles which control microglia activity can be distinguished here: so-called 
"ON" - and "OFF"-signals (Biber et al., 2007; Hanisch and Kettenmann, 2007) (Fig. 1.2). 
ON-signals trigger microglia activation and include factors which are normally not 
present in the CNS (microbial pathogens, blood-derived components, complement 
factors, protein aggregates), and endogenous factors which are presented in case of 
injury (cell debris, inflammatory mediators such as cytokines, chemokines, purines, etc.) 
(Aloisi, 2001 ; Hanisch, 2002; Hanisch and Kettenmann, 2007). Conversely, microglia 
activation in the healthy and injured CNS can be downregulated or suppressed through 
molecular interactions and/or soluble factors expressed by endogenous cells, in 
particular neurons and astrocytes (Biber et al., 2007; Galea et al., 2007). Disappearance 
of these OFF-signals, for example caused by decreased neuronal activity (= decrease in 
local neurotransmitter levels) or d isruption of molecular interactions, results in activation 
of microglia. An example is the cell-cell interaction between neuron and microglia 
through CD200 and CD200L, respectively, which keeps microglia in the na'ive brain in an 
immune-restive state (Hoek et al., 2000; Wright et al., 2000).Transgenic animals that 
lack CD200 expression display spontaneous microglia activation in the CNS and have 
worsened disease outcome and microglia activity in a model for multiple sclerosis (MS) 
as well as in other disease models (Broderick et al., 2002; Deckert et al., 2006; Hoek et 
al., 2000). 
In addition, CD200-expression has been observed in reactive astrocytes in primary MS 
lesions, suggesting also a role for astrocytes in the suppression of microglia activation 
under pathological conditions (Koning et al., 2009). Other neuron-microglia interactions, 
which have been shown to suppress microglia activation either in vivo or in vitro, are 
CX3CL 1-CX3CR1 (Cardona et al., 2006), CD47-SIRP1 a (Adams et al., 1 998) and 
CD22-CD45 (Mott et al., 2004). 
1 ,  
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Alternatively, soluble factors expressed by neurons and astrocytes can inhibit or 
downregulate microglia function, in order to prevent or to minimize potential bystander 
damage. These inhibitory mediators of microglia activation include glucocorticoids, 
prostaglandins and anti-inflammatory cytokines such as transforming growth factor-13 
(TGF-13), interleukin (IL)-4, and IL-10  (discussed in Hanisch, 2002). 
'OFF' SIGNALS � I BENEFICIAL 
• controlled phagocytosis 
• membrane interactions (CD200, • directed migration 
CD22, CD47, CX3CL1) • selective cytokine release 
• cytokines (TGFl3, IL4, IL 10) • neurotrophin release 
• neurotransmitters 
• glucocorticoids 
• neurotrophins (NGF, BDNF, NT3) 
• prostaglandins 
'ON' SIGNALS 
• disruption of membrane interactions 
• pro-inflammatory cytokines 
• various chemokines 
• TREM2-DAP12 
• glutamate 
• purines (ATP/UTP) 
• bacterial and viral components � I HARMFULL 
• cell debris/dead cells • uncontrolled phagocytosis 
• excessive cytokine release 
• nitric oxide release 
Figure 1.2 "ON" and "OFF" signals controlling microglia activity. ON-signals lead to microglia 
activation, while OFF-signals suppress or downregulate microglia activation. ON- and OFF-signals 
are defined by mode of action, not by outcome. Both signaling types can contribute to the beneficial 
or detrimental effects of microglia activation. Adapted from (Biber et al., 2007; Galea et al., 2007). 









Neuroprotective versus neurotoxic effects of microglia activity 
Taken together, microglia activation in the CNS is dictated by both ON- and OFF-signals 
(Fig. 1 .2). Both types of signals individually or simultaneously shape microglia function. 
The outcome however can have neuroprotective as well as neurotoxic effects. In 
general, microglia activation is considered as a beneficial process, aimed at the 
protection of neurons under pathological conditions (Kreutzberg, 1996; Streit, 2002). 
Indeed, upon minor insults (e.g. small blood vessel rupture), microglia direct their 
dendritic processes within minutes to the site of injury and shield it in order to prevent 
leakage and to promote repair (Davalos et al., 2005; Nimmerjahn et al., 2005). Moreover, 
the neuroprotective action of microglia has been demonstrated in animal models for 
ischemia (Imai et al., 2007; Kitamura et al., 2004; Lalancette-Hebert et al., 2007), nitric 
oxide (NO)- and AMPA-induced excitotoxicity (Turrin and Rivest, 2006; Xapelli et al., 
2008) and Alzheimer's disease (El Khoury et al., 2007). 
Conversely, excessive/chronic activation can have detrimental effects on neuronal 
survival as it might lead to uncontrolled phagocytosis and excessive release of 
inflammatory mediators, such as TNFa, NO and reactive oxygen species (Hanisch, 
2002; Hanisch and Kettenmann, 2007; van Rossum and Hanisch, 2004). Indeed, 
neurotoxic properties of activated microglia have been described in animal models for 
MS (Heppner et al., 2005; Huitinga et al., 1990), animal- and in vitro models for 
excitotoxicity (Hailer et al., 2005; Tikka and Koistinaho, 2001; Yrjanheikki et al., 1998) 
and Parkinson's disease (Mount et al., 2007), in which suppression of microglia function 
attenuated disease development and promoted neuronal survival. 
In conclusion, microglia are critically involved in the pathology of various CNS disease 
models, in which their activity might prove either beneficial or detrimental for neuronal 
survival. It is therefore of importance to understand the molecular mechanism(s) behind 
the process of microglia activation in CNS disease development as it may provide 
opportunities to intervene therapeutically in order to either reduce/prevent neuronal injury 
or to promote neuronal survival and repair. 
ASTROCYTES 
Astrocytes in the healthy CNS 
Astrocytes represent the most abundant glial cell population within the CNS and are 
essentially involved in brain homeostasis and neuronal function. In the healthy brain, 
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astrocytes have a variety of functions, including the regulation of the extracellular 
environment (extracellular ion buffering and water homeostasis), BBB-maintenance (e.g. 
tight junction formation and blood-flow regulation), metabolic support (production and 
release of glutamine after uptake of glutamate and release of glycogen and lactate) and 
release of trophic factors controlling neuronal maturation and synaptogenesis (Abbott, 
2002; Seth and Kaul, 2008; Wang and Bordey, 2008). 
An exciting feature of astrocytes that has gained a lot of attention in recent years is their 
suggested involvement in the regulation and modulation of neurotransmission (Fig 1.3A) 
(Fellin, 2009; Perea and Araque, 2005; Wang and Bordey, 2008). Astrocytes are closely 
associated with neuronal synapses and express a wide range of neurotransmitter 
receptors (including receptors for glutamate, GABA, ATP, acetylcholine etc.) (Porter and 
McCarthy, 1997). Several lines of evidence suggest a bidirectional communication 
between neurons and astrocytes as astrocytes respond to presynaptic release of several 
neurotransmitters with intracellular calcium (Ca2+) transients and subsequent Ca2+­
dependent release of gliotransmitters (such as glutamate, adenosine-5'-triphosphate 
(ATP), D-serine and TNFa) back to the neuron, thereby directly modulating neuronal 
excitability and/or synaptic transmission (Agulhon et al., 2008; Fellin, 2009; Perea and 
Araque, 2005; Perea and Araque, 2007; Volterra and Meldolesi, 2005). Moreover, 
spontaneous intracellular Ca2+-oscillations and subsequent glutamate release from 
astrocytes in the absence of neuronal activity has been observed, suggesting that 
astrocytes might also generate and modulate neuronal activity autonomously (Parri et 
al., 2001). 
In addition, astrocytic Ca2+ transients may be propagated to neighbouring astrocytes (so­
called intercellular "Ca2+ waves") through gap junctions and/or via purinergic signaling, 
allowing long-distance astrocyte-astrocyte and astrocyte-neuron communication (Fig. 
1.3B). Although this type of Ca2+-signaling between astrocytes has been shown in vitro in 
primary brain cell cultures and in organotypic slices in response to receptor stimulation or 
mechanical/electrical stimulation (Scemes and Giaume, 2006), it remains to be 
elucidated whether Ca2+ waves are evoked under physiological conditions. Considering 
the fact that the induction of astrocytic Ca2+ waves requires powerful stimuli, this type of 
signaling may relate to neuropathological conditions. Indeed, intercellular Ca2+ waves in 
astrocytes have been associated with a process known as cortical spreading depression, 
which is characterized by a slowly moving wave of tissue depolarization evoked by brain 








Astrocytes in CNS pathology 
The functions of astrocytes in neuropathology may be as versatile as those reported for 
microglia. Upon neuronal injury, local astrocytes respond rapidly with a series of 
structural and functional changes (Pekny and Nilsson, 2005; Ridet et al., 1997). This 
response is accompanied by increased expression of structural proteins such as glial 
fibrillary acidic protein (GFAP) and results in astrocyte hypertrophy and proliferation, a 
process termed "reactive astrogliosis". In general, reactive astrogliosis is a beneficial 
process aimed at the isolation of the lesion site from the rest of the CNS, and 
simultaneously facilitates the induction of BBB-repair and remodelling of neuronal circuits 
surrounding the lesion (Pekny and Nilsson, 2005; Ridet et al., 1997). Conversely, 
reactive astrogliosis may also be a harmful process. In the near vicinity of lesion sites, 
astrocyte hypertrophy and proliferation may lead to glial scar formation (anisomorphic 
gliosis), thereby impeding axonal regeneration and neurite outgrowth (Chen and 
Swanson, 2003; Fawcett and Asher, 1999). 
At the same time, reactive astrocytes are a potent source for both anti- and pro­
inflammatory factors, which are critically involved in the orchestration of both innate- and 
adaptive inflammatory responses within the CNS (Dong and Benveniste, 2001; Farina et 
al., 2007). An important factor in the initial step of local innate immune responses is the 
release of ATP by reactive astrocytes, which activates and recruits microglia to sites of 
local injury (Davalos et al., 2005; Nimmerjahn et al., 2005). Moreover, microglial 
migration has been shown to be dependent on the activation of P2Y12 receptors, while 
phagocytosis is induced through P2Y6 receptor activation, suggesting an important role 
for purinergic signaling in the initial response to neuronal injury (Koizumi et al., 2007; 
Sasaki et al., 2003). 
Other mediators expressed by reactive astrocytes include various cytokines, chemokines 
and neurotrophic factors (Dong and Benveniste, 2001; Farina et al., 2007). Release of 
neurotrophic factors may promote neuronal survival and repair after injury, while release 
of cytokines and chemokines may trigger two types of events (Farina et al., 2007): 1) 
activation of neighbouring cells (astrocytes and microglia), thereby amplifying the initial 
innate immune response and 2) modification of BBB permeability and recruitment of 
leukocytes from the periphery, thereby supporting an adaptive immune response. 
Release of cytokines and chemokines may influence both inflammatory and 
immunosuppressive processes. A balance between these pathways proves critical for 
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A neuron-astrocyte (tripartite synapse) communication 
presynapt1c terminal 
postsynapt1c terminal 
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Figure 1.3 Bidirectional communication between neurons and astrocytes (A) and astrocyte­
to-astrocyte calcium wave propagation (8). A: astrocytes are closely associated with neuronal 
synapses (termed "tripartite synapse"). Neurotransmitters released from the presynaptic terminal act 
on postsynaptic receptors and on astrocytic receptors following "spill-over" from the synaptic cleft. 
Neurotransmitter-induced calcium transients in astrocytes may trigger the release of gliotransmitters 
via vesicles and/or via calcium-dependent chloride channels back to the neurons. This may lead to 
(extrasynaptic) activation of pre- and/or postsynaptic receptors leading to changes in synaptic 
transmission. B: long-range communication through astrocytes may occur through calcium wave 
propagation. Two mechanisms have been proposed. Calcium waves may be propagated by 
diffusion of inositol triphosphate (IP3) and calcium (Ca2•) through intercellular gap junctions (1) or 
through calcium-dependent release of ATP, which subsequently induces intracellular calcium 
mobilization in neighboring astrocytes through activation of purinergic receptors (2,3). Both 
mechanisms may occur simultaneously. Adapted from references (Agulhon et al., 2008; Fellin, 









controlled immune responses in the CNS. Disturbances in this balance may have severe 
consequences and could lead to the development of chronic neuroinflammatory disease. 
In contrast to the antigen presenting capacity of microglia, the ability of astrocytes to 
function as professional APCs in the CNS has been a matter of debate and studies 
addressing the functional expression of MHC class II and co-stimulatory molecules in 
astrocytes both in vivo as in vitro are highly contradictory (discussed in Dong and 
Benveniste, 2001 ). However, expression of certain chemokines and inflammatory 
cytokines by astrocytes may influence T-cell responses within the CNS, suggesting that 
astrocytes are at least partly involved in the regulation of adaptive immune responses 
within the CNS. 
Taken together, glia cells are intimately involved in CNS homeostasis and participate in 
various processes associated with CNS development, signal transduction and immune 
surveillance. Moreover, both astrocytes and microglia have been implicated in the 
initiation and regulation of neuroinflammatory responses within the CNS (Fig. 1.4). Tight 
regulation of these immune responses are a prerequisite for neuronal survival under 
these conditions and therefore requires intimate interactions between neurons, glia cells 
and (in some cases) peripheral immune cells through cell-cell contact and expression of 
soluble factors, such as cytokines and chemokines. However, glia reactions in response 
to CNS injury are not inevitably neurosupportive as excessive or chronic activation of 
these cells may lead to neurotoxic responses. Identification of the mechanisms 
underlying supportive and detrimental glia reactions might give important insight in the 






















release of (anti-) inflammatory factors 
Figure 1.4 Simplified scheme of neuron-glia and gl ia-glia interactions in response to 
neuronal damage. Upon neuronal injury, release of neuronal factors and/or disruption of neuron­
glia interactions activate both astrocytes and microglia. Microglia respond by retraction of their 
dendritic processes and migrate to the lesion site, where they remove cellular debris by 
phagocytosis and release neurotrophic and (anti-) inflammatory factors (cytokines, chemokines, 
etc.). The net effect of microgiia activation can be beneficial or detrimental for neuronal survival, 
depending on the insult. Activation of local astrocytes may lead to reactive astrogliosis and 
concomitant expression of neurotrophic and (anti-) inflammatory factors. Expression of gliai factors 
might further activate (cytokines, purines) and/or recruit (chemokines, purines) neighboring glia 
cells, thereby amplifying the initial innate immune response. Finally, glial- and/or neuron-derived 
cytokines and chemokines may be presented on the luminal surface of cerebro-vascular endothelial 
cells in order to activate and recruit leukocytes from the periphery. 
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1.2 EXCITOTOXICITY: GLUTAMATE-INDUCED NEURODEGENERA TION 
Any type of CNS injury inevitably results in the loss of neurons. Although primary and 
secondary signaling pathways leading to neurodegeneration are difficult to discern, there 
is strong evidence that excessive glutamate-signaling in the CNS is a major cause for 
the progressive loss of neurons in many CNS pathologies. Indeed, in the early 1950s it 
was already recognized that direct exposure to high levels of the neurotransmitter 
glutamate in the CNS induced seizures in animals (Hayashi, 1952) and resulted in the 
degeneration of specific brain regions when injected systemically (Lucas and Newhouse, 
1957; Olney and Sharpe, 1969). In the following years, these studies were extended by 
showing that excessive extracellular levels of glutamate were directly and specifically 
toxic to neurons, an effect that could be mimicked by application of glutamate receptor 
agonists or counteracted by concomitant application of specific glutamate receptor 
antagonists, which led to the concept of "excitotoxicity'', or neurotransmitter-induced 
neurotoxicity (Choi, 1988; Olney, 1994). Nowadays, it is generally appreciated that 
excitotoxicity is the primary mechanism leading to neuronal cell death in many acute 
CNS pathologies including traumatic injury, ischemia and epilepsy (Arundine and 
Tymianski, 2004; Choi and Rothman, 1990; Vincent and Mulle, 2009). There is also 
mounting evidence that the process of excitotoxicity-induced neurodegeneration plays a 
role in more chronic neurological disorders such as Huntington's disease (Fan and 
Raymond, 2007), MS (Gonsette, 2008), Alzheimer's disease (Walton and Dodd, 2007), 
Parkinson's disease (Koutsilieri and Riederer, 2007) and amyotrophic lateral sclerosis 
(ALS) (Van Damme et al., 2005). Although in the last decades research on excitotoxicity 
has primarily focused on the intracellular pathways leading to acute glutamate-induced 
neuronal cell death, there is now strong evidence that the activation of glia cells may be 
a critical factor in the propagation and amplification of this neurodegenerative process. 
Glutamate and its receptors in the CNS 
Glutamate is the primary excitatory neurotransmitter for neurons in the CNS. Upon 
release, glutamate induces excitatory responses in postsynaptic neurons via 
pharmacologically and functionally distinct members of the ionotropic- and metabotropic 
glutamate receptor families (Fig. 1.5). lonotropic receptors are ligand-gated ion channels 
and subsequent activation results in the opening of their channel pores leading to 
permeability for sodium (Na\ potassium (K+) or Ca2+-ions. Three types of ionotropic 
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Figure 1.5 lonotropic- and metabotropic glutamate receptors. Members of the ionotropic 
glutamate receptor class (A) are divided into the NMDA, kainate (KA) and AMPA receptors, which 
are ligand-gated ion channels. AMPNKA-receptors have fast kinetics and are highly permeable to 
extracellular Na·. Activation of AMPA receptors can be potentiated by Zn2•. NMDA receptors are 
slow gating channels that are highly permeable to extracellular ca2• and to a lesser extent Na•. 
NMDA receptors are unique in that they require binding of both glutamate (Glu) and glycine (Gly) for 
efficient channel opening as well as membrane depolarization. Membrane depolarization (facilitated 
by Na• influx through AMPNKA receptors) releases the Mg2• block of the NMDA receptor, allowing 
glutamate to bind. NMDA receptor activation can be blocked by zn2• or by drugs that bind to the 
phencyclidine (PCP) site within the open channel. Metabotropic glutamate receptors (8) are seven 
trans-membrane spanning receptors that couple to heterotrimeric GTP-binding proteins (G-proteins) 
to induce their action. Activation of the G-protein results in GDP/GTP-mediated dissociation of the 
complex into an a- and a J3y-subunit, each initiating distinct signaling pathways within the cell. Both 
ionotropic- and metabotropic receptors can be subdivided into distinct subtypes based on their 
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receptors have been described, named after their respective affinity for specific agonists: 
N-methyl-D-aspartate (NMDA), a-amino-3-hydroxy-5-methyl-4-isoxazole propionate 
(AMPA) and kainate (KA) receptors (Fig 1.5A). Each of these ionotropic receptor types 
can be further divided into differently composed tetramers of glutamate receptor channel 
subunits which form together the channel-pore (Fig. 1.5C). AMPA and KA receptors 
have fast kinetics and are permeable for Na+ and K\ but are normally impermeable to 
Ca2+ (Hollmann et al., 1991). However, Ca2+-permeable AMPA receptors that specifically 
lack the GLUR2 subunit have also been described and their expression has been 
associated with certain CNS disorders (Liu and Zukin, 2007). In contrast, NMDA 
receptors are slow gating and opening of the channel pore relies on a voltage-dependent 
removal of magnesium (Mg2+) (Fig 1.5A). Upon activation, NMDA receptors are highly 
permeable to Ca2+ and K+, and to a lesser extent Na+ (Harding ham and Bading, 2003). 
Metabotropic glutamate receptors consist of eight distinct subtypes (mGLUR1-8) and 
mediate their actions through G-protein dependent signaling leading to Ca2+ mobilization 
from intracellular stores and activation of other downstream signaling pathways (Fig. 
1.58). 
Under physiological conditions, glutamate-induced activation of postsynaptic glutamate 
receptors is tightly regulated both spatially and temporally. Upon release in the synaptic 
cleft, extracellular glutamate is rapidly sequestered through plasma membrane 
transporters on the presynaptic terminal and stored within intracellular compartments. In 
addition, astrocytes actively take up extracellular glutamate via the membrane­
associated glutamate transporters GLAST and GL T1 (EAA T1 and EAA T2 in humans, 
respectively). Once taken up, glutamate is converted into glutamine and is shuttled back 
to presynaptic terminals where it is used again for glutamate synthesis. In this way, 
astrocytes are responsible for over 80% of the glutamate uptake in the brain (Yi and 
Hazell, 2006). 
Excessive accumulation of extracellular glutamate causes neurotoxicity 
As mentioned before, glutamate has potent neurotoxic activity when extracellular 
glutamate levels exceed the physiological threshold in the CNS. Excessive accumulation 
of extracellular glutamate can have several causes, but is most prominent in case of 
acute CNS injury, in particular traumatic injury and ischemia (Arundine and Tymianski, 
2004). Here, sudden deprivation of local energy supplies (oxygen and glucose) causes a 
rapid loss of intracellular ATP and subsequent depolarization of neurons, resulting in 
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reduced glutamate re-uptake and excessive synaptic release of glutamate (Nicholls and 
Attwell, 1990). Moreover, the sudden loss of energy supplies may lead to depolarization 
of local astrocytes in the centre of the lesion resulting in "glutamate transporter reversal", 
which is characterized by functional impairment of ATP-dependent astrocytic glutamate 
transporters, ultimately leading to reduced glutamate uptake and concomitant increase in 
glutamate release (Yi and Hazell, 2006). 
Signaling pathways involved in excitotoxicity 
The neurotoxic effect of chronically elevated glutamate levels arises from the strong 
activation of (in particular) postsynaptic ionotropic glutamate receptors (AMPA-, KA- and 
NMDA-R), leading to a sudden increase in influx of Na+ and ca2• ions (Aarts and 
Tymianski, 2004; Choi, 1987). This drastic increase of intracellular Na+ and Ca2+ initiates 
two distinct processes, which differ in time- and receptor-dependency. The first 
component is an acute swelling of neuronal cell bodies that depends on the persistent 
activation of AMPA/KA receptors, and to a lesser extent NMDA-receptors. Prolonged 
opening of these ion channels leads to continuous Na+ influx and consequent 
depolarization of the neuronal membrane, leading to passive influx of chloride (Cr) and 
water (Choi, 1987; Olney et al., 1986; Rothman, 1985). This neuronal swelling occurs 
within minutes after glutamate exposure and can be blocked in vitro by removal of 
extracellular Na• and er (Olney et al., 1986; Rothman, 1985). 
The second component is a delayed neurodegeneration, predominantly triggered by a 
drastic increase in intracellular Ca2+ (Fig. 1.6). This excessive increase in cytosolic free 
Ca2• is predominantly caused by direct influx of Ca2+ through activation of NMDA 
receptors (after removal of their Mg2• block as a result of membrane depolarization), but 
also through secondary opening of voltage-gated Ca2+ channels and reverse operation 
of Na·1ca2• exchangers (NCX) on the membrane (Arundine and Tymianski, 2003; Choi, 
1994). It is now believed that this excessive influx of Ca2·, together with any ca2• release 
triggered from intracellular stores, exceeds the capacity of Ca2·-sequestering 
mechanisms, leading to over-activation of ATP-ases and potentially harmful proteins that 
either directly damage the cell or induce formation of free oxygen radicals that induce 
neuronal apoptosis (Fig. 1.6) (Arundine and Tymianski, 2003; Choi, 1994). Proteins 
activated downstream of Ca2• that are potentially harmful for the cell when over-activated 
include endonucleases (DNA degradation), phospolipases (breakdown of the cell 
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formation), proteases such as calpain (cytoskeletal breakdown), and protein kinases 
(alterations in membrane associated Ca2+ channels leading to enhanced Ca2+ influx) 
(Arundine and Tymianski, 2003; Choi, 1994). Finally, cell lysis may result in release of 
intracellular stored glutamate thus creating a vicious circle. 
Several lines of evidence suggest that the persistent activation of NMDA receptors and 
subsequent intracellular Ca2+ overload is the crucial step in glutamate-induced neuronal 
cell death. In line with this, it has been demonstrated in vitro that neuronal cell death 
induced by excessive glutamate stimulation or oxygen/glucose deprivation is effectively 
prevented by application of selective NMDA receptor inhibitors, while selective inhibition 
of AMPA/KA receptors has only minor effects (Choi et al., 1 988; Koh and Choi, 1991). 
Moreover, treatment with selective NMDA receptor antagonists has proven beneficial for 
neuronal survival in animal models for ischemia and hypoglycemia (Simon et al., 1984; 
Wieloch, 1985), emphasizing the role of NMDA receptors in excitotoxic-related 
pathologies. In spite of the beneficial effects of NMDA receptor antagonists in cellular 
and animal models, these drugs are unfortunately of limited clinical use for several 
reasons. One reason is the very limited time frame for therapeutic intervention as 
activation of NMDA receptors may occur to early for effective treatment. Secondly, 
human clinical trials with various antagonists that have been performed so far were 
unsuccessful due to significant side effects of the treatments, including psychosis, 
memory impairment, respiratory problems and even neuronal cell death (Lee et al., 
1999; Waxman and Lynch, 2005). 
Although the initial process of excitotoxicity-induced neuronal damage at the primary 
lesion site might prove to be difficult if not impossible to counteract, there is a reasonable 
time window for potential therapeutic intervention in the first twenty four hours after the 
primary insult for the following reason. In many acute CNS injuries, and in particular in 
traumatic brain injury and ischemia, primary neuronal degeneration at the lesion site is 
often followed by an anterograde/retrograde degeneration of neurons in secondary 
regions (Horn and Schlote, 1992; Kirino and Sano, 1984). The fact that this type of 
secondary neuronal damage is relatively resistant to delayed treatment with (non)­
selective NMDA antagonists, as demonstrated in an animal model for traumatic brain 
injury (Bernert and Turski, 1 996), suggests that the amplification or propagation of 
secondary neuronal damage depends on secondary signaling mechanisms other than 
NMDA. 
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It is therefore of interest to identify these secondary signaling systems in order to 
develop therapeutic agents with no or tolerable side effects that have protective potential 
when administered several hours after the primary insult. 
Selective neuronal vulnerabil ity in excitotoxicity: involvement of g lia cells? 
As mentioned above, an additional feature of excitotoxic-related injuries in the CNS, 
such as ischemia and hypoglycemia, involves the temporal profile of delayed neuronal 
damage in selective CNS regions such as the hippocampus, neocortex, striatum and 
thalamus (Horn and Schlote, 1992; Kirino and Sano, 1984; Rosenblum, 1997). 
Interestingly, similar patterns of neuronal damage are observed in vivo after intracerebral 
injection with glutamate agonists (Acarin et al., 1996; Schauwecker, 2002; Won et al., 
1999). Moreover, within these brain regions a selective order of vulnerability between 
distinct neuronal subpopulations has been observed, in particular in the neocortex and 
hippocampus. In the hippocampus, pyramidal neurons of the cornu ammonis (CA) CA1 
region are most vulnerable to an ischemic insult followed by neurons from the CA3 
region, whereas neurons in the dentate gyrus (DG) region are largely resistant (Schmidt­
Kastner and Freund, 1991). In the neocortex, prolonged ischemia results in the spread of 
neuronal loss specifically in the cortical layers Ill, V and VI (Pulsinelli et al. , 1982). These 
profiles of selective neuronal vulnerability can be reproduced in vitro in organotypic 
hippocampal and neocortical slice cultures in response to oxygen/glucose deprivation or 
glutamate (agonist)-induced excitotoxicity (Bernaudin et al., 1998; Kristensen et al. ,  
2001; Tasker e t  al., 1992; Vornov e t  al., 1991). Differences in selective vulnerability may 
occur depending on the type of glutamate agonist used (Kristensen et al., 2001 ; Vornov 
et al., 1991). However, reasons for the selective vulnerability of neurons in these regions 
are not well understood. In line with this, it has been proposed that heterogeneity in 
NMDA receptor combination and receptor density may correlate with differences in 
patterns of excitotoxicity (Coultrap et al., 2005; Lynch and Guttmann, 2002; Martens et 
al., 1998). As the NMDA receptor density is most abundant in the hippocampal CA1 
region, this might explain the relative vulnerability of these neurons towards an 
excitotoxic insult. However, this suggestion was placed into question as neurons in the 
DG region, which are largely resistant to excitotoxicity, are also rich in NMDA receptor 
expression. It is therefore likely that additional signaling mechanisms contribute to the 
selective death of specific neuronal subpopulations. Although differences in endogenous 
neuronal properties are not excluded, recent evidence suggests that non-neuronal cells, 
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in particular glia cells, are critically involved in the process of secondary neuronal 
degeneration. 
Like any other type of CNS injury, excitotoxicity-induced neurodegeneration coincides 
with local reactive astrogliosis and rapid activation and recruitment of microglia, as 
demonstrated in vivo (Acarin et al., 1996; Jorgensen et al., 1 993; Marty et al., 1991) and 
in vitro in organotypic slice cultures (Bernaudin et al., 1998). As discussed before, 
activation of microglia significantly contributes to the development and progress of CNS 
injury. Microglia activation can be either beneficial or detrimental for neuronal survival, 
depending on the type of signals and injury involved (Hanisch and Kettenmann, 2007; 
van Rossum and Hanisch, 2004). Previous research concerning the role of microglia in 
excitotoxicity-related pathologies has suggested that microglia activation in this type of 
injury might be detrimental for neuronal survival (Dehghani et al., 2003; Dehghani et al., 
2004; Hailer et al., 2005; Tikka et al., 2001; Tikka and Koistinaho, 2001; Yrjanheikki et 
al., 1998). Upon excitotoxic injury, activated microglia release pro-inflammatory factors 
such as TNFa, I L-1, NO, inducible nitric oxide synthase (iNOS) and cycloxygenase-2 
(COX2) that are all damaging to neurons when expressed at large quantities (Aloisi, 
2001; Barone and Feuerstein, 1999; Campuzano et al., 2008). 
Figure 1.6 (right) Signaling pathways leading to neuronal cell death in excitotoxicity: 
involvement of calcium (Ca2•). Increased energy metabolism (ATP 1) as a result of loss of oxygen 
supply or loss of ion-homeostasis may lead to dysregulation of the presynaptic vesicle release 
machinery resulting in excessive release (and reduced uptake) of glutamate from presynaptic 
terminals (1) .  This build-up of toxic extracellular glutamate levels may be enhanced by neighbouring 
astrocytes as ATP-deprivation leads to impaired function/downregulation of membrane-associated 
glutamate transporters GLAST and GL T-1 (2), resulting in a decrease in glutamate uptake and an 
increase in glutamate release (glutamate transporter 'reversal'). High levels of extracellular 
glutamate in the synaptic cleft persistently activate AMPA- and KA receptors (3) located at the 
postsynaps, leading to membrane depolarization through strong influx of Na• (4). AMPNKA 
receptor-mediated membrane depolarization opens voltage-sensitive calcium channels (VSCC, 5) 
and removes the Mg2• block from NM DA-receptors (6) , allowing glutamate-induced activation of the 
NMDA-receptor resulting in excessive influx of calcium. Additionally, calcium release from 
intracellular stores through activation of metabotropic glutamate receptors (mGLURs) might 
contribute to the excessive increase in intracellular calcium (7). Excessive increases of intracellular 
calcium may over-activate potentially harmful proteins such as endonucleases (DNA degradation), 
proteases (cytoskeletal/NCX breakdown), phospholipases and calmodulin (free radical formation), 
protein kinases and others (8). Additionally, excessive calcium leads to mitochondrial calcium 
overload (9), resulting in impaired ATP production and release of cytochrome c, which is involved in 
the activation of caspase-mediated pathways leading to programmed cell death (apoptosis). NCX: 
Na·1ca2• exchanger. Adapted from references (Anderson and Swanson, 2000: Arundine and 
Tymianski, 2003; Baskys and Blaabjerg. 2005; Choi, 1988; Choi, 1994; Estrada Sanchez et al . ,  
2008; Sheldon and Robinson, 2007; Yi and Hazell, 2006). 
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In line with these findings, it was demonstrated that treatment with an anti-inflammatory 
compound (minocycline) reduced infarct size following focal ischemia, a process which 
coincided with reduced proliferation and production of inflammatory mediators in 
microglia (Yrjanheikki et al., 1998; Yrjanheikki et al., 1999). Moreover, treatment with 
minocycline inhibited activation and proliferation of microglia in vitro and protected mixed 
(neurons + glia) spinal cord cultures against NMDA-induced neurotoxicity (Tikka et al., 
2001; Tikka and Koistinaho, 2001 ). However, treatment with minocycline has also been 
shown to directly protect primary neuronal cultures from glutamate-toxicity, suggesting 
that the therapeutic range of this drug exceeds that of microglia inhibition alone 
(Yrjanheikki et al., 1999). Potential neurotoxic effects of microglia activation have also 
been described in organotypic hippocampal slice cultures exposed to NMDA, while 
treatment with various drugs that (in)directly inhibit microglia function attenuated 
neuronal cell death in this paradigm (Dehghani et al., 2003; Dehghani et al., 2004; Hailer 
et al., 2005; Hailer, 2008). 
Conversely, there are several lines of evidence indicating that microglia activation 
correlates with the reduction of neuronal damage under excitotoxic conditions (Imai et 
al., 2007; Kitamura et al., 2004; Lalancette-Hebert et al., 2007; Simard and Rivest, 2007; 
Xapelli et al., 2008). In an animal model for ischemia, selective ablation of proliferating 
microglia using a transgenic approach resulted in a significant increase in infarct size, 
which coincided with a significant increase in apoptotic neurons (Lalancette-Hebert et al., 
2007). Similarly, depletion of microglia from organotypic hippocampal slice cultures prior 
to NMDA exposure resulted in increased neuronal damage in the DG region when 
compared to control conditions (Kohl et al., 2003). The neuroprotective properties of 
microglia in ischemia in vivo have also been demonstrated in rats and Mongolian gerbils 
using a different approach (Imai et al., 2007; Kitamura et al., 2004). Ventricular injection 
of exogenous microglia in rats and subsequent migration of these cells to ischemic 
lesions in the cerebral cortex and striatum resulted in significant neuroprotection in these 
areas when compared to control animals (Kitamura et al., 2004). Using a similar 
approach, arterial injection of microglia in Mongolian gerbils resulted in migration of 
these cells to ischemic lesions in the hippocampus and an increase in local expression of 
neurotrophic factors was observed, which coincided with an increase in surviving 
neurons in this region when compared to control conditions (Imai et al. , 2007). 
Taken together, the role of microglia in excitotoxic-related injuries remains elusive. 
However, results obtained so far suggest that microglia activation per se is beneficial in 
(J 
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excitotoxicity as full ablation of these cells results in increased neuronal loss. 
Conversely, the fact that immunosuppressive agents reduce excitotoxicity-induced 
neurodegeneration by (in)direct inhibition of microglia function suggests that microglia 
acquire an inflammatory profile that is detrimental for neuronal survival under these 
conditions. Identification of the signals leading to this apparent inflammatory microglia 
profile under excitotoxic conditions might prove beneficial for the development of 
therapeutic strategies aimed to suppress or redirect microglia function in order to reduce 
neuronal loss and promote neuronal regeneration. 
1 .3 CHEMOKINES: VERSATILE MESSENGERS IN THE CNS 
Chemokines are small chemotactic cytokines of approximately 8-12 kDa and are pre­
dominantly known for their ability to facilitate peripheral immune cell trafficking 
(Baggiolini, 1998; Moser and Loetscher, 2001; Rot and von Andrian, 2004). Numerous 
studies have demonstrated that chemokines and their receptors are also expressed 
within the CNS, where they play a crucial role in a variety of functions both under 
physiological and pathological conditions. Not only are chemokines involved in CNS 
development and homeostasis, neuronal transmission and nociception, but they also 
seem to function as key regulators in the communication between neurons and glia cells 
in response to CNS injury and disease-associated neuroinflammation (Bertollini et al., 
2006; Charo and Ransohoff, 2006; Limatola et al., 2000; Ma et al., 1998; Oh et al., 2001; 
Rostene et al., 2007; Ubogu et al., 2006). Understanding the mechanism of chemokine 
regulation in the injured CNS may provide essential insight in the initiation and/or 
development of several neuropathologies. 
Chemokine nomenclature and classification 
The first molecule with chemotactic properties (IL-8 or CXCL8) was identified in 1987 
(Yoshimura et al., 1987) and since then the chemokine family has expanded rapidly 
(Rossi and Zlotnik, 2000). The family now consists of nearly 50 chemokines (Laing and 
Secombes, 2004) and almost 20 chemokine receptors (Murphy, 2002), but more are 
likely to be discovered (Fig. 1.7). 
The family of chemokines has been classified into four subfamilies (CC, CXC, CX3C and 
C), based on the number and spacing of their highly conserved cysteine residues in the 
amino (NH2)-terminus. The two major chemokine subfamilies are the CXC- (or a) and 
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CC- (or 13) chemokines, where the two cysteines are either separated by one amino acid 
or are adjacent to each other, respectively (Fernandez and Lolis, 2002; Rossi and 
Zlotnik, 2000). The CXC-chemokines are further divided into two subclasses based on a 
distinct Glu-Leu-Arg (ELR)-motif that is located between the N-terminus and the first 
cysteine (Rollins, 1 997). The two smaller chemokine subfamilies are the C- (or y) 
chemokines, which contain only one cysteine in the N-terminal region, and the CX3C- (or 
l>) subfamily, which has only one member, namely CX3CL 1, in which the first two 
cysteines are separated by three other amino acid residues (CX3C or l> chemokines) 
(Rossi and Zlotnik, 2000). 
Chemokine receptors and chemokine promiscuity 
Chemokines exert their effects through surface receptors that belong to the superfamily 
of seven-transmembrane spanning G-protein coupled receptors (GPCRs). The 
nomenclature of the chemokine receptors follows that of the chemokine subfamily they 
preferentially bind to, namely CCR, CXCR, XCR and CX3CR (Murphy, 2002). 
Accordingly, CC-chemokines bind to CC-receptors, etcetera. However, certain 
promiscuity exists between chemokines and their receptors as multiple receptors can 
recognize more than one ligand and, vice versa, various ligands can bind to more than 
one receptor (Bajetto et al., 2002). A few specific chemokine-chemokine receptor pairs 
like CCR6-CCL20, CCR9-CCL25, CXCR4-CXCL 12, CXCR5-CXCL 13, CXCR6-CXCL 16 
and CX3CR1-CX3CL 1 appear to be monogamous (Bajetto et al., 2002). Although most 
chemokines recognize more than one receptor it seems to be a general rule that CC­
receptors only bind CC-chemokines, whereas CXC-chemokines are recognized by CXC­
receptors. Accordingly, there is no cross reactivity between members of the four 
chemokine subclasses (Murphy et al., 2000). One exception to this rule is chemokine 
CCL21, which not only binds CCR?, but also has been shown to bind a member of the 
CXCR-family, namely CXCR3 (see below) (Biber et al., 2001: Dijkstra et al., 2004; 
Rappert et al., 2002; Soto et al. ,  1 998). 
Chemokine receptor signaling 
GPCRs mediate their action through activation of scaffolding proteins (e.g. 13-arrestin 1 
and 2) and through activation of various membrane-associated heterotrimeric G-proteins 
(G.,0, Gs, Gq and others), which consist of a Ga- and Gpy-subunit complex (Defea, 2008; 
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Figure 1.7 Classification of chemokine receptors and their agonists, based on the structural 
characteristics of their relative chemokine ligands {images). C: cysteine, X: an amino acid other 
than cysteine. Current list is adapted from the NC-IUPHAR (International Union of Pharmacology 
Committee on Receptor Nomenclature and Drug Classification), www.iuphar-db.org/index.jsp, 
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Neves et al., 2002). Activation of G-proteins results in GDP/GTP-mediated dissociation 
of the heterotrimeric complex into the Gpy- and Ga-subunit, each initiating distinct 
signaling cascades within the cell (Mellado et al., 2001). In general, chemokine receptors 
are associated with G,-proteins as the majority of chemokine-induced responses are 
inhibited by pertussis toxin (PTX), which prevents the dissociation of these heterotrimeric 
protein complexes (Murphy, 1996). Intracellular signaling pathways induced through 
activation of G;-proteins involve G0;-mediated downregulation of cyclic adenosine 
monophosphate (cAMP) and Gpy-mediated mobilization of Ca2+ from intracellular stores 
through activation of phospholipase C (PLC) (Thelen, 2001). Ca2+ is vital for the cell as it 
functions as a second messenger in a plethora of signaling cascades. Moreover, 
induction of intracellular Ca2+ transients is one of the most characteristic effects in 
response to chemokine stimulation and has been widely used to test chemokine receptor 
functionality in response to various ligands (Bajetto et al., 1999; Gillard et al., 2002; 
Thelen, 2001). Other main signaling pathways induced by chemokine receptor activation 
(Fig 1.8) include the mitogen-activated protein kinase (MAPK)-cascade and activation of 
phosphatidylinositol-3-kinases (Pl3Ks) (Balkwill, 1998; Bondeva et al., 1998; Mellado et 
al., 2001 ;  Murdoch and Finn, 2000; Thelen, 2001). Chemokine-induced activation of 
Pl3Ks leads to accumulation of phosphatidyl (3,4,5)-triphosphate (PIP3), which in its turn 
activates protein kinase B (Akt/PKB) and small GTPases such as Rae, Rho and Cdc42, 
which are required for cell polarization and cytoskeletal re-organization necessary for 
cellular migration (Fig 1.8) (Bondeva et al., 1998; Hu et al. ,  2008; Muessel et al., 2008; 
Thelen, 2001 ). Furthermore, chemokine stimulation may lead to cell proliferation and 
differentiation through activation of MAPKs (Fig. 1.8), specifically through activation of 
extracellular signal- regulated kinase 1 /2 (ERK1/2) and protein tyrosine kinase 2 (PY2K) 
(Bajetto et al., 2001a; Del et al., 2001 ;  Tilton et al., 2000). Taken together, these findings 
show that chemokine receptor activation results in the induction of various (parallel) 
signaling pathways and, depending on the ligand, may result in the induction of various 
processes, including cell proliferation, differentiation, directed migration and/or cell 
adhesion (Fig 1 .8). 
Moreover, the effective outcome of chemokine receptor signaling might be influenced by 
secondary signaling events. For example, it has been shown that certain chemokine 
receptors may form homo- or heterodimers, which has been described for the chemokine 
receptors CCR2, CCR5, CXCR2 and CXCR4 (Babcock et al . ,  2003; Rodriguez-Frade et 
al., 1999; Rodriguez-Frade et al., 2001; Trettel et al., 2003; Vila-Coro et al., 1999). 
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Interestingly, heterodimer formation of CCR2-CCR5 may lead to changes in signaling 
properties. Whereas ligand binding to either of the receptors alone would result in 
directed migration mediated by G0;-proteins, heterodimerization introduces a PTX­
insensitive rise in intracellular Ca2+ concentration and instead of inducing directed 
migration, it induces cell adhesion (Mellado et al., 2001). 
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Figure 1.8. Simplified scheme of main signaling pathways and downstream effects as a 
result of chemokine receptor activation. AC, adenylyl cyclase; Akt/PKB, protein kinase B; a/l3y, 
heterotrimeric G-protein complex; Ca2+, calcium; Cdc42, cell division cycle 41; ERK1/2, 
extracellular signal-regulated kinase; GDP, guanine diphosphate; GTP, guanine triphosphate; 
Pl3K, phosphoinositide 3-kinase; PLC, phospholipase C; PY2K, protein tyrosine kinase 2; Rac1, 
Ras-related C3 botulinum toxin substrate 1; RhoA, Ras-homolog gene family member A; SRC, 








Furthermore, it has been described that homo- and heterodimerization may augment the 
sensitivity of target cells as it was shown that cells expressing CCR5 and CCR2 display 
a lower threshold for chemokine-induced Ca2+ signaling (Mellado et al . .  2001 ) .  In 
conclusion, homo- and heterodimerization between chemokine receptors may further 
increase the complexity of chemokine signaling as this leads to changes in downstream 
effects. 
Chemokines in the periphery 
In the last two decades, research has focused primarily on the role of chemokines in 
peripheral immune surveillance as these molecules have proven to be crucial in the 
facilitation of immune cell trafficking and the recirculation of leukocyte populations 
between lymphoid organs and target tissues both under physiological as pathological 
conditions (Cyster, 2005; Kunkel and Butcher, 2002; van Andrian and Mempel, 2003). 
However, in recent years it has become evident that chemokines are more than mere 
facilitators of cellular migration. Nowadays, chemokines have not only been implicated in 
early development and formation of secondary lymphoid organs, but also in wound 
healing, angiogenesis and angiostasis ,  regulation of adhesion molecule expression, 
development of T cell helper 1 and 2 (Th1 /Th2) profiles, tumour growth and metastasis 
(Benelli et al. , 2006; Charo and Ransohoff, 2006; Kunkel, 1 999; Mackay, 2001 ; Murray et 
al. , 2006; Pease and Williams, 2006; Rittner and Brack, 2006; Rossi and Zlotnik, 2000; 
Zlotnik, 2006). Thus,  from being molecules thought to solely orchestrate migration of 
immune cells, chemokines are now considered as versatile messengers with the ability 
to control the interaction between a wide diversity of cell types .  
Expression o f  chemokines and their receptors i n  the CNS 
Expression of chemokines in CNS-resident cells was described for the first time in the 
early 1 990s (Aloisi et al. , 1 992; Ransohoff et al., 1 993). In the same period, chemokine 
expression in the CNS was found to be enhanced in an animal model for MS, showing 
for the first time a disease-associated increase in chemokine expression by distinct 
subsets of CNS-residing cells (Hulkower et al . ,  1 993; Ransohoff et al. , 1 993). Since then, 
many in vitro and in vivo studies on functional expression of chemokines and their 
receptors in the CNS have been published and its findings have been reviewed 
extensively (Ambrosini and Aloisi, 2004; Bajetto et al . ,  200 1 b; Bajetto et al. , 2002; Biber 
et al., 2006; Cartier et al. , 2005). 
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Taken these findings together, it is now appreciated that all CNS-residing cell types 
(including microglia, astrocytes, oligodendrocytes, neurons and endothelial cells) 
functionally express chemokine receptors, making them potential targets for the action of 
chemokines (Ambrosini and Aloisi, 2004; Bajetto et al., 2002; Biber et al., 2006; Cartier 
et al., 2005). 
In the healthy human CNS, constitutive expression of chemokine receptors CCR2, 
CCR5, CXCR2, CXCR3, CXCR4 and CXaCR1 has been observed, indicating a function 
for these receptors in normal CNS homeostasis (Biber et al., 2006; Cartier et al., 2005; 
Rostene et al., 2007; Tran and Miller, 2003). Moreover, expression of these receptors is 
enhanced under various pathological conditions in the human CNS, including stroke 
(Trebst et al., 2003a) and neurodegenerative diseases like HIV-associated dementia 
(Lavi et al., 1997; McManus et al. ,  2000; Petito et al., 2001; Sanders et al., 1998; Tong et 
al., 2000; Vallat et al., 1998; van der Meer et al., 2000), Alzheimer's disease (Xia et al., 
1997; Xia et al., 1998), and multiple sclerosis (MS) (Balashov et al., 1999; Hulshof et al., 
2003; Simpson et al., 2000a; Simpson et al., 2000b; Sorensen et al. ,  1999; Trebst et al., 
2001). These findings are corroborated by in vitro studies, which show that chemokine 
receptor expression in human CNS cell types can be enhanced by stimulation with 
inflammatory mediators IFNy, IL-113 and TNFa (Aloisi et al., 1992; Flynn et al., 2003; 
Guillemin et al., 2003). 
Similar to chemokine receptors, expression of chemokines in the CNS can be roughly 
divided into two categories: 1) "constitutive" chemokines which are either 
developmentally regulated or constitutively expressed in the healthy CNS and 2) 
"inducible" chemokines which are only expressed in case of CNS injury or in response to 
inflammatory stimuli. Overlap may exist as some constitutive chemokines are shown to 
be expressed at higher levels in response to pathological conditions. Constitutive 
chemokines, although few in number, have been implicated in CNS development and 
homeostasis (Rostene et al., 2007; Tran and Miller, 2003), while inflammatory 
chemokines seem to play a critical role in the communication between neurons, glia cells 
and infiltrating leukocytes under various pathological conditions (see below) (Ambrosini 
and Aloisi, 2004; Biber et al., 2006; De Haas et al., 2007). 
Astrocytes and microglia are the main chemokine-producing cells under pathological 
conditions (Ambrosini and Aloisi, 2004). Depending on the stimulus or pathological 
conditions, both types of glia cells have been demonstrated to express chemokines 
CCL2, CCL3, CCL4, CCL5, CXCL8 and CXCL 10, while in vivo expression of CXCL9, 
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CXCL 12 and CX3CL 1 has been observed in astrocytes only (for review see (Biber et al., 
2006)). However, expression of "inducible" chemokines is not restricted to glia cells as 
neurons have also been reported to express chemokines under certain 
neurodegenerative conditions in the human CNS, such as CXCL 10, CXCL 12 and 
CX3CL 1 in HAD/HIV-encephalitis (Rostasy et al., 2003; Sui et al., 2004; Tong et al., 
2000), CCL2 in amyotrophic lateral sclerosis (ALS) (Baron et al., 2005) and CX3CL 1 in 
MS (Hulshof et al., 2003). 
Chemokines in CNS development and homeostasis 
Although constitutive expression of chemokine receptors can be found throughout the 
human CNS, there is little evidence for constitutive expression of chemokines in the 
healthy brain. So far, only a few chemokines have been reported in the healthy human 
CNS such as CCL2 (Meng et al., 1999), CCL4 (Sanders et al., 1998; Xia et al., 1998), 
CXCL 12 (Rostasy et al., 2003) and CX3CL 1 (Hulshof et al., 2003). In vivo experiments 
with rodents and in vitro experiments with rodent- and human primary cells suggest a 
role for these chemokines in CNS development. Especially CXCL 12 and its receptor 
CXCR4 seem to be important regulators of CNS development as they are expressed at 
high levels at the early stages of the developing CNS (McGrath et al., 1999; Rostasy et 
al., 2003; Tham et al., 2001). Indeed, it has been shown that CXCL12/CXCR4 signaling 
facilitates axonal guidance and migration of neuronal progenitor cells during 
hippocampal and cerebellar neurogenesis (Arakawa et al., 2003; Bagri et al., 2002; 
Belmadani et al., 2005; Chalasani et al. , 2003b; Pujol et al., 2005). Moreover, it has been 
shown that mice lacking expression of CXCL 12 or CXCR4 (CXCL 12- and CXCR4-
deficient mice) die prematurely and display abnormal development of specific brain 
regions, in particular the cerebellum and the hippocampus, emphasizing the importance 
of CXCL 12-CXCR4 signaling in CNS development (Lu et al. ,  2002; Ma et al., 1998; Zhu 
et al., 2002). 
Other suggested roles for chemokines in the developing CNS are the facilitation of 
astrocyte proliferation (CXCL 12, CCL2, CCL3 and CCL5) (Bajetto et al., 2001a; Bakhiet 
et al., 2001; Rezaie et al., 2002), migration of microglia precursor cells to the CNS (CCL2 
and CCL5) (Rezaie and Male, 1999), regulation of oligodendrocyte maturation and 
myelination of the spinal cord (CXCL 1) (Robinson et al., 1998; Robinson and Franic, 
2001; Tsai et al., 2002; Wu et al., 2000), and neuronal survival (CXCL 12) (Chalasani et 
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al., 2003a; Vlahakis et al., 2002). Whether these proposed functions for chemokines also 
play a role in the development of the human CNS remains to be established. 
A recently described feature of chemokine function in the adult CNS might be the 
modulation of neuronal signaling (Rostene et al., 2007). Several chemokines (including 
CXCL 1, CXCL8, CXCL 10, CXCL 12, CX3CL 1 and several CC-chemokines) have been 
shown to either modulate synaptic activity, neurotransmitter release, neuronal excitability 
or induction of Ca2+ transients in various primary neuronal cultures (Gillard et al., 2002; 
Giovannelli et al., 1998; Gosselin et al., 2005; Limatola et al., 2000; Liu et al., 2003; 
Meucci et al., 1998; Nelson and Gruol, 2004; Oh et al., 2002; Puma et al., 2001; White et 
al., 2005). Depending on the chemokine and neuronal cell type, the nature of these 
modulatory effects can be either excitatory or inhibitory. Similar neuromodulatory effects 
of chemokines (including CXCL 10, CXCL 12 and CX3CL 1) have also been described in 
brain slices (Bertollini et al. ,  2006; Dong and Xiong, 2006; Guyon et al., 2005; Guyon et 
al., 2006; Limatola et al., 2000; Limatola et al., 2005; Liu et al. , 2003; Ragozzino et al., 
2002; Vlkolinsky et al., 2004). However, the presence of glia cells in these slices makes 
it difficult to determine whether the neuromodulatory effects of chemokines are induced 
through chemokine receptors on neurons and/or on glia cells, since electrophysiological 
changes in neurons might also be due to chemokine-induced transmitter release from 
glia cells (Limatola et al., 2000; Ragozzino et al., 1998; Bertollini et al. ,  2006). In line with 
this, it has been shown that CXCL 12 indirectly regulates neuronal excitability of 
cerebellar Purkinje cells by enhancing glutamate release from astrocytes through a 
TN Fa-dependent mechanism (Bezzi et al., 2001; Limatola et al. , 2000). Although these 
findings underline the importance of chemokine-signaling in the developing- and adult 
CNS under physiological conditions, there is now ample evidence that chemokines might 
be of equal importance in the development of several CNS-related pathologies. 
Chemokines in CNS pathology 
The expression of "inducible" chemokines within the CNS is primarily associated with 
neuropathological conditions. Indeed, upregulation of chemokine expression by CNS­
residing cells (including neurons, astrocytes, microglia and endothelial cells) has been 
described in various pathologies and/or inflammatory processes associated with human 
CNS disease (see also table 1.1) (Ambrosini and Aloisi, 2004; Biber et al., 2006; Cartier 
et al., 2005; De Haas et al., 2007; Gerard and Rollins, 2001). Interestingly, cellular 
expression of these chemokines was predominantly observed within or in close vicinity of 
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primary CNS lesions. As specific chemokines have shown to trigger glia cell activation 
and/or migration of leukocytes in vitro, it has been hypothesized that chemokines in the 
injured CNS may facilitate local immune responses through activation of local glia cells 
and by recruitment of blood leukocytes to local sites of CNS injury. 
Chemokines in CNS pathology: leukocyte attraction and extravasation 
Under physiological conditions, the BBB acts as a structural barrier between the blood 
stream and the CNS parenchyma limiting the entry of leukocytes and immune-related 
molecules into the CNS (Bechmann et al., 2007; Galea et al., 2007). From a classical 
point-of-view, the isolating capacity of the BBB diminishes under pathological conditions 
such as MS, ischemia and infection, thereby allowing infiltration of activated immune 
cells into the CNS. The recruitment and infiltration of leukocytes from the blood into the 
CNS tissue requires a multi-step process, involving tethering, rolling and adhesion to the 
cerebrovascular endothelium, followed by activation and transmigration of the leukocytes 
into the CNS parenchyma. Various steps in this process are facilitated by chemokines 
(Baggiolini, 1 998; Engelhardt, 2008; Johnston and Butcher, 2002; Moser and Loetscher, 
2001). 
The initial process of leukocyte extravasation is facilitated by interaction with various 
types of adhesion molecules expressed on the cerebrovascular endothelium. Tethering 
and rolling of leukocytes along the endothelium is mediated through interaction with 
selectins and their corresponding carbohydrate receptors expressed at the endothelial 
surface. At the same time, chemokines produced by the inflamed neuronal tissue are 
transported intracellularly to the luminal site of the endothelium, where they are 
immobilized through glycosaminoglycans (GAGs) and presented to the "rolling" 
leukocytes. Upon recognition, the leukocytes undergo a rapid activation step that 
upregulates integrin affinity and avidity, resulting in arrest and firm adhesion to the 
endothelium through interaction with endothelial adhesion receptors. Once adhered, 
chemokine gradients guide the leukocytes across the endothelium towards the site of 
inflammation. Subsequent infiltration of eosinophils and at a later time-point 
macrophages and lymphocytes into the damaged/inflammatory area may lead to 
perivascular inflammatory reactions, in which the BBB plays an active role by production 
of inflammatory mediators and the presentation of chemotactic substances. 
Taken together, chemokine expression by CNS-residing cells in response to pathological 
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Table 1.1 in vivo expression of chemokines in neurons and glia cells associated with human 
CNS disease. Adapted from (Biber et al., 2006; De Haas et al., 2007). 
CNS pathology chemokine cell type(s) 
Aicardi-Goutieres 
Alzheimer's disease 








CXCL 1 0  
CCL2 
CXCL1 0  











































conditions and the subsequent presentation of these chemokines at the luminal side of 
the BBB cerebrovascular endothelium provides a regulatory mechanism for the 
recruitment of specific leukocyte subtypes to the site of injury. This feature may be 
important in the development of autoimmune diseases in the CNS such as MS, which is 
characterized by the destruction of myelin sheaths by infiltrating myelin specific auto­
reactive T cells and macrophages leading to axonal damage and loss of neurons. 
Indeed, studies in an animal model for MS, known as experimental autoimmune 
encephalitis (EAE), have indicated an important role for chemokine-receptor couples 
such as CCL2-CCR2 and CXCL 1 0-CXCR3 in the development of MS-like pathologies. 
Mice lacking expression of CCL2 (CCL2-1-) or CCR2 (CCR2-1') develop strongly reduced 
EAE pathology when compared to wild type littermates, which coincides with a strong 
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reduction in infiltrating macrophages in the CNS (Babcock et al., 2003; Fife et al., 2000; 
Huang et al., 2001; lzikson et al., 2000). Conversely, CXCL 10 expression in EAE and 
MS has been associated with the attraction of CXCR3-positive Th1 cells into the CNS. 
However, studies using CXCL 10-neutralizing antibodies and studies in CXCL 10- and 
CXCR3-knockout mice do not give a uniform answer regarding the role of this 
chemokine-receptor couple in the development of EAE pathology. Administration of 
CXCL 10-neutrilizing antibodies has shown to decrease the infiltration of CD4+ T cells as 
well as the clinical and histological disease incidence in EAE (Fife et al., 2001 ). In 
contrast, induction of EAE in CXCL 10- or CXCR3-knockout mice provoked more severe 
clinical and histological symptoms and earlier onset compared to healthy controls (Klein, 
2004; Liu et al., 2006; Muller et al., 2007). Moreover, the number of infiltrating T cells in 
these knockout studies was similar to that observed wild type conditions, suggesting a 
compensatory mechanism (Klein, 2004; Liu et al., 2006; Muller et al., 2007). Taken 
together, targeting CXCL 10 as a therapeutic strategy in MS should be addressed with 
caution (Liu et al., 2005). 
Endogenous role for CXCL 1 0-CXCR3 signaling in CNS injury 
Expression of CXCL 10 in the CNS has been associated with many neuropathologies, 
including ischemia (Wang et al., 1998), Alzheimer's disease (Galimberti et al., 2006; Xia 
et al. , 2000), MS (Balashov et al., 1999; Simpson et al., 2000b; Sorensen et al., 2002), 
and HIVE (Cinque et al., 2005; Sanders et al., 1 998). Depending on the pathology, 
CXCL 1 O was predominantly found in astrocytes surrounding primary lesions (Balashov 
et al . ,  1999; Omari et al., 2005; Simpson et al., 2000b; Tanuma et al., 2006; Wang et al., 
1 998; Xia et al., 2000), but several reports have also demonstrated CXCL 10  expression 
in neurons (Rappert et al., 2004; Wang et al., 1998). As mentioned previously, initial 
research was focused on the role of CNS-expressed CXCL 10 in the recruitment of 
leukocytes from the periphery under inflammatory conditions, as infiltrating T cells were 
found to express its corresponding receptor CXCR3 (Boztug et al., 2002; Liu et al., 2000; 
Simpson et al., 2000b; Sorensen et al., 1999; Sorensen et al., 2002; Trebst et al., 
2003b). However, knockout studies in CXCL 10-1- and CXCR3_,_ mice could not univocally 
prove this concept (Klein, 2004; Liu et al., 2006; Muller et al., 2007). In addition to T 
cells, expression of CXCR3 has also been reported in CNS-residing cells, in particular 
microglia (Biber et al. ,  2001; Biber et al., 2002; De Haas et al., 2008; Dijkstra et al., 2004; 
Li et al., 2006; Rappert et al., 2004; Tanuma et al., 2006) and reactive astrocytes 
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(Goldberg et al., 2001; Omari et al., 2005; Simpson et al., 2000b; Tanuma et al., 2006), 
suggesting that CXCL 10 may activate and/or recruit local glia cells to the site of injury. 
This suggestion is corroborated by in vitro findings showing that CXCL 10 induces 
CXCR3-mediated migration of primary microglia (Biber et al., 2001; Biber et al., 2002; 
Rappert et al., 2002) and proliferation of primary astrocyte cultures (Flynn et al., 2003). 
Nonetheless, the proposed role and consequences of CXCL 1 0/CXCR3-signaling 
between neurons and/or glia cells under pathological conditions are far from understood. 
The importance of CXCR3-signaling in the activation of microglia in vivo has been 
demonstrated recently in the entorhinal cortex lesion (ECL) model (Rappert et al., 2004). 
In this model, in vivo axotomy of the neuronal fibers connecting the entorhinal cortex and 
the hippocampus leads to axonal degeneration and subsequent loss of neuronal 
dendrites in the middle and outer layer of the DG, a process which coincides with local 
activation of astrocytes and recruitment of microglia to the site of axonal damage. In 
CXCR3·'· mice, microglia activation and subsequent recruitment to sites of axonal 
degeneration was impaired after ECL when compared to wild type conditions, while 
aberrations in astrocyte activation were not observed (Rappert et al., 2004). Moreover, it 
was demonstrated that, in contrast to wild type conditions, dendrites of denervated DG 
interneurons in CXCR3·'· mice were maintained. These findings not only show that 
CXCR3 is important in the recruitment of microglia to sites of neuronal injury, but also 
suggest that this recruitment may be important for neuronal reorganization after injury 
(Rappert et al., 2004). However, a direct link between microglia recruitment and neuronal 
survival in this paradigm, as well as which CXCR3 ligands are involved here, remains to 
be established. 
CCL21-CXCR3, an alternative communication pathway between endangered 
neurons and glia cells? 
Previously, we have shown in a middle cerebral artery occlusion (MCAO) mouse model 
for CNS ischemia that cortical neurons in the penumbra zone surrounding the ischemic 
core rapidly express the chemokine CCL21 (Biber et al., 2001). Since expression of 
CCL21 was not detected in healthy brain tissue, it was assumed that CCL21 is 
specifically expressed by endangered neurons (Biber et al., 2001). This finding was 
rather surprising as CCL21 is well known for its constitutive expression in the periphery, 
where it controls the homing of CCR7-positive mature dendritic cells and na'ive T- and 8 
cells to secondary lymphoid organs (Dieu et al., 1998; Forster et al., 2008; Lira, 2005; 
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Sallusto et al., 1998; Stein et al., 2000; Yanagihara et al. ,  1998). Thus, CCL21 
expression in the periphery was generally considered as a homeostatic feature. 
Recently, another group has demonstrated CCL21 expression in dorsal horn neurons 
after spinal cord injury, supporting a role for CCL21 in neuronal pathology (Zhao et al., 
2007). Moreover, CCL21 expression was demonstrated in vitro in cortical neuronal 
cultures and in neurons in hippocampal slice cultures when exposed to glutamate­
induced excitotoxicity (Biber et al., 2001 ;  De Jong et al., 2005). Taken together, it is 
suggested that injury-induced expression of CCL21 in endangered neurons reflects a 
specific role for this chemokine in CNS pathology. This assumption is corroborated by 
findings in transgenic mice in which CCL21 was expressed ectopically in various tissues 
(Chen et al., 2002b; Chen et al., 2002a). Transgenic expression of CCL21 in the CNS of 
intact mice induced severe neuropathology and premature death (Chen et al., 2002a), 
whereas CCL21 expression in the skin was not accompanied by any alterations (Chen et 
al., 2002b). 
Several lines of evidence suggest that rapid induction of CCL21 in endangered neurons 
might provide a stress signal that recruits surrounding glia cells (Biber et al., 2001; De 
Jong et al., 2005; Dijkstra et al., 2004; Rappert et al., 2002; Zhao et al., 2007). This 
assumption is based on in vitro findings, showing activation and migration of both human 
and mouse microglia in response to recombinant CCL21 (Biber et al., 2001; Dijkstra et 
al., 2004; Rappert et al., 2002). Moreover, it has been demonstrated very recently that 
injection of CCL21 into the thalamus of intact mice results in transient activation of local 
microglia (Zhao et al., 2007). An interesting feature here is that the activation of microglia 
in response to CCL21 in vitro has been shown not to be dependent on its native receptor 
CCR7, but on the presence of CXCR3 (Biber et al., 2001 ;  Dijkstra et al., 2004; Rappert 
et al., 2002). Cross-desensitization experiments with CXCR3-ligand CXCL 10 prevented 
CCL21-induced activation of both human and mouse microglia, and microglia derived 
from CXCR3·'· mice did not migrate in response to CCL21, while microglia derived from 
CCRT'· mice did migrate in response to this chemokine (Biber et al., 2001; Dijkstra et al., 
2004; Rappert et al., 2002). Taken together, these results suggest that neuron-derived 
CCL21 might provide a signaling system between endangered neurons and CXCR3-
expressing glia cells that is associated with a neuroimmune response. However, whether 
CCL21-induced activation of glia cells triggers a neuroprotective or a neurotoxic 
response in these cells remains to be elucidated. 
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1 .4 THESIS OUTLINE 
Summary 
Any type of neuronal injury in the CNS inevitably results in the activation of local glia 
cells, in particular microglia and astrocytes. Activation of these cells is generally 
considered a beneficial process, aimed at the protection and restoration of normal CNS 
homeostasis. However, chronic or excessive glia activation might lead to uncontrolled 
responses with detrimental consequences for neuronal survival under pathological 
conditions. 
Neuronal excitotoxicity is a process associated with many CNS pathologies and is 
characterized by progressive loss of neurons as a result of excessive glutamate release. 
This process of glutamate-induced neurodegeneration coincides with reactive 
astrogliosis and local accumulation of highly activated microglia. Studies addressing the 
role of microglia in excitotoxicity are controversial as inhibition of microglia function in this 
paradigm proved to be either beneficial or detrimental for neuronal survival. The aim of 
the first part of this thesis was to get more insight in the role of microglia under 
excitotoxic conditions. 
In Chapter 2 we took a closer look at the neuroprotective/neurotoxic properties of 
microglia in the process of excitotoxicity-induced neurodegeneration. For this purpose, 
we set up an ex vivo model for excitotoxicity using mouse organotypic hippocampal slice 
cultures. Subsequently, we selectively removed the microglia population from these slice 
cultures by treatment with liposome-encapsulated clodronate and determined its effect 
on excitotoxicity-induced neurodegeneration by means of immunohistochemistry and 
confocal imaging. 
The second part of this thesis was focused on the role of specific chemokines as 
potential messengers between injured neurons and local glia cells under excitotoxic 
conditions. A prominent candidate is the chemokine CXCL 10, which mediates its actions 
through its receptor CXCR3. Expression of CXCL 10 and CXCR3 in both glia and 
neuronal cells has been associated with the clinical signs of several excitotoxicity-related 
CNS disorders. Interestingly, interference with CXCL 10/CXCR3 signaling in various CNS 
disease models has been shown to alter the progression and severity of disease 
symptoms. However, the mechanism and cell-types involved in CXCL 10/CXCR3 
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CXCL 1 0  and its receptor CXCR3 in excitotoxicity-induced neurodegeneration has been 
examined using mouse hippocampal slice cultures as a model. The expression and 
localization of CXCL 10 and CXCR3 were determined by RNA- and protein analysis of 
whole slice culture lysates, flow cytometry and in situ hybridisation in combination with 
immunohistochemistry. To address the role of CXCL 10/CXCR3-signaling in 
hippocampus excitotoxicity, we determined the degree of NMDA-induced neuronal cell 
death and glia activation in wild type hippocampal slice cultures and compared these 
findings with those acquired in slice cultures derived from CXCL 10·1• and CXCR3-1- mice. 
Another chemokine that might play a role in CNS-excitotoxicity is CCL21. CCL21 
expression in vivo has been observed in ischemic cortical neurons and in dorsal horn 
neurons after spinal cord injury. Neuronal expression of CCL21 in vitro has been 
observed in hippocampal slice cultures and in primary neuronal cultures when exposed 
to toxic levels of glutamate. Moreover, CCL21 was demonstrated to induce activation of 
microglia both in vivo and in vitro, suggesting a role for this chemokine in the 
communication between injured neurons and glia cells. However, the consequence of 
CCL21 -signaling in the injured CNS remains to be elucidated. In Chapter 4 we have 
addressed this question by comparing excitotoxicity-induced neuronal cell death in 
hippocampal slice culture preparations derived from wild type- and CCL21/CCL19 (p/t)­
deficient mice. In addition, the involvement of its receptors CCR7 and CXCR3 are 
addressed. 
Previously, it has been demonstrated that CCL21 induces activation and migration of 
both human and mouse microglia in vitro, a process dependent on the presence of 
CXCR3. It has been well established that astrocytes, like microglia, functionally express 
CXCR3. However, effects of CCL21-signaling on astrocytes have not been investigated 
yet. Therefore, we have examined the effect of CCL21 on intracellular calcium 
mobilization and proliferation in primary mouse astrocytes and compared these findings 
with the effects observed in response to CXCR3-ligand CXCL 10. The results are 
presented in Chapter 5. 
Chapter 6 provides a summary of all the results presented in this thesis and their 
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ABSTRACT 
Upon any type of central nervous system (CNS) injury microglia become rapidly 
activated, a process which has long been thought to be detrimental for neuronal survival. 
However, recent findings suggest that microglia display neuroprotective properties in 
various CNS pathologies. In the present study we determined the effect of microglia 
depletion on excitotoxicity-induced neurodegeneration using mouse organotypic 
hippocampal slice cultures. Treatment of slice cultures with 10-50 µM N-methyl-D­
aspartic acid (NMDA) induced a region-specific increase in neuronal cell death with CA 1 
neurons being most vulnerable to NMDA-exposure, followed by CA3 and DG neurons, 
respectively (CA 1 >CA3>DG). This selective neuronal vulnerability strongly correlated 
with activation of local microglia. At 10 µM NMDA, microglia activation was restricted to 
the CA1 region, while in the CA3 region changes in microglia morphology were only 
evident at 1 5  µM NMDA or higher. As DG neurons were most resistant to NMDA­
excitotoxicity, microglia activation in this region was only observed at NMDA­
concentrations of 25 µM or higher. Interestingly, ablation of microglia by treatment of 
slice cultures with liposome-encapsulated clodronate, and subsequent exposure to 
NMDA, resulted in severely enhanced neuronal cell death in the CA3 and DG region. 
Particularly, the resistance of DG and CA3 neurons to NMDA-induced toxicity in the 
presence of ramified microglia, and the severely increased vulnerability of these neurons 
in the absence of microglia, suggests that ramified microglia contribute to the protection 
of neurons under pathological conditions. 
0 
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INTRODUCTION 
Brain tissue is highly vulnerable to injury because of its restricted regenerative capacity . 
From the outside, the brain is protected by the skull and the blood-brain barrier 
(Bechmann et al., 2007). Within the central nervous system (CNS), microglia are the first 
line of defense and are activated upon any type of brain injury (Kreutzberg, 1 996; 
Rossum and Hanisch, 2004; Hanisch and Kettenmann, 2007; Streit, 2002). The original 
definition of microglia activation as a stereotypic and graded process (Kreutzberg, 1 996; 
Streit, 2002) has been challenged in the last couple of years (Hanisch and Kettenmann, 
2007). The current view is that in response to activating stimuli, microglia rapidly change 
their morphology. They first direct their dendritic processes towards the injury in order to 
shield it before they retract their processes and become motile cells that migrate to the 
site of injury. Microglia activation can also be accompanied by proliferation (Hailer et al., 
1 999; O'Donnell et al . ,  2002). It is now clear that microglia respond with a variety of 
different reactions by integrating multifarious inputs (Hanisch, 2002; Hanisch and 
Kettenmann, 2007; Schwartz et al., 2006). In line with this, microglia responses are not 
inevitably neurotoxic as long been thought. Various neuroprotective effects of activated 
microglia have been demonstrated recently in vivo. Microglia were found beneficial in a 
model of nitric oxide-dependent excitotoxicity (Turrin and Rivest, 2006) and in stroke 
(Lalancette-Hebert et al., 2007). Moreover, protective microglia activity was described in 
mouse models of amyotrophic lateral sclerosis (Boillee et al., 2006) and Alzheimer's 
disease (El Khoury et al., 2007). However, microglial neurotoxicity can occur in case of 
overshooting and uncontrolled stimulation of microglia (Cardona et al., 2006; Rossum 
and Hanisch, 2004) or when microglia function is impaired (Boillee et al., 2006; 
Neumann and Takahashi, 2007; Streit, 2006). Proper facilitation of microglia activation is 
therefore of crucial importance for the survival of neurons under pathological conditions. 
It is important to note that the studies mentioned above all focus on the functions of 
morphologically activated (non-ramified) microglia. Although it is clear today that ramified 
microglia can not be considered anymore as "resting", as it has been shown in vivo that 
these cells actively screen their microenvironment with highly motile dendritic processes 
(Davalos et al., 2005; Haynes et al., 2006; Nimmerjahn et al., 2005), very little is known 
about possible other functions of ramified microglia in the CNS. 
In order to study the role of ramified microglia we made use of a mouse organotypic 
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morphology comparable to the in vivo situation. Since microglia can be specifically 
eliminated from these slice cultures by treatment with the biphosphonate clodronate 
(Kohl et al., 2003) without affecting other cell-types (Marin-Teva et al., 2004; Markovic et 
al., 2005), this model provides an ideal system to analyze the function of microglia in 
their ramified state. Here, we provide evidence that the presence of ramified microglia is 
essential for the survival of dentate gyrus (DG) and CA3 neurons in N-methyl-D-aspartic 
acid (NMDA)-induced excitotoxicity, strongly indicating that ramified microglia, next to 
their monitoring function, display neuroprotective properties. 
EXPERIMENTAL PROCEDURES 
Animals 
All experiments have been approved by the Dutch animal experimental committee. The 
C57BU6J mice (Harlan) were housed and handled in accordance with the guidelines of 
the central animal laboratory (CDL) facility of Groningen. 
Chemicals 
Culture media and supplements were all obtained from GIBCO® (lnvitrogen Corporation; 
Breda, The Netherlands), unless mentioned otherwise. Multi-lamellar CL2MDP 
(clodronate)-liposomes (Lip-CL) were obtained from the Department of Molecular Cell 
Biology of the Free University of Amsterdam, The Netherlands (for an extensive 
preparation protocol see (Van Rooijen and Sanders, 1994). Clodronate was a gift of 
Roche Diagnostics (Mannheim, Germany), phosphatidylcholine (Lipoid EPC) was 
obtained from Lipoid (Ludwigshafen, Germany) and cholesterol was purchased from 
Sigma (USA). 
Preparation of organotypic hippocampal slice cultures 
Organotypic hippocampal slice cultures (OHSCs) were prepared as described (Stoppini 
et al., 1991) with minor modifications. In brief, OHSCs were prepared from 2-3 day old 
C57BU6J mouse pups under sterile conditions. After decapitation, the brains were 
removed and the hippocampi from both hemispheres were acutely isolated in ice cold 
serum-free Hank's Balanced Salt Solution (HBSS), supplemented with 0.5% glucose 
(Sigma) and 15 mM HEPES. Isolated hippocampi were cut into 375 µM thick slices using 
a tissue chopper (Mcilwain) and were transferred to 0.4 µM culture plate inserts 
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(Millipore, PICM03050). These culture plate inserts, containing four to six slices, were 
placed in six-well plates containing 1.2 ml of culture medium per well. Culture medium 
(pH 7.2) consisted of 0.5x minimum essential medium containing 25% heat-inactivated 
horse serum, 25% BME basal medium without L-glutamine, 2 mM glutamax and 0.65% 
glucose (Sigma). The slice cultures were kept at 35°C in a humidified atmosphere (5% 
CO2) and the culture medium was refreshed the first day after preparation and every 
consecutive two days. 
Induction of excitotoxicity in OHSCs 
After six days in culture, OHSCs were placed in culture medium containing various 
concentrations of the glutamate receptor-agonist N-methyl-D-aspartic acid (NMDA; 
Sigma) for 4 hours to induce excitotoxicity and subsequently the medium was replaced 
with standard culture medium. NMDA-treated OHSCs were kept in culture for 24 hours 
after the NMDA challenge. Vehicle-treated OHSCs and OHSCs pre-treated with NMDA­
antagonist MK-801 (30 µM) served as controls. 
lmmunohistochemistry 
For immunohistochemical analysis, control and NMDA-challenged OHSCs were shortly 
rinsed in phosphate-buffered saline (PBS, 35°C) and fixated with 4% paraformaldehyde 
overnight at 4°C. After fixation, the slice cultures were rinsed in PBS and pre-incubated 
with 5% normal goat serum (NGS; Vector) in PBS containing 0.3% Triton X-100 (PBS+) 
for at least one hour. Subsequently, the slice cultures were incubated with the 
appropriate primary antibodies overnight in 1% NGS/PBS+ at 4°C. The following primary 
antibodies were used: rabbit-anti-lba1 (1:1000; Waka 019-19741) for detection of 
microglia, mouse-anti-GFAP (1 :600; Chemicon MAB3402) for detection of astrocytes 
and mouse-anti-NeuN (1:1000; Chemicon MAB377) for detection of neuronal nuclei. 
Secondary antibodies used were donkey-anti-mouse-Alexa488 (Molecular Probes) for 
NeuN, donkey-anti-rabbit-Alexa633 (Molecular Probes) for lba1 and goat-anti-mouse­
Cy3 (Jackson IR Laboratories) for GFAP. Analysis of the slice cultures was done by 









Quantification of neuronal cell death 
To quantify neuronal cell death in response to NMDA-induced excitotoxicity OHSCs were 
incubated with 5 µglml propidium iodide (Pl; Sigma) during and after the NMDA­
challenge (Pozzo Miller et al., 1994; Vornov et al., 1991). Pl-positivity was restricted to 
the neuronal layers CA 1, CA3 and DG and co-localized with the neuronal nuclear marker 
NeuN (see also figure 1). Confocal images of the neuronal layers were taken mid-section 
at 40x magnification and double positive cells (NeuNIPI) were quantified manually using 
lmageJ software. The percentage of neuronal cell death was determined by the number 
of double positive cells (NeuNIPI) divided by the total number of NeuN-positive cells per 
neuronal layer. 
Depletion of microg/ia from OHSCs using clodronate-/iposomes 
To deplete microglia from slice cultures, freshly prepared OHSCs were placed on culture 
plate inserts and incubated with approximately 0.5 mg/ml Lip-CL solution (1:10 liposome 
dilution in standard slice culture medium) for 24 hours at 35°C. Subsequently, the slice 
cultures were carefully rinsed in PBS (35°C) to wash away residual liposomes and 
placed on fresh culture medium. After depletion the medium was refreshed every two 
days. 
Statistical Analysis 
Data are represented as the mean ± standard error of the mean (SEM). Statistical 
comparison between groups was performed using one-way analysis of variance 
(ANOVA) with Gabriel's posthoc test and p-values smaller than 0.05 were considered 
significant. All statistical tests were performed in SPSS version 14.0.2 (SPSS Inc., 
Chicago). 
RESULTS 
NMDA-induced excitotoxicity in mouse organotypic hippocampal slice cultures 
To examine the effects of NMDA-induced excitotoxicity on neuronal degeneration and 
microglial activation, we established a mouse organotypic hippocampal slice culture 
(OHSC) model. After six days in culture, the neuronal layers CA 1, CA3 and DG were 
well-preserved under standard culture conditions and neuronal cell death, as determined 
by Pl-uptake, was minimal (<1%; Fig. 2.1A/B control). Treatment with 10, 15, 25 and 50 
' l 
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µM NMDA induced a concentration-dependent, region-specific increase in neuronal cell 
death in the slice cultures, as determined by NeuN/PI positivity (Fig. 2.1A/C). Highest 
vulnerability towards NMDA was observed in the CA1 region with 67.1 ± 16.3% cell 
death at 10 µM NMDA. At concentrations of 15-50 µM NMDA neuronal cell death in the 
CA1 reached maximum levels (97.1 ± 1.1-100%). In contrast, CA3 neurons were less 
susceptible to NMDA as almost no cell death was detected at 10 µM NMDA (1.9 ± 0.8%) 
and pronounced cell death was only detected at concentrations of 15 µM NMDA (41.7 ± 
1 1.3%), 25 µM NMDA (79.9 ± 8.6%) and 50 µM NMDA (96.4 ± 1.5%). 
Figure 2.1. NMDA-induced neurodegeneration in mouse hlppocampal slice cultures. After six 
days in culture, hippocampal slice cultures were treated with increasing concentrations of 0 
(control), 10, 15, 25 and 50 µM NMDA. Treatment with NMDA clearly induced cell death in the slice 
cultures as determined by propidium iodide uptake (Pl; red), which co-localized with the neuronal 
nuclear marker NeuN (C, white arrow), indicating that NMDA specifically induced neuronal cell 
death. A concentration-dependent vulnerability towards NMDA was observed as neurons of the 
CA1 region were most sensitive to the NMDA-treatment (with 67.1% cell death at 10 µM NMDA), 
followed by the CA3 (41.7% at 15 µM NMDA) and finally the DG, which showed relatively low levels 
of cell death even at 50 µM NMDA (30.7%). Control slice cultures showed hardly any cell death 
(<1%, B). Treatment of slice cultures with the NMDA-antagonist MK-801 (30 µM) for one hour prior 
to NMDA-treatment completely blocked NMDA-induced neuronal cell death. The percentages of 
neuronal cell death per neuronal cell layer (DG/CA3/CA 1) were quantified and are represented in 









The DG region was least sensitive to NMDA with 6.5 ± 2% cell death at 10 µM NMDA, 
12.7 ± 1% at 15 µM NMDA, 23.5 ± 2.1% at 25 µM NMDA and 30.7 ± 4.1% at 50 µM 
NMDA. NMDA-concentrations lower than 10 µM did not induce significant cell death in 
any of the neuronal regions (data not shown). Pre-treatment for one hour with the 
NMDA-antagonist MK-801 prior to NMDA-treatment completely inhibited NMDA-induced 
neuronal cell death (Fig. 2.1A) in all regions and percentages of neuronal cell death were 
equal to control conditions (DG; 2.3 ± 1 %, CA3; 4.0 ± 0.5, CA 1 ;  1 .4 ± 0.6%). 
Microg/ial activation in response to excitotoxicity coincides with selective neuronal 
vulnerability towards NMDA 
Next, we determined the effects of NMDA-induced excitotoxicity on microglial activation. 
After six days in culture, microglia were evenly distributed throughout the slice culture 
(Fig. 2.2A) and showed typical ramified morphology with small somata and long 
processes with secondary and tertiary branches (Fig. 2.28, CA 1; C, CA3; D, DG). 
Treatment of slice cultures with toxic concentrations of NMDA caused pronounced 
microglia activation (Fig. 2.2E-L). Treatment with 10 µM NMDA induced accumulation 
and activation of microglia in the CA1 region (Fig. 2.2E, arrow) as evidenced by rounded 
morphology and retraction of dendrites (Fig. 2.2F). In contrast, in the CA3 region (Fig. 
2.2G) and the DG region (Fig. 2.2H) microglial accumulation was not detected and 
microglia morphology predominantly resembled the ramified phenotype as seen in 
control slice cultures. Treatment with 15 µM NMDA (Fig. 2.21) induced microglia 
activation and accumulation in both the CA 1 region (Fig. 2.2J) and the CA3 region (Fig. 
2.2K). Microglial accumulation in the DG region however was minimal in response to 15 
µM NMDA, and microglia displayed a typical "hypertrophic" phenotype with thickened 
and shortened dendrites (Fig. 2.2L). 
Figure 2.2 (right). Mlcrogllal activation coincides with selective neuronal vulnerability 
towards excitotoxicity. Confocal images of microglia in control (A-D), 10 µM (E-H) and 15 µM (1-L) 
NMDA-treated slice cultures, as determined by lba1-immunohistochemistry. After six days in culture 
(A), microglia were evenly distributed throughout the slice cultures and displayed a typical ramified 
morphology (B:CA1, C:CA3, D:DG). At 10 µM NMDA (E), changes in the CA1 region were clearly 
visible as numerous microglia accumulated at the site of injury (E, arrow). Morphologically, these 
microglia displayed an "activated" phenotype (F, CA1) with enlarged somata and loss of secondary 
and tertiary branching. In contrast, accumulation of microglia did not occur in the CA3 (G) and DG 
(H) and these cells retained their ramified phenotype. At 15 µM NMDA, pronounced accumulation of 
morphologically activated microglia (I, arrows) was observed in both CA 1 (J) and CA3 (K). In 
contrast, microglia in the DG (L) showed only mild activation and accumulation of microglia was 
minimal in this region. Scale bars indicate 300 µM (overviews) and 25 µM (magnifications). Confocal 
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Treatment with 25 µM NMDA and 50 µM NMDA resulted in pronounced accumulation of 
morphologically activated microglia in all three neuronal regions (data not shown). As 
expected, the morphological activation and recruitment of microglia in the three 
hippocampal layers coincided with the selective vulnerability of neurons towards NMDA­
induced excitotoxicity. 
Depletion of microg/ia from OHSCs using /iposome-encapsulated clodronate 
Next, we developed a protocol to specifically deplete microglia from mouse OHSCs 
using liposome-encapsulated clodronate (Lip-CL) to study the role of these cells in 
NMDA-induced excitotoxicity. Lip-CL has been shown to successfully deplete microglia 
from mouse organotypic slice cultures, without affecting other cell-types (Marin-Teva et 
al., 2004; Markovic et al., 2005). Overnight treatment with 0.5 mg/ml Lip-CL directly after 
slice culture preparation and subsequent culturing in standard culture medium for six 
days reduced the microglia population to less than 5% compared to its original quantity 
(Fig. 2.3AfD). In line with previous findings, both astrocytes (Fig. 2.3E) and neurons (Fig. 
2.3F) were not affected by the Lip-CL treatment and the number and morphology of 
these cells did not differ from those in untreated controls (Fig. 2.3B/C). Treatment with 
liposomes without clodronate (Lip-PBS) did not result in microglia depletion (data not 
shown). Although treatment with Lip-PBS resulted in mild activation of microglia, no 
neuronal cell death was observed and the total number of microglia did not change 
compared to untreated control conditions. 
Ablation of microglia results in severe neuronal loss in response to excitotoxicity 
To determine the role of microglia in excitotoxicity, control and microglia-depleted slice 
cultures were treated with 0, 10, 1 5, 25 and 50 µM NMDA (Fig. 2.4). Already at a low 
concentration of NMDA (10 µM) a severe increase in neuronal cell death was observed 
in microglia-depleted slice cultures, when compared to control conditions (Fig. 2.4A-C). 
Especially in the DG (Fig. 2.4A) neuronal cell death was severely enhanced in the 
absence of microglia with 30.9 ± 5.1 % cell death at 10 µM NMDA (compared to 6.5 ± 2% 
in controls), 66.0 ± 4.8% at 15 µM NMDA (compared to 12.7 ± 1 %  in controls), 74.7 ± 
2.5% at 25 µM NMDA (compared to 23.5 ± 2.1 % in controls) and 89.4 ± 4.5% at 50 µM 
NMDA (compared to 30. 7 ± 4.1 % in controls). Neuronal cell death in the CA3 region (Fig. 
2.4B) was also significantly enhanced in microglia-depleted slice cultures in response to 
10 µM NMDA (33.0 ± 8.8% compared to 1.9 ± 0.8% in controls) and 15 µM NMDA (94.0 
C.B 
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Figure 2.3. Liposomic c lodronate specifically depletes microglia from hlppocampal slice 
cultures. Untreated mouse hippocampal slice cultures showed preserved organotypic structure with 
ramified microglia (A, lba1), astrocytes (B, GFAP) and neuronal layers CA1/CA3/DG (C, Neun). 
Overnight treatment with liposome-encapsulated clodronate (Lip-CL) directly after slice culture 
preparation resulted in specific depletion of microglia (D), while astrocytes (E) and neurons (F) 
remained unaffected. After six days in culture, the microglia population in Lip-CL treated slice 
cultures was reduced to less then 5% (D). Scale bars indicate 300 µM (overviews) and 25 µM 
(inserts). Confocal images were grey-scaled. 
± 2.6% compared to 41. 7 ± 11.3% in controls). At concentrations of 25 µM and 50 µM 
NMDA differences in neuronal cell death were minimal and reached maximum levels 
under both conditions (99.6 ± 0.3% and 100% compared to 79.9 ± 8.6% and 96.4 ± 1.5% 
respectively in controls). In the CA 1 region, no significant differences in neuronal cell 
death were observed between control and microglia-depleted slice cultures as treatment 
with 10 µM NMDA already resulted in severe neuronal cell death in both conditions (Fig. 
2.4C, 95.2 ± 1.4% compared to 67.1 ± 16.3% in controls). Treatment of microglia-free 
slice cultures with NM DA-concentrations lower than 10 µM did not induce neuronal cell 
death in any of the three hippocampal regions (data not shown). Taken together, these 
results show a clear neuroprotective property for microglia in NMDA-induced 
excitotoxicity as depletion of resident microglia results in severely enhanced neuronal 
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Figure 2.4. Depletion of mlcroglla leads to severely enhanced loss of neurons in response to 
excltotoxicity. Graphs represent the percentages of neuronal cell death per hippocampal sub­
region (A to C) in response to 0, 10, 15, 25 and 50 µM NMDA in untreated (WT control) and 
microglia-depleted slice cultures (WT Lip-CL). Microglial depletion alone did not lead to a significant 
increase in neuronal cell death (A-C; CNTR). However, in the absence of microglia, neuronal cell 
death in response to NMDA-induced excitotoxicity was severely enhanced in the DG (A) and CA3 
(B). Confocal images clearly show the effect of microglial depletion on neuronal degeneration in 
response to 1 5  µM NMDA (D-K). Here, in the absence of microglia, neuronal cell death was 
significantly enhanced in the DG from 12.7% to 66.0% (F,G) and in the CA3 from 41.7% to 94.0% 
(H, I). In the CA1 (J,K) no significant effect in response to 15 µM NMDA was observed between 
control and Lip-CL treated slice cultures (97. 1 %  versus 99.8%, respectively). Data are a summary 
of three individual experiments with at least 6 slice cultures per condition. Bars indicate mean ± 
SEM. **p < 0.01, ***p < 0.001, ANOVA. Scale bars indicate 300 µM (D,E) and 75 µM (F-K). 
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Interestingly, the selective neuronal vulnerability to NMDA as observed in control slice 
cultures was partly abolished in microglia-depleted slice cultures. Both CA3 and CA 1 
neurons were equally affected upon treatment with 15-50 µM NMDA and cell death in 
the DG was severely enhanced in response to these concentrations, resulting in an 
attenuation of the selective neuronal vulnerability between the various hippocampal 
regions. At 50 µM NMDA, this selectivity was even completely abolished as all three 
hippocampal regions were equally affected in terms of neuronal cell death. Clearly, the 
region-dependent hippocampal vulnerability as observed in this model is at least partly 
dependent on the presence of microglia. 
DISCUSSION 
We have investigated the effect of microglia-depletion on the survival of neurons during 
NMDA-induced excitotoxicity in a mouse hippocampal slice culture model. Our results 
show that morphological activation of microglia coincides with local neuronal cell death in 
the hippocampal regions CA1, CA3 and DG. However, in the absence of microglia, 
neuronal vulnerability in response to NMDA-excitotoxicity is severely enhanced, 
suggesting that microglia are neuroprotective under these conditions. 
Selective hippocampal neuronal vulnerability in excitotoxicity: involvement of microglia 
In our system neurons of the hippocampal regions CA 1, CA3 and DG showed selective 
vulnerability towards NMDA-excitotoxicity with CA 1 neurons being most susceptible to 
NMDA followed by CA3 and DG neurons, respectively. Similar patterns of selective 
neuronal vulnerability towards excitotoxicity or (hypoxic-) ischemic insults in the 
hippocampus have been observed previously both in vivo (Kirino and Sano, 1984; Horn 
and Schlote, 1992; Acarin et al. ,  1996; Schauwecker, 2002; Won et al., 1999) and in vitro 
in organotypic slice cultures (Gee et al., 2006; Boscia et al., 2006; Cron berg et al., 2005; 
Keynes et al., 2004; Kristensen et al., 2001; Strasser and Fischer, 1995; Vornov et al., 
1991 ), corroborating our findings. Reasons for this selective neuronal vulnerability in the 
hippocampus are not well understood. Variability in glutamate receptor (-subtype) 
expression (Coultrap et al., 2005; Martens et al., 1998) and/or endogenous properties of 
the distinct neuronal populations in the CA 1, CA3 and DG regions could (in part) explain 
their selective vulnerability towards excitotoxicity (Chen et al., 1999; Cronberg et al., 
2005; Grishin et al., 2004; Sakaguchi et al., 1997). In line with this, it has been shown 








that CA1 neurons express relatively high levels of AMPA- and NMDA-receptor (­
subtypes), while neurons in the CA3 region express relatively high levels of kainate­
receptors (Martens et al. ,  1998; Coultrap et al., 2005). Accordingly, it has been 
demonstrated that CA1 neurons are most vulnerable to glutamate- and NMDA-induced 
insults, whereas CA3 (and DG) neurons are most sensitive to the excitotoxin kainic acid 
(Kristensen et al., 200 1 ;  Schauwecker, 2002; Vornov et al., 1 991). Moreover, selectivity 
towards NMDA has been shown to be independent of an intact hippocampal neuronal 
circuitry (lkegaya and Matsuki, 2002) as isolated CA3, CA 1 and DG slice cultures still 
respond with a selective vulnerability towards NMDA, with the CA 1 and CA3 regions 
being more susceptible to NMDA than the DG region. 
Here, we provide evidence that selective vulnerability is not solely based on endogenous 
neuronal properties. In our slice culture model, the absence of microglia did not simply 
sensitize neurons for NMDA-toxicity since concentrations below 10 µM NMDA did not 
induce neuronal cell death, irrespective of the presence of microglia in the slice cultures. 
Moreover, the differences in neuronal sensitivity to NMDA between the three 
hippocampal regions were attenuated in the absence of microglia. Without microglia, 
neurons from both the CA3 and CA 1 region were equally affected upon treatment with 
15-25 µM NMDA. Treatment of microglia-free slice cultures with 50 µM NMDA even fully 
abrogated selective vulnerability as all three hippocampal regions (CA 1, CA3 and DG) 
were equally affected in terms of neuronal cell death. These results suggest that 
microglia are at least partly involved in the selective vulnerability of hippocampal neurons 
towards NMDA. How the impact of microglia on the region-specific vulnerability of 
neurons is achieved is not yet clear. Whether neuron-microglia signaling in the 
hippocampus shows region-specific properties (Biber et al. ,  2007) or whether different 
subpopulations of microglia can be found in the various hippocampal layers remains to 
be established. 
Evidence for neuroprotective properties of ramified microglia upon excitotoxicity 
In our slice culture model morphological activation of microglia coincided with the 
selective neuronal vulnerability to NMDA and was restricted to sites of neuronal cell 
death. This is a well-known feature of microglia and has been reported in vivo (Acarin et 
al., 1996) and in vitro in OHSCs (Bernardino et al. , 2005). We show that ablation of 
microglia severely increased the vulnerability of CA3 and DG neurons upon NMDA­
induced excitotoxicity, suggesting that microglia in these neuronal regions have profound 
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neuroprotective properties. These results are in line with other reports describing 
neuroprotective properties for microglia upon excitotoxic or ischemic injury (Imai et al., 
2007; Kitamura et al., 2004; Lalancette-Hebert et al., 2007; Turrin and Rivest, 2006) . 
Interestingly, our results suggest that a morphological activation of microglia is not 
required for their neuroprotective function. At 10 µM NMDA we did not observe neuronal 
loss in the CA3 and DG region and therefore no morphological microglia activation in 
these regions. From the classical point of view one could assume that microglia are not 
active here. However, neuronal loss was profound in these regions in the absence of 
microglia, clearly indicating that also ramified (morphologically non-activated) microglia 
have the capacity to support neurons in excitotoxicity. In line with this observation, recent 
reports have shown that ramified microglia express neurotrophic factors (Elkabes et al., 
1996; Xapelli et al., 2008; Shein et al., 2008), supporting our hypothesis. Our findings, 
together with the observations that ramified microglia in vivo continuously scan their 
environment for homeostatic irregularities (Davalos et al., 2005; Haynes et al . ,  2006; 
Nimmerjahn et al., 2005) and express neurotrophic factors (Elkabes et al., 1996; Shein 
et al., 2008; Xapelli et al., 2008), clearly shows that ramified microglia contribute to the 
protection of neurons both under healthy and pathological conditions. In conclusion, one 
should not regard ramified microglia as solely inactive "resting" cells, but as active 
contributors in the protection of CNS neurons. 
Acknowledgements 










1 .  Acarin L, Gonzalez B ,  Castellano B, Castro AJ. 1996. Microglial response to N-methyl-D-aspartate-mediated 
excitotoxicity in the immature rat brain. J Comp Neurol 367:361-374. 
2. Bechmann I, Galea I, Perry VH. 2007. What is the blood-brain barrier (not)? Trends lmmunol 28:5-1 1 . 
3. Bernardino L, Xapelli S, Silva AP, Jakobsen B, Poulsen FR, Oliveira CR, Vezzani A, Malva JO, Zimmer J. 
2005. Modulator effects of inter1eukln-1 beta and tumor necrosis factor-alpha on AMPA-induced excitotoxicity 
in mouse organotypic hippocampal slice cultures. J Neurosci 25:6734-6744. 
4 .  Biber K,  Neumann H, Inoue K,  Boddeke HW. 2007. Neuronal 'On' and ·otr signals control microglia. Trends 
Neurosci 30:596-602. 
5. Boillee S, Yamanaka K, Lobslger CS, Copeland NG, Jenkins NA, Kassiotis G. Kollias G, Cleveland OW. 
2006. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 
312:1389-1392. 
6. Boscia F, Annunziato L. Taglialatela M. 2006. Retigabine and flupirtine exert neuroprotective actions in 
organotypic hippocampal cultures. Neuropharrnacology 51 :283-294. 
7 . Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, Huang D, Kidd G, Dombrowski S, 
Dutta R, Lee JC, Cook ON, Jung S, Lira SA, Littman DR, Ransohoff RM. 2006. Control of microglial 
neurotoxicity by the fractalkine receptor. Nat Neurosci 9:91 7-924. 
8. Chen Y, Chad JE, Cannon RC, Wheal HV. 1999. Reduced Mg2+ blockade of synaptically activated N­
methyl-D-aspartate receptor-channels in CA 1 pyramidal neurons in kainic acid-lesioned rat hippocampus. 
Neuroscience 88. 727-739. 
9. Coultrap SJ, Nixon KM, Alvestad RM, Valenzuela CF, Browning MD. 2005. Differential expression of NMDA 
receptor subunits and splice variants among the CA 1 ,  CA3 and dentate gyrus of the adult rat. Brain Res Mol 
Brain Res 1 35:1 04-1 1 1 . 
1 0. Gronberg T, Jensen K, Rytter A. Wieloch T. 2005. Selective sparing of hippocampal CA3 cells following in 
vitro ischemia is due to selective Inhibition by acidosis. Eur J Neurosci 22:310-316. 
1 1 . Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S. Littman DR, Dustin ML, Gan WB. 2005. ATP 
mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 8·752-758. 
1 2. El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD. 2007. Ccr2 deficiency impairs 
microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 13:432-438. 
13 .  Elkabes S,  Cicco-Bloom EM, Black 18 .  1 996. Brain microglia/macrophages express neurotrophins that 
selectively regulate microglial proliferation and function. J Neurosci 16:2508-2521 .  
1 4. Gee CE, Benquet P, Raineteau 0, Rietschin L, Kirbach SW, Gerber U. 2006. NMDA receptors and the 
differential ischemic vulnerability of hippocampal neurons. Eur J Neurosci 23:2595-2603. 
1 5. Grishln AA, Gee CE, Gerber U, Benquet P. 2004. Differential calcium-dependent modulation of NMDA 
currents in CA1 and CA3 hippocampal pyramidal cells. J Neurosci 24:350-355. 
1 6. Haller NP. Grampp A, Nitsch R. 1 999. Proliferation of microglia and astrocytes in the dentate gyrus following 
entorhlnal cortex lesion: a quantitative bromodeoxyuridine-labelling study. Eur J Neurosci 1 1  :3359-3364. 
1 7. Hanisch UK. 2002. Microglia as a source and target of cytokines Glia 40:140-155. 
1 8. Hanisch UK, Kettenmann H. 2007. Microglia: active sensor and versatile effector cells in the normal and 
pathologic brain. Nat Neurosci 1 0:1 387-1 394. 
1 9. Haynes SE, Hollopeter G, Yang G, Kurpius D, Dailey ME, Gan WB, Julius D. 2006. The P2Y12 receptor 
regulates microglial activation by extracellular nucleotides. Nat Neurosci 9 :1 512-1 519. 
20. Horn M, Schlote W. 1 992. Delayed neuronal death and delayed neuronal recovery in the human brain 
following global ischemia. Acta Neuropathol 85:79-87. 
2 1 . lkegaya Y, Matsuki N 2002. Regionally selective neurotoxicity of NMDA and colchicine is independent of 
hippocampal neural circuitry. Neuroscience 1 1 3:253-256. 
22. Imai F, Suzuki H, Oda J, Ninomiya T, Ono K, Sano H, Sawada M. 2007. Neuroprotective effect of 
exogenous microglia in global brain ischemia. J Cereb Blood Flow Metab 27:488-500. 
23. Keynes RG, Duport S, Garthwaite J. 2004. Hippocampal neurons in organotypic slice culture are highly 
resistant to damage by endogenous and exogenous nitric oxide. Eur J Neurosci 19 : 1 163-1 1 73. 
24. Klrino T, Sano K. 1 984. Selective vulnerability in the gerbil hippocampus following transient ischemia. Acta 
Neuropathol 62:201-208. 
MICROGLIA IN EXC ITOTOXICITY 
25. Kitamura Y, Takata K, lnden M, Tsuchiya D, Yanagisawa D, Nakata J, Taniguchi T. 2004. 
lntracerebroventricular injection of microglia protects against focal brain ischemia. J Pharmacol Sci 
94:203206. 
26. Kohl A, Dehghani F, Korf HW, Hailer NP. 2003. The bisphosphonate clodronate depletes microglial cells in 
excitotoxically injured organotypic hippocampal slice cultures. Exp Neurol 1 8 1 :  1 - 1 1 .  
27. Kreutzberg GW. 1 996. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1 9:31 2-318. 
28. Kristensen BW, Noraberg J, Zimmer J. 2001 .  Comparison of excitotoxic profiles of ATPA, AMPA, KA and 
NMDA in organotypic hippocampal slice cultures. Brain Res 91 7:21 -44. 
29. Lalancette--Hebert M, Gowing G, Simard A, Weng YC, Kriz J. 2007. Selective ablation of proliferating 
microglial cells exacerbates ischemic injury in the brain. J Neurosci 27:2596-2605. 
30. Marin-Teva JL, Dusart I, Colin C, Gervais A, van RN, Mallat M. 2004. Microglia promote the death of 
developing Purkinje cells. Neuron 41:535-547. 
3 1 .  Markovic DS, Glass R ,  Synowitz M,  Rooijen N, Kettenmann H .  2005. Microglia stimulate the invasiveness of 
glioma cells by increasing the activity of metalloprotease-2. J Neuropathol Exp Neurol 64:754-762. 
32. Martens U, Capito B, Wree A 1 998. Septotemporal distribution of [3H]MK-801 , [3H]AMPA and [3H]Kainate 
binding sites in the rat hippocampus. Anat Embryo! (Bert) 1 98:195-204. 
33. Neumann H, Takahashi K. 2007. Essential role of the microglial triggering receptor expressed on myeloid 
cells-2 (TREM2) for central nervous tissue immune homeostasis. J Neuroimmunol 1 84:92-99. 
34. Nimme�ahn A, Kirchhoff F, Helmchen F. 2005. Resting microglial cells are highly dynamic surveillants of 
brain parenchyma in vivo. Science 308:1 31 4-1 318. 
35. O'Donnell SL, Frederick TJ, Krady JK, Vannucci SJ, Wood TL. 2002. IGF-1 and microglia/macrophage 
proliferation in the ischemic mouse brain. Glia 39:85-97. 
36. Pozzo Miller LD, Mahanty NK, Connor JA, Landis DM. 1 994. Spontaneous pyramidal cell death in 
organotypic slice cultures from rat hippocampus is prevented by glutamate receptor antagonists, 
Neuroscience 63:471-487. 
37. Rossum Dv, Hanisch UK. 2004. Microglia. Metab Brain Dis 1 9:393-41 1 .  
38. Sakaguchi T, Okada M, Kuno M, Kawasaki K. 1 997. Dual mode of N-methyl-D-aspartate-induced neuronal 
death in hippocampal slice cultures in relation to N-methyl-D-aspartate receptor properties. Neuroscience 
76:4 1 1 -423. 
39. Schauwecker PE. 2002. Modulation of cell death by mouse genotype: differential vulnerability to excitatory 
amino acid-induced lesions. Exp Neurol 1 78:21 9-235. 
40. Schwartz M, Butovsky 0, Bruck W, Hanisch UK. 2006. Microglial phenotype: is the commitment reversible? 
Trends Neurosci 29:68-74. 
41 . Shein NA, Grigoriadis N, Horowitz M, Umschwief G, Alexandrovich AG, Simeonidou C, Grigoriadis S, 
Touloumi 0, Shohami E. 2008. Microglial involvement in neuroprotection following experimental traumatic 
brain injury in heat-acclimated mice. Brain Res 1 244:1 32-141 . 
42. Stoppini L, Buchs PA, Muller D. 1 991 .  A simple method for organotypic cultures of nervous tissue. J 
Neurosci Methods 37:173-182. 
43. Strasser U, Fischer G. 1 995. Quantitative measurement of neuronal degeneration in organotypic 
hippocampal cultures after combined oxygen/glucose deprivation. J Neurosci Methods 57:177-1 86. 
44. Streit WJ. 2002. Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 40: 1 33-1 39. 
45. Streit WJ. 2006. Microglial senescence: does the brain's immune system have an expiration date? Trends 
Neurosci 29:506-51 0. 
46. Turrin NP, Rivest S. 2006. Tumor necrosis factor alpha but not interleukin 1 beta mediates neuroproteclion 
in response to acute nitric oxide excitotoxicity. J Neurosci 26:143-1 51 .  
47. Van Rooijen N, Sanders A 1 994. Liposome mediated depletion of macrophages: mechanism of action, 
preparation of liposomes and applications. J lmmunol Methods 174:83-93. 
48. Vomov JJ, Tasker RC, Coyle JT. 1 991 .  Direct observation of the agonist-specific regional vulnerability to 
glutamate, NMDA, and kainate neurotoxicity in organotypic hippocampal cultures. Exp Neurol 1 14:1 1 -22. 
49. Won SJ, Ko HW, Kim EY, Park EC, Huh K, Jung NP, Choi I ,  Oh YK, Shin HC, Gwag BJ. 1 999. Nuclear 
factor kappa B-mediated kainate neurotoxicity in the rat and hamster hippocampus. Neuroscience 94:83-91 .  
50. Xapelli S, Bernardino L, Ferreira R, Grade S, Silva AP, Salgado JR, Cavadas C, Grouzmann E, Poulsen FR, 
Jakobsen B, Oliveira CR, Zimmer J, Malva JO. 2008. Interaction between neuropeptide Y (NPY) and brain­
derived neurotrophic factor in NPY-mediated neuroprotection against excitotoxicity: a role for microglia. Eur 










Cl-· APTE-8 '3 -------- - - -- -
ABSTRACT 
The chemokine CXCL 10 and its receptor CXCR3 have been implicated in various CNS 
pathologies and their expression has been demonstrated in both neurons and glia cells. 
Interference with CXCL 10/CXCR3 signaling alters the onset and progression of 
pathological signs in various CNS disease models. However, the mechanism and cell­
types involved in CXCL 1 0/CXCR3 signaling under pathological conditions are far from 
understood. Here, we investigated the potential role for CXCL 10/CXCR3 signaling in 
neuronal cell death and glia activation in response to N-methyl-D-aspartic acid (NMDA)­
induced excitotoxicity in mouse organotypic hippocampal slice cultures (OHSCs). Our 
findings demonstrate that astrocytes rapidly express CXCL 1 0  in response to NMDA­
induced excitotoxicity. To determine the effect of CXCL 10 on NMDA-induced neuronal 
cell death we prepared OHSCs derived from CXCL 10-deficient (CXCL 10-11 and CXCR3-
deficient (CXCR3-'-) mice and subsequently exposed these slice cultures to 0 (control), 
10, 15, 25 or 50 µM NMDA. In the absence of CXCL 10 or CXCR3, neuronal cell death in 
the hippocampal regions CA 1 and CA3 was attenuated in response to NM DA-treatment 
when compared to wild type conditions. In contrast, neuronal cell death in the DG region 
was enhanced in both CXCL 10-1- and CXCR3_,_ OHSCs in response to a high (50 µM) 
NMDA-concentration. Furthermore, we show that in the absence of microglia these 
differential changes in neuronal vulnerability between CXCR3_,_ and wild type OHSCs are 
fully abrogated, suggesting a prominent role for microglia in this process. Taken 
together, our results identify a region-specific role for CXCL 1 0/CXCR3 signaling in 
neuron-glia and glia-glia interactions under pathological conditions. 
,8 
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INTRODUCTION 
Excitotoxicity is a pathological process in the central nervous system (CNS) by which 
persistent activation of glutamate receptors by high extracellular glutamate levels leads 
to the progressive loss of neurons (Arundine and Tymianski, 2003; Choi and Rothman, 
1990). Excitotoxicity has been associated with several neurological disorders such as 
ischemia (Arundine and Tymianski, 2004), multiple sclerosis (MS) (Gonsette, 2008), 
Parkinson's disease (Henchcliffe and Beal, 2008), Alzheimer's disease (Walton and 
Dodd, 2007), Huntington's disease (Fan and Raymond, 2007), amyotrophic lateral 
sclerosis (Van Damme et al., 2005) and epilepsy (Vincent and Mulle, 2009). Persistent 
activation of neuronal glutamate receptors provokes a lethal increase in intracellular 
calcium levels which results in activation of numerous enzymes that damage neuronal 
structure and induces formation of free radicals, ultimately leading to cell death 
(Arundine and Tymianski, 2003; Choi, 1988). 
For a long time, the concept of excitotoxicity-induced neuronal cell death has been 
viewed as a result of solely endogenous processes but recent data suggest a major role 
for glial cells in excitotoxic insults. Microglia, the immunocompetent cells of the CNS, 
have been shown to rapidly respond to excitotoxicity by proliferation and morphological 
changes enabling them to migrate towards sites of neuronal injury to exert their function 
(Acarin et al. ,  1996; Heppner et al., 1998). Interestingly, inhibition of microglia activity 
has been shown to considerably affect the extent of excitotoxicity-induced 
neurodegeneration (Kohl et al., 2003; Lalancette-Hebert et al., 2007; Dehghani et al., 
2003; Tikka and Koistinaho, 2001), suggesting a prominent role for these cells in 
excitotoxicity. However, the source and type of signals for excitotoxicity-induced 
microglial activation are largely unknown. 
In the last years, chemokines have emerged as potential modulators of glia activity under 
pathological conditions (Cartier et al., 2005; De Haas et al., 2007). Chemokines are 
small cytokines (8-12 kDa) that are predominantly known for their ability to mediate 
directed migration of various cell-types. Of interest here is the chemokine CXCL 10, 
which mediates its actions through chemokine receptor CXCR3 (Loetscher et al., 1998). 
CXCL 10 is a well known chemo-attractant for CXCR3-positive immune cells in the 
periphery including specific subsets of circulating NK cells and macrophages, dendritic 
cells and activated CD4+ T-cells and has therefore been implicated in the modulation of 
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al., 1997; Liu et al., 2005). In the CNS, enhanced expression of CXCL 1 0  has been 
demonstrated in various pathologies such as ischemia (Wang et al., 1 998), Alzheimer's 
disease (Xia et al., 2000; Galimberti et al., 2006), MS (Balashov et al., 1 999; Simpson et 
al., 2000; Sorensen et al., 1 999), and human immunodeficiency virus (HIV)-encephalitis 
(Sanders et al., 1 998; Cinque et al., 2005). Depending on the type of insult, CXCL 10  has 
been predominantly found expressed in neurons (Rappert et al., 2004; Wang et al., 
1 998) and in astrocytes surrounding primary lesions (Balashov et al., 1 999; Omari et al., 
2005; Simpson et al., 2000; Tanuma et al., 2006; Wang et al., 1 998; Xia et al., 2000), 
while CXCR3 expression has been demonstrated in microglia (Biber et al., 2001 ;  Biber et 
al., 2002; De Haas et al., 2008; Dijkstra et al., 2004; Li et al., 2006; Rappert et al., 2004; 
Tanuma et al., 2006) and in reactive astrocytes (Goldberg et al., 2001 ;  Omari et al., 
2005; Simpson et al., 2000; Tanuma et al., 2006). Moreover, CXCL 10  has been shown 
to induce activation and migration of CXCR3-positive microglia in vitro (Biber et al., 2002; 
Rappert et al., 2002) and proliferation in primary astrocyte cultures (Flynn et al., 2003). 
These findings suggest that CXCL 1 0  might provide a signal in the CNS that is involved in 
the activation and/or recruitment of local glia cells under pathological conditions. 
Interestingly, interfering with CXCL 10/CXCR3 signaling in various CNS disease models 
has been shown to alter the progression and severity of disease symptoms (reviewed in 
Liu et al., 2005). Blocking of CXCL 10  with specific antibodies reduced neuronal 
apoptosis in spinal cord injury (Glaser et al., 2006), suggesting a pro-inflammatory role 
for CXCL 1 0. In line with these findings, it has been shown that administration of anti­
CXCL 1 0  decreased the clinical and histological disease incidence in a model for MS, 
known as experimental autoimmune encephalomyelitis (EAE) (Fife et al., 2001 ). In 
contrast, induction of EAE in knockout animals for CXCL10 or CXCR3 provoked more 
severe clinical and histological symptoms and earlier onset compared to wild type 
controls (Klein et al., 2004; Liu et al., 2006; Muller et al. ,  2007). Apart from variations in 
experimental design, these conflicting observations suggest that CXCL 10  and its 
receptor CXCR3 have multiple functions in the development of CNS pathologies. 
In summary, expression of CXCL 1 0  and CXCR3 in both glia and neuronal cells has been 
associated with the clinical signs of several excitotoxicity-related CNS disorders. 
Furthermore, in vitro findings suggest a role for this chemokine-receptor couple in the 
communication between damaged neurons and glia cells. However, the proposed role 
for CXCL 1 0  in neuron-glia and glia-glia signaling under pathological conditions is far 
from understood. Therefore, we have studied the implication of CXCL10/CXCR3 
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signaling on neuronal cell death and glia activation in an ex vivo model for excitotoxicity, 
known as N-methyl-D-aspartic acid (NMDA)-induced excitotoxicity, in mouse 
hippocampal slice cultures. 
EXPERIMENTAL PROCEDURES 
Animals 
All experiments have been approved by the Dutch animal experimental committee. The 
C57BU6J (Harlan) and CXCR3-deficient (CXCR3_,_) mice were housed and handled in 
accordance with the guidelines of the central animal laboratory (CDL) facility of 
Groningen. The CXCR3_,_ mice were kindly provided by B. Lu, MD, and Prof. C. Gerard, 
MD/PhD (Children's Hospital, Harvard Medical School, Boston (MA). The CXCL 10-
deficient (CXCL 10·1·) mice were kindly provided by Prof. A.R. Thomsen, MD/PhD 
(Experimental Virology, Department of International Health, Immunology & Microbiology, 
University of Copenhagen, Copenhagen, Denmark). 
Chemicals 
Culture media and supplements were all obtained from GIBCO® (lnvitrogen Corporation; 
Breda, The Netherlands), unless mentioned otherwise. Recombinant murine CXCL 10 
was obtained from PeproTech® (London, United Kingdom). 
Preparation of organotypic hippocampal slice cultures 
Organotypic hippocampal slice cultures (OHSCs) were prepared as described with minor 
modifications (Stoppini et al., 1991). In brief, OHSCs were prepared from 2-3 day old 
C57BU6J, CXCL10_,_ and CXCR3_,_ mouse pups under sterile conditions. After 
decapitation, the brains were rapidly removed and the hippocampi from both 
hemispheres were acutely isolated in ice cold serum-free Hank's Balanced Salt Solution 
(HBSS), supplemented with 0.5% glucose (Sigma) and 15 mM HEPES. Isolated 
hippocampi were cut into 350-375 µM thick slices using a tissue chopper (Mcilwain) and 
were transferred to 0.4 µM culture plate inserts (Millipore, PICM03050). These culture 
plate inserts, containing four to six slices, were placed in six-well plates containing 1.2 ml 
of culture medium per well. Culture medium (pH 7.2) consisted of 0.5x minimum 
essential medium containing 25% heat-inactivated horse serum, 25% BME basal 
medium without L-glutamine, 2 mM glutamax and 0.65% glucose (Sigma). The slice 
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cultures were kept at 35°C in a humidified atmosphere (5% CO2) and the culture medium 
was refreshed the first day after preparation and every consecutive two days. 
Depletion of microg/ia from OHSCs using clodronate-liposomes 
Multi-lamellar CL2MDP (clodronate)-liposomes (Lip-CL) were prepared as described 
elsewhere (Van Rooijen and Sanders, 1 994). Clodronate was a gift of Roche Diagnostics 
(Mannheim, Germany), phosphatidylcholine (Lipoid EPC) was obtained from Lipoid 
(Ludwigshafen, Germany) and cholesterol was purchased from Sigma (USA). Depletion 
of microglia was achieved by incubation of freshly prepared OHSCs with approximately 
0.5 mg/ml Lip-CL solution (1 : 1 0  liposome dilution in standard slice culture medium) for 
24 hours at 35°C. Subsequently, the slice cultures were carefully rinsed in PBS (35°C) to 
wash away residual liposomes and placed on fresh culture medium. After depletion the 
medium was refreshed every two days. Liposomes containing PBS (Lip-PBS) and PBS 
served as negative controls. 
Induction of excitotoxicity in OHSCs 
After 6 days in culture, OHSCs were placed in culture medium containing 0, 1 0, 1 5, 25 or 
50 µM N-methyl-D-aspartic acid (NMDA; Sigma) for 4 hours to induce excitotoxicity and 
subsequently the medium was replaced with standard culture medium. NMDA-treated 
OHSCs were kept in culture for maximally 48 hours after the NMDA challenge, 
depending on the experiment. 
lmmunohistochemistry 
For immunohistochemical analysis, control and NMDA-challenged OHSCs were shortly 
rinsed in phosphate-buffered saline (PBS, 35°C) and fixated with 4% paraformaldehyde 
overnight at 4 °C. After fixation, the slice cultures were rinsed in PBS and pre-incubated 
with 5% normal goat serum (NGS; Vector) in PBS containing 0.3% Triton X-1 00 (PBS
+
) 
for at least one hour. Subsequently, the slice cultures were incubated with the 
appropriate primary antibodies overnight in 1 % NGS/PBS
+ 
at 4 °C. The following primary 
antibodies were used: rabbit-anti-lba1 ( 1 : 1 000; Waka 01 9-1 9741)  for detection of 
microglia, mouse-anti-GFAP (1 :600; Chemicon MAB3402) for detection of astrocytes 
and mouse-anti-NeuN ( 1 : 1000; Chemicon MAB377) for detection of neuronal nuclei. 
Secondary antibodies used were donkey-anti-mouse-Alexa488 (Molecular Probes) for 
NeuN, donkey-anti-rabbit-Alexa633 (Molecular Probes) for lba1 and goat-anti-mouse-
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Cy3 (Jackson IR Laboratories) for GFAP. Analysis of the slice cultures was done by 
confocal imaging using a Leica SP2 AOBS system (Leica Microsystems). 
Quantification of neuronal cell death 
To determine neuronal cell death in response to NMDA-induced excitotoxicity, OHSCs 
were incubated with 5 µg/ml propidium iodide (Pl) during and up to 24 hours after the 
NMDA-challenge (Pozzo Miller et al. ,  1994; Vornov et al., 1991). Confocal images of the 
neuronal layers were taken mid-section at 40x magnification and both NeuN• and 
NeuN+/PI+ cells were quantified manually using lmageJ software. The percentage of 
neuronal cell death was determined by the number of NeuN+/p( cells divided by the total 
number of NeuN+ cells per neuronal layer. 
Quantitative polymerase chain reaction (QPCR) 
For RNA analysis, OHSCs (6 slice cultures per condition) were lysed in guanidinium 
isothiocyanate/ monopthiolglycerol buffer (both from Sigma) and total RNA was extracted 
and precipitated with a one-chloroform-phenol step (Chomczynski and Sacchi, 1987). 
The quality and quantity of the total RNA were determined with the Agilent 2100 
bioanalyzer and the NanoDrop® ND-1000. RNA integrity number (RIN) values were 
between 9.9 and 8.8 and the 260/280 nm ratios around 1.9. 1 µg of total RNA was 
transcribed into cDNA as described previously (Biber et al., 1997). Amplification 
reactions were performed in a total volume of 10 µI containing 0.8 µI cDNA solution, 5.0 
µI TaqMan® universal PCR master mix, 0.5 µI TaqMan® primer-probe (Applied 
biosystems: 13-actin, Mm00607939_s1 and CXCL 10, Mm00445235_m1) and 3.7 µI pure 
water (Sigma). Reactions were run in triplets on the ABI Prism® 7900 HT real time PCR 
instrument. After 15 minutes at 95°C, the cDNA samples were run for 40 cycles, 
consisting of 15 seconds at 95°C for denaturation and 1 min at 60°C for annealing and 
elongation. Threshold cycles were determined manually by setting thresholds for 
fluorescence intensity. Relative gene expression levels were analysed by the 2-LlllCT 
method, using 13-actin as a reference gene (Livak and Schmittgen, 2001). The 
amplification efficiency was verified by linear regression with the fluorescence per cycle 
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In situ hybridisation (/SH) followed by immunohistochemistry 
The CXCL 10 PCR product (147 bp) was cloned into a dual PCRII vector (lnvitrogen) and 
linearized. CXCL 10 sense- and antisense probes were synthesised by run-off 
transcription with SP6 or T7 RNA polymerase and digoxigenin (DIG)-conjugated UTP 
according to manufaturers protocol (Roche). 
Control and NMDA-challenged OHSCs were shortly rinsed in phosphate-buffered saline 
(PBS, 35°C) and fixated with 4% paraformaldehyde (PFA) in 0.1 borate buffer (pH 9.5) 
overnight at 4°C. After rinsing in ice-cold KPBS, fixated OHSCs were dehydrated with 
20% sucrose in KPBS for 10 hours. Then, the OHSCs were carefully removed from the 
culture plate inserts and cut in 10 µM sections using a Leica CM3050 S cryostat (Leica 
Microsystems). Subsequently, the sections were mounted on APES (Sigma)-coated 
glass slides, air-dried and post-fixated with 4% PFA for 30 minutes at 37°C. After post­
fixation, the sections were rinsed in KPBS and digested with 0.5 µg/ml proteinase K 
(Sigma) for 30 minutes at 37°C. Then, the sections were rinsed in 2x SSC (300 mM 
NaCl, 30 mM sodium citrate, pH 7.0), dehydrated in an ethanol serie and air-dried. 
Subsequently, the sections were hybridized overnight at 60°C in 1x Denhardt's solution, 
containing 10 mM Tris (pH 8.0), 0.3 M NaCl, 50% formamide, 1 mM EDTA, 0.05% tRNA, 
10% dextran sulfate and 0.6 ng/µI of the DIG-coupled RNA probe. After hybridization, the 
sections were treated with 10 µg/ml RNase A (Sigma) at 37°C for 30 minutes and 
washed in 0.1x SSC at 60°C. For immunodetection of the DIG-labelled RNA-RNA 
complexes, the slides were pre-incubated with 0.1 M Tris/0.15 M NaCl (buffer 1 ;  pH 7.5) 
containing 2% blocking reagent (Roche) and subsequently labelled with anti-DIG-alkaline 
phosphatase (AP; Roche, 1:500) for 2 hours at room temperature (RT) in buffer 1, 
containing 1% blocking reagent. After labelling, the slides were thoroughly rinsed and 
equilibrated in an alkaline buffer solution (0.1 M Tris, 0.1 M NaCl, 0.05 M MgCl2.6H2O; pH 
9.5). The AP-conjugates were visualized by adding 0.34 mg/ml nitroblue tetrazoleum and 
0.17 mg/ml 5-bromo-4-chloro-3-indolyl phospatase (Roche) in alkaline buffer solution, 
supplemented with 0.24 mg/ml levamisole (Sigma). Finally, the slides were mounted with 
glass coverslips using glycerol jelly and brightfield images were taken with an Olympus 
BX50 system, equipped with an Olympus DP70 camera. 
For CXCL 10 ISH combined with immunohistochemistry, the cover slips were removed by 
gentle shaking in H2O and incubated overnight with primary antibodies against microglia 
(lba1, Waka), astrocytes (GFAP, Chemicon) or neurons (NeuN, Chemicon) in 
PBS/1%NGS at 4°C. After short rinsing steps in PBS, the sections were incubated with 
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the appropriate biotinylated secondary antibodies (1 :400, Vector) for one hour at RT. 
Antibody-antigen reactions were detected using the biotin-streptavidin method 
(Vectastain® ABC-kit, Vector Labs) and the complex was visualized with 
diaminobenzidin (OAB)/H2O2. 
Western blot analysis 
After a short rinse in PBS (35°C), both control and NMOA-challenged OHSCs (12 slice 
cultures per condition) were lysed at set time-points in 200 µI ice-cold RIPA buffer (PBS, 
containing 0.1 % Nonidet P40, 0.5% sodium deoxylate, 0.1 % SOS and proteinase 
inhibitors (Complete Mini; Roche)). Subsequently, one volume of 2x sample buffer 
(175mM Tris-HCI (pH 6.8) with 4% SOS, 4M urea, 4.5% glycerol, 0.05M OTT and 0.01% 
bromophenol) was added and the samples were heated for 5 minutes at 95°C. 30 µg of 
total protein was loaded on a 10% SOS polyacrylamide gel and transferred to a Hybond­
ECL nitrocellulose membrane (Amersham Biosciences). Next, the membranes were 
blocked with Odyssey® Blocking Buffer (OBB) in PBS (1:1) for one hour at RT and 
subsequently incubated with rabbit-anti-mouse CXCL 10 (1: 1000, Peprotech) and mouse­
anti-11-actin (1:8000, Abeam) in 1:1 OBB/PBS, containing 0.1% Tween-20 
(overnighU4°C). 
After four rinsing steps with PBS/0.1 % Tween-20 (PBS-T), the membranes were 
incubated with donkey-anti-rabbit IROey
"' 
800CW and donkey-anti-mouse IROey
™ 
680 
(both 1 :8000; LI-COR®) in PBS-T for one hour at RT. Labeled proteins were visualized 
by paired exposure at 700 nm and 800 nm using the Odyssey® Infrared Imaging System 
(LI-COR® Biosciences GmbH). 
Rapid isolation of microglia and flow cytometry 
To isolate microglia from OHSCs, the slice cultures were removed from the culture 
membrane using a Pasteur pipette and directly triturated in HBSS, containing 0.1 % 
glucose and 15 mM HEPES. Single-cell suspensions were filtered using a 70 µm cell 
strainer (BO Biosciences) and rinsed in PBS. Then, the cells were pelleted at 1000 x g 
for 10 min at 4°C. These cell pellets were resuspended in 3.3 ml ice-cold 75% Percell 
(GE Healthcare 17-0891) in PBS and transferred into 12 ml polystyrene tubes. Then, the 
cell suspension was gently over-layered with 5 ml ice-cold 25% Percoll and subsequently 
with 3 ml PBS. The density gradient was centrifuged at 800 x g (with minimal 
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layer at the 0-25% interface was carefully removed with a pipette and the cells at the 25-
75% interface were collected with a fresh pipette. To pellet these cells, the collected 
suspension was diluted threefold with PBS and centrifuged at 1000 x g for 10 min at 4°C. 
The cell pellet was resuspended in PBS, containing 10% normal rat serum (lnvitrogen, 
10710C) and anti-CD16/32 (eBioscience 14-0161, 1:100) for flow cytometric analysis. 
Next, the microglia were stained for phycoerythyrin-coupled monoclonal anti-mouse 
CXCR3 (R&D, FAB1685P) or concentration-matched isotype lgG2A control 
(eBioscience, 12-4321) for 20 minutes at 4°C in PBS containing 1% FCS. Cell-size, 
granularity and fluorescence intensity were analyzed by flow cytometry using a 488-nm 
laser FACSCalibur (Becton Dickinson), supported by CellQuest software (Becton 
Dickinson) and the acquired data was analyzed using WinMDI version 2.9 (Joseph 
Trotter). 
Statistical Analysis 
Data are represented as the mean ± standard error of the mean (SEM). Statistical 
comparison between groups was performed using one-way analysis of variance 
(ANOVA) with Gabriel's posthoc test and p-values smaller than 0.05 were considered 
significant. All statistical tests were performed in SPSS version 14.0.2 (SPSS Inc., 
Chicago). 
RESULTS 
NMDA-induced excitotoxicity in mouse hippocampal slice cultures 
In order to determine the role of CXCR3 and its ligand CXCL 10 in excitotoxicity we 
devised a model for NMDA-induced excitotoxicity using mouse organotypic hippocampal 
slice cultures (OHSCs). After six days in culture, slice cultures showed preserved 
hippocampal structure with intact neuronal layers CA 1, CA3 and DG (Fig. 3.1A). While 
control slice cultures showed almost no cell death in the three neuronal regions (CA 1; 
0.7 ± 0.2%, CA3; 0.8 ± 0.3%, DG; 1.6 ± 0.3%, see also Fig. 3.1 B), treatment with NMDA 
for 4 hours and subsequent culturing for 24 hours in standard culture medium clearly 
induced cell death, as determined by Pl-uptake. Pl+-cells co-localized with the neuronal 
marker NeuN, showing that NMDA specifically induced cell death in neurons (Fig. 3.1C, 
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Figure 3.1. NMDA-induced excitotoxicity in mouse hippocampal slice cultures. Hippocampal 
slice cultures were challenged with increasing concentrations of O (control), 10, 15, 25 and 50 µM 
NMDA to induce excitotoxicity. After six days in culture, control slice cultures showed preserved 
hippocampal structure with intact neuronal layers CA 1, CA3 and DG as determined by neuronal 
nuclear marker NeuN (A, in green). Cell death was determined by propidium iododide (Pl, in red) 
uptake. Whereas almost no cell death was detected in control slice cultures (>1%, B), treatment 
with NMDA for 4 hours and subsequent culturing for 24 hours clearly induced cell death (C), which 
was restricted to the neuronal layers CA 1, CA3 and DG and co-localized with NeuN (C, white 
arrow). The percentages of neuronal cell death per subregion (CA 1/CA3/DG) were quantified as the 
number of NeuN•/pJ' cells divided by the total number of NeuN• cells with the various NMDA 
concentrations in µM on the x-axis. Note that individual hippocampal regions showed selective 
vulnerability towards NM DA-treatment with CA 1 >CA3>DG, which was dependent on the 
concentration used. Data are a summary of three separate experiments with at least five slice 
cultures per condition. *p<0.05, **p<0.01, ***p<0.001, ANOVA. Bars indicate mean ± SEM. Scale 
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arrow). The percentage of neuronal cell death in response to 0, 10, 15, 25 and 50 µM 
NMDA was quantified as the number of NeuN+/PI+ cells divided by the total number of 
NeuN+ cells per region (Fig. 3.1 D). Note that neurons from the different regions showed 
selective vulnerability towards NM DA-induced excitotoxicity (CA 1 >CA3>DG). 
NMDA-excitotoxicity induces CXCL 10 expression in reactive astrocytes 
Next, we determined the expression of CXCL 10 in NM DA-exposed slice cultures. Real­
time PCR (rt-PCR) analysis of whole slice culture total RNA lysates showed clear 
upregulation of CXCL10 mRNA in response to NMDA-treatment (Fig. 3.2A) with a 
significant twelve-fold increase 8 hours after induction (p=0.002). CXCL 10 mRNA levels 
were back at control levels 24 hours after the NMDA-treatment (p=1.000). Western Blot 
analysis of whole slice culture protein lysates (Fig. 3.28) showed clear upregulation of 
CXCL 10 protein as soon as 4 hours up to 24 hours after excitotoxicity-induction with a 
clear peak at 10 hours. CXCL 10 protein was almost non-detectable 48 hours after the 
NMDA-treatment. To localize the cellular source for CXCL 10 we combined non­
radioactive in situ hybridization (ISH) for CXCL 10 mRNA with immunohistochemistry for 
NeuN (neurons), lba1 (microglia) and GFAP (astrocytes). As rt-PCR analysis revealed a 
significant increase in CXCL 10 mRNA expression 8 hours after excitotoxicity-induction 
(Fig. 3.2A), we used slice cultures which were fixated at this time-point. ISH for CXCL 10 
mRNA alone revealed multiple CXCL 10+-cells in NMDA-treated slice cultures (Fig. 3.2C, 
white arrowheads). These CXCL 10+-cells were predominantly located in the stratum 
radiatum, stratum lacunosum-moleculare and the hilar area (Fig. 3.2E, closed arrows), 
although some CXCL 10+-cells were also observed inside the suprapyramidal and 
granular cell layers. Slice cultures hybridized with a sense probe were devoid of signal 
(Fig. 3.20). Interestingly, ISH for CXCL 10 mRNA (Fig. 3.2E, closed arrows) in 
combination with GFAP-immunohistochemistry showed 100% overlap (Fig. 3.2F, open 
arrows), demonstrating that the CXCL 1 0+-cells are astrocytes. CXCL 10-positivity was 
pre-dominantly found in morphologically "reactive" astrocytes, as determined by 
morphology and upregulation of GFAP expression (Fig. 3.2F). In contrast, co-localization 
for CXCL 10 mRNA with NeuN- or lba1 immunohistochemistry was never observed (data 
not shown). 
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Figure 2. NMDA-excitotoxicity Induces CXCL 10 expression in astrocytes. (A) Real-time PCR 
analysis of whole slice culture lysates reveals upregulation of CXCL 10 mRNA in response to 
NMDA-excitotoxicity as soon as 4 hours after induction with a twelve fold increase at 8 hours 
(p=0.002). 24 hours after the NMDA-challenge CXCL 10 mRNA expression was reduced to control 
levels (p=1.000). Data are a summary of four individual experiments. Bars indicate mean ± SEM, 
""p<0.01, Student's t-test. (B) Western blot analysis of whole slice culture lysates shows clear 
upregulation of CXCL 1 O protein (in green) from 4 hours up to 24 hours in response to the NMDA­
treatment. CXCL 10 expression was reduced to almost non-detectable levels at 48 hours after the 
challenge. Expression of ,B-actin (in red) was stable in all samples and therefore served as a 
positive control. Western blot results are a representation of three individual sets of experiments. 
(C-F) ISH experiments revealed multiple CXCL 1 o• cells in NM DA-treated slice cultures (C, white 
arrows) which were scattered throughout the slice culture. Slice cultures hybridized with a sense 
probe were devoid of signals (D). ISH experiments for CXCL 10 (E, black arrows) in combination 
with immunohistochemistry for GFAP (F) reveals 100% overlap (F, open arrows), showing that 
these CXCL 10• cells are astrocytes. (C) and (D) are phase contrast images, scale bars indicate 100 
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Figure 3.3 (right). Regional differences in cell death in NMDA-treated CXCL 10
.,. slice cultures 
compared to wild types. Graphs represent the percentages of neuronal cell death per 
hippocampal region (CA 1. CA3, DG) in response to 0, 10, 15, 25 and 50 µM NMDA. CXCL 1 o.,· 
OHSCs (open bars) showed significantly lower percentages in cell-death in response to 10 µM 
NMDA in the CA1 region (p=0.035), and in response to 15 µM NMDA (p=0.001) and 25 µM NMDA 
(p<0.001) in the CA3 region compared to wild types (closed bars). Treatment with 50 µM NMDA 
resulted in significantly higher cell death in the DG of CXCL 10·1• OHSCs compared to wild types 
(p=0.041). Administration of 10.a M recombinant CXCL 10 (grey bars) directly after NMDA-treatment 
"rescued" the effects seen in CXCL 1 o.,· OHSCs as it resulted in an increase in cell death in the CA 1 
and CA3, but not in the DG. This CXCL 10-mediated increase in cell-death in CXCL 10.,. OHSCs 
equalled wild type conditions. Data are a summary of three separate experiments with at least five 
slice cultures per condition. Bars indicate mean ± SEM. "p<0.05, ··p<0.01, ""p<0.001, ANOVA. 
Regional changes in NMDA-induced cell death in CXCL 10-l·s/ice cultures 
To determine the role of astrocytic CXCL 10 on NMDA-induced neuronal cell death, we 
prepared hippocampal slice cultures from CXCL 10-deficient (CXCL 10"1") mice and 
exposed these slice cultures to O (control), 10, 15, 25 and 50 µM NMDA to induce 
excitotoxicity. After six days in culture, CXCL 10+ slice cultures showed preserved 
hippocampal structure, and the basal rate of neuronal cell death in the three 
hippocampal regions was equal to control wild type conditions (CA1; 1.2 ± 0.3%, CA3; 
1.6 ± 0.3%, DG; 1.9 ± 0.5%). Interestingly, in response to NMDA-treatment, regional 
differences in neuronal cell death were observed when compared to wild type conditions 
(Fig. 3.3). In the CA1 and CA3 region of CXCL 10+ slice cultures (Fig. 3.3, white bars) a 
significant decrease in neuronal vulnerability to NMDA was observed compared to wild 
types (Fig. 3.3, black bars), which was dependent on the NMDA-concentration. Neuronal 
cell death in response to 1 0  µM NMDA was significantly lower in the CA1 (38.8 ± 8.3%) 
compared to wild type conditions (67.1 ± 16.3%, p=0.035). In the CA3 region a decrease 
in neuronal cell death was observed in response to 15 µM NMDA (11.2 ± 1.9% versus 
41.7 ± 11.3% in wild types, p=0.001) and in response to 25 µM NMDA (28.6 ± 5.6% 
versus 79.9 ± 8.6% in wild types, p<0.001). 
Surprisingly, the detrimental effect of CXCL 10 observed in the CA 1 and CA3 regions 
was not detected in the DG in response 10-25 µM NMDA (Fig. 3.3; DG). In contrast, we 
observed a significant increase in neuronal cell death in the DG in response to 50 µM 
NMDA (53.3 ± 7.3% versus 30.7 ± 4.1% in wild types, p=0.041 ), suggesting that the 
presence of CXCL 10 in wild type slice cultures has a protective effect on DG neurons at 
a high (50 µM) NMDA concentration. 
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Figure 3.4 (right). Regional differences in cell death in NMDA-treated CXCR3·'· slice cultures 
compared to wild types. Graphs represent the percentages of neuronal cell death per 
hippocampal region (CA1, CA3, DG) in response to 0, 10, 15, 25 and 50 µM NMDA. Like in 
CXCL 104• slice cultures, CXCR3·'· slice cultures (open bars) show significantly lower percentages in 
cell death in the CA1 region In response to 1 0  µM NMDA (p<0.001), and in the CA3 region in 
response to 15 µM NMDA (p<0.001) and 25 µM NMDA (p=0.038) compared to wild types (closed 
bars). Also here, a significant increase in neuronal cell death was observed at 50 µM NMDA in the 
DG region of CXCR3-1- OHSCs (p<0.001). Administration of 10·9 M recombinant CXCL10 directly 
after NMDA-treatment had no effect in CXCR34• OHSCs at any NMDA-concentration. Data are a 
summary of three separate experiments with at least five slice cultures per condition. Bars indicate 
mean ± SEM. 
0
p<0.05, .. p<0.01, -·p<0.001, ANOVA. 
Application of CXCL 10 to CXCL 10-1- slice cultures mimics wild type conditions 
Application of 10-8 M recombinant CXCL 10 to CXCL 10+ slice cultures directly after the 
NMDA-challenge (in the aim to "mimic" wild type conditions in response to NMDA) partly 
"rescued" the differences observed in CXCL 10-1- slice cultures compared to wild type 
conditions (Fig. 3.3, grey bars). In the CA1 region, application of CXCL10 directly after 
treatment with 10 µM NMDA resulted in a significant increase (p=0.015) in neuronal cell 
death in the CXCL 10+ slice cultures, which was equivalent to wild type conditions (64.2 
± 12.3% versus 67.1 ± 16.3% in wild types, p=1.000). In the CA3 region, the effect of 
CXCL 10 application was less pronounced after treatment with 15 µM NMDA in CXCL 1 f
f 
,_ slice cultures (18.5 ± 4.5% versus 41. 7 ± 11.3% in wild types, p=0.132). However, 
application of CXCL 10 after treatment with 25 µM resulted in a strong increase (p<0.001) 
in neuronal cell death in the CA3 region of CXCL 10-1• slice cultures, which again was 
equivalent to wild type conditions (58.2 ± 9.7% versus 79.9 ± 8.6% in wild types, 
p=0.277). 
In the DG region, application of CXCL 10 to CXCL 10-1- slice cultures directly after 
treatment with 10-25 µM NMDA had no significant effect on neuronal cell death in this 
region (Fig 3.3). However, neuronal cell death in the DG induced by 50 µM NMDA in 
CXCL10·1• slice cultures (46.5 ± 5.4%) was slightly decreased by application of CXCL10 
(44.7 ± 9.8%) and did not differ significantly anymore from wild type conditions (30.7 ± 
4.1 %, p=0.265). 
Regional changes in NMDA-induced cell death in CXCR3·1· slice cultures 
To verify that the effects of CXCL10 on NMDA-induced excitotoxicity observed in the 
CXCL10-1. slice cultures are mediated through CXCR3 we performed experiments in 
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CXCR3_,_ slice cultures (Fig. 3.4). Also here, a decrease in neuronal sensitivity towards 
NMDA was observed in the CA1 and CA3 region, which was similar compared to the 
effects seen in the CXCL 1 0_,_ slice cultures. In response to 1 0 µM NMDA, neuronal cell 
death in the CA1 of CXCR3_,_ slice cultures (open bars, 24.5 ± 5.5%) was significantly 
lower compared to wild types (black bars, 67.2 ± 16.3%, p<0.001). In addition, neuronal 
cell death in the CA3 was significantly lower upon treatment with 15 µM NMDA (3.3 ± 
1 .4% versus 41. 7 ± 11.3% in wild types, p<0.001)  and with 25 µM NMDA (55. 7 ± 6.6% 
versus 79.9 ± 8.6% in wild types, p=0.038). Similar to CXCL 10_,_ slice cultures, an 
increase in cell death was observed in the DG of CXCR3_,_ slice cultures in response to 
50 µM NMDA (Fig. 3.4; 47.9 ± 3.7% versus 30.7 ± 4.1% in wild types, p<0.001). 
Application of 10-s M recombinant CXCL 1 0  directly after the NMDA-insult (grey bars) for 
24 hours had no effect on the amount of neuronal cell death in CXCR3_,_ slice cultures at 
any condition, suggesting that the effects observed in CXCL 1 O_,_ slice cultures in 
response to CXCL 10 application are mediated through CXCR3. 
Activation of microg/ia coincides with regional differences in cell death in CXCR3-1- slice 
cultures 
Acutely isolated microglia from wild type slice cultures (6 DIV) clearly expressed CXCR3 
surface protein as determined by flow cytometry (Fig. 3.5A). Previous research has 
shown that microglia in vitro respond to CXCL 10 with intracellular calcium transients and 
migration, processes both mediated through CXCR3 (Biber et al., 2001; Biber et al., 
2002; Dijkstra et al., 2004; Rappert et al., 2004). Therefore, we hypothesized that 
abrogation of CXCR3-signaling could result in impaired microglia activation in CXCR3_,_ 
slice cultures ,  partly explaining the differences in neuronal cell death observed in 
CXCR3+ and wild type slice cultures. Treatment with 10 µM NMDA resulted in prominent 
cell death and local accumulation of morphologically activated microglia in the CA 1 
region of wild type slice cultures (Fig. 3.58). As discussed above, neurons in the CA1 
region of CXCR3_,_ slice cultures were less affected by treatment with 10 µM NMDA 
when compared to wild type conditions. The lower level of neuronal cell death in CXCR3-
,_ slice cultures coincided with lower numbers of activated microglia in this region (Fig. 
3.5C). At concentrations of 15-50 µM NMDA no distinction could be made in the number 
and activation of microglia in the CA 1 region between wild type and CXCR3_,_ slice 
cultures (data not shown). Similar effects were observed in the CA3 region in response 









rapid isolated microglia 
1 10 CXCR3-PE 
10• 
fluorescence intensity (log) 
1 0  µM NMDA 
lba1 
;_�'I ,.. , ,, . ,r: 
·' • �,!'· 
•,' 
. /'" : ,.-














1 5  µM NMDA 
� -
.. -- -<- -- - -. - - - -:--
50 µM NMDA 
•. ' 
Figure 3.5. Differences in neuronal cell death in CXCR3·'· slice cultures coincide with 
differences in microglia activation. Rapidly isolated microglia from OHSCs express CXCR3 
surface protein as determined by flow cytometry (A). Grey dotted line indicates isotype control, 
black line indicates CXCR3-PE. Confocal images 8-G show the correlation between neuronal cell 
death (NeuN, green/Pl ,  red) and microglia activation (lba1 , black) in wild type (B,D,F) and CXCR3.,. 
slice cultures (C,E,G) at 10 µM NMDA (CA1) ,  1 5  µM NMDA (CA3) and 50 µM NMDA (DG). Note 
that a decrease in neuronal cell death in CXCR3·'· slice cultures in the CA 1 region (C) in response to 
10 µM NMDA and in the CA3 region (E) in response to 1 5  µM NMDA coincides with a decrease in 
microglia activation compared to wild type conditions (B,D). In the DG region, no d ifferences in 
microglia activation could be detected between wild type (F) and CXCR3·1• slice cultures (G) in 
response to 50 µM NMDA, although neuronal cell death was higher in CXCR34' slice cultures. Scale 
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Figure 3.6. Application of CXCL 1 O alone does not induce microglia activation or neuronal cell 
death In wild type slice cultures. After 6 DIV, wild type OHSCs were treated with or without 10·5 M 
CXCL 10 for 24 hours together with 5 µg/ml Pl to asses the effects of CXCL 10 on microglia 
activation and neuronal cell death. In both control (A) and CXCL 10-treated slice cultures (B) no 
morphological activation of microglia (lba1) could be detected as all microglia showed typical 
·ramified" morphology (C, D). No effect of CXCL 10-treatment on neuronal (NeuN) cell death (Pl) 
was observed (F) as compared to control conditions (E). Scale bars indicate 300 µm (A-B, E-F) and 
30 µm (C, D). 
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3.5E) coincided with a decreased accumulation of microglia compared to wild type 
conditions (Fig. 3.50). Also here, no differences in microglia activation were observed in 
the CA3 region in response to 25 and 50 µM NMDA when compared to wild type 
conditions (data not shown). In the DG region, no differences in microglia activation were 
observed between wild type (Fig. 3.5F) and CXCR3·1· (Fig. 3.5G) slice cultures in 
response to 50 µM NMDA. These results indicate that morphological activation and 
accumulation of microglia at sites of neuronal cell death were not impaired in CXCR3-1. 
slice cultures, but rather coincided with the delayed neuronal cell death observed in 
these slice cultures. 
CXCL 10 per se does not induce microglia activation or cell death in wild type slice 
cultures 
Next, we determined whether application of CXCL 10 alone would induce activation of 
microglia and/or neuronal cell death in wild type slice cultures. Treatment of wild type 
slice cultures with 10-a M CXCL 10 for 24 hours did not induce morphological activation of 
microglia (Fig. 3.6B/O) when compared to untreated controls (Fig. 3.6NC). Microglia in 
CXCL 10-treated slice cultures maintained their ramified morphology with small somata 
and secondary/tertiary branching, suggesting that CXCL 10 per se is not sufficient to 
induce microglia activation (Fig. 3.60). In addition, treatment with 10·8 M CXCL 10 for 24 
hours did not induce neuronal cell death in wild type slice cultures (Fig. 3.6F), 
demonstrating that the presence of CXCL 10 per se, in the absence of an excitotoxic 
stimulus, does not induce neurodegeneration in this model. 
Differences in neuronal cell death between wild type and CXCR3·1· slice cultures are fully 
abrogated by ablation of microg/ia 
To further investigate the role of microglia in NMDA-induced excitotoxicity we depleted 
wild type- and CXCR3·1• slice cultures from their endogenous microglia population by 
treatment with liposomic clodronate (lip-CL), without affecting other cell-types (Marin­
Teva et al., 2004; Markovic et al., 2005), and subsequently exposed these slice cultures 
to various concentrations of NMDA (Fig. 3.7). The basal rate of neuronal cell death in 
microglia-depleted CXCR3+ slice cultures (CA1; 1.0 ± 0.7%, CA3; 1.2 ± 0.4%; DG; 4.0 ± 
2.0%, p=1.000) and wild type slice cultures (CA 1; 2.5 ± 0.6%, CA3; 3.1 ± 0.8%; DG; 4.1 







Figure 3.7 (right). Differences in NMDA-induced cell death between wild type and CXCR3·'· 
slice cultures are fully abrogated In the absence of m icroglia. Graphs represent the 
percentages of neuronal cell death per hippocampal region (CA 1, CA3, DG) in response to 0 
(CNTR), 10, 15, 25 and 50 µM NMDA in microglia-depleted CXCRa·'· (CXCR34• Lip-CL) and wild 
type (WT Lip-CL) slice cultures. Depletion of the microglia population by treatment with Lip-CL for 
24 hours did not induce significant cell death in any of the hippocampal regions and was equal in 
both conditions (CNTR). In the absence of microglia, the percentage of NMDA-induced neuronal 
cell death in the CXCR34• slice cultures (closed bars) was equivalent to that observed in microglia­
depleted wild types slice cultures (open bars) at all concentrations in both CA 1, CA3 and DG 
regions. Data are a summary of three individual experiments with at least six slice cultures per 
condition. Bars indicate mean ± SEM. 
respectively (Fig. 3.7). Note that in response to NMDA-treatment, neuronal cell death 
was severely enhanced in the absence of microglia in both CXCR3-1- and wild type slice 
cultures, suggesting a profound neuroprotective role for microglia in excitotoxicity (Fig. 
3.7, compare with Fig. 3.4). These results are in accordance with previous findings in our 
lab and have been discussed elsewhere (Van Weering, manuscript submitted). However, 
when comparing the percentages of neuronal cell death in microglia-depleted CXCR3+ 
slice cultures (Fig. 3.7; black bars) with those in microglia-free wild type slice cultures 
(Fig. 3.7, white bars) in response to NMDA-treatment, no differences were found at any 
concentration in any hippocampal region. 
DISCUSSION 
Expression of CXCL 10 and its receptor CXCR3 in glia cells and/or neurons has been 
shown to correlate with clinical signs of many if not all CNS pathologies. However, the 
potential role for CXCL 10 in neuron-glia and/or glia-glia signaling under pathological 
conditions is far from understood. Therefore, we studied the implication of 
CXCL 1 0/CXCR3 signaling in a model for CNS excitotoxicity in mouse organotypic 
hippocampal slice cultures. 
CXCL 10 differently affects CA and DG neurons upon excitotoxicity 
Our primary finding here is that CXCL 10/CXCR3 signaling differentially affects neuronal 
survival in the three hippocampal regions upon NMDA-induced excitotoxicity. 
Accordingly, we demonstrated that neurons in the CA regions displayed a decreased 
vulnerability to NM DA-treatment in the absence of CXCL 10 (CXCL 10-1·), suggesting that 
CXCL 10 has a negative effect on the survival of these neurons upon excitotoxicity. 
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In contrast, abrogation of CXCL 10 signaling did not desensitize neurons of the DG 
region in response to NMDA-induced excitotoxicity, but resulted in an increased 
vulnerability of these cell to high (50 µM) NMDA-concentrations. Interestingly, this 
differential neuronal vulnerability to CXCL 10 observed in CXCL 10-1- slice cultures was 
similar to that observed in CXCR3_,_ slice cultures, suggesting that here CXCL 10 
mediates its actions through CXCR3. Accordingly, we demonstrated that application of 
exogenous CXCL 10 directly after NM DA-treatment "rescued" the phenotype observed in 
CXCL 10-1- slice cultures, but not in CXCR3_,_ slice cultures, supporting these findings. 
Our observations that exposure to exogenous CXCL 10 only affected neuronal survival in 
the presence of NMDA and did not lead to neuronal cell death or glia activation in 
untreated (control) slice cultures suggests that CXCL 10 per se does not induce 
neurodegeneration nor does it directly trigger glia activation under healthy conditions. 
Indeed, it has been shown previously that chronic expression of CXCL 10 in the non­
challenged CNS in vivo did not lead to the development of neuropathological signs 
(Boztug et al., 2002), corroborating our observations. Since it is not yet known through 
which cell types CXCL 10 affects neuronal survival under excitotoxic conditions (see 
below) it is difficult at the moment to speculate why CXCL 10 does not have any effect in 
untreated slice cultures. A possible explanation for this finding might be that NMDA 
treatment renders the slice cultures sensitive for CXCL 10. In preliminary experiments we 
observed an up-regulation of CXCR3 mRNA in response to NMDA treatment (Van 
Weering et al., unpublished findings), which might corroborate this hypothesis. 
Alternatively, CXCL 10 might only modulate the signaling cascade leading to 
excitotoxicity-induced neurodegeneration rather than being a direct cause of 
neuropathological signs in our paradigm. Studies that directly investigate these 
alternative hypotheses are at the moment ongoing in our laboratory. 
Effects of CXCL 10 on neurons 
Although CXCL 1 O per se did not induce neuronal cell death, it is not unlikely that this 
chemokine might have direct effects on neurons as several studies have shown CXCR3-
expression in these cells (Coughlan et al., 2000; Nelson and Gruol, 2004; Xia et al., 
2000). Recently, it has been demonstrated that acute exposure of CXCL 10 altered 
neuronal signaling properties in rat hippocampal neuron-glia cultures (Nelson and Gruol, 
2004) and reduced long-term potentiation via CXCR3 in acute adult hippocampal slices 
(Vlkolinsky et al., 2004). Although in both studies it could not be excluded whether these 
1 I 
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CXCL 10-mediated neuronal effects were direct or mediated through glia cells, these 
findings suggest that CXCL 10 can have a modulatory effect on neuronal properties in the 
hippocampus. In line with this, it has been shown very recently that exposure of rat 
hippocampal neuron-glia cultures to relatively high levels of CXCL 10 for nine days 
resulted in (in)direct downregulation of synaptic proteins GAD65/67, GABAsR1 and 
GABAARa2 and upregulation of NMDAR1 and mGluR2/3 in the neuronal population 
(Cho et al., 2009). Whether such changes may account for the differences we observed 
in neuronal excitotoxicity between wild type slice cultures and CXCL 10-/- and CXCR3-/­
slice cultures is not yet clear. However, a CXCL 10-induced downregulation of inhibitory 
synaptic proteins and upregulation of glutamate-subtype receptors in neurons could in 
part explain the relative insensitivity of CA neurons in CXCL 10-1- and CXCR3+ slice 
cultures towards NMDA and may also account for the increased vulnerability of these 
neurons in CXCL 1 o-t- slice cultures when exposed to CXCL 10. 
CXCL 10 is expressed in astrocytes in response to excitotoxicity 
We demonstrated that upon NMDA-induced neuronal cell death CXCL 10 is expressed in 
astrocytes, but not in neurons or microglia. Expression of CXCL 10 in astrocytes in vivo 
has been observed in various excitotoxicity-related neuropathologies such as in stroke 
(Wang et al., 1998), encephalitis (Bhowmick et al., 2007), Alzheimer's disease (Xia et al . ,  
2000), MS (Balashov et al., 1999; Omari et al., 2005; Simpson et al . ,  2000; Tanuma et 
al., 2006) and in it's experimental animal model EAE (Carter et al., 2007; Ransohoff et 
al., 1993). Similar to our findings, these studies demonstrated that local upregulation of 
CXCL 10 expression in reactive astrocytes was highly correlated with sites of neuronal 
injury (Balashov et al., 1999; Carter et al., 2007; Omari et al., 2005; Ransohoff et al., 
1993; Simpson et al., 2000; Tanuma et al., 2006; Wang et al., 1998; Xia et al., 2000), 
suggesting that the process of neurodegeneration itself may provide the signals which 
trigger CXCL 10 expression in these cells. Possible signaling candidates under 
excitotoxic conditions are (pro-)inflammatory factors such as IFNl31/2, IFNy, IL-10/!3 and 
TNFa, which all have been shown to induce CXCL 10 expression in astrocytes in vitro 
(Croitoru-Lamoury et al . ,  2003; Oh et al., 1999; Omari et al., 2005; Salmaggi et al . ,  2002; 
Hua and Lee, 2000). However, direct evidence that these factors also stimulate 
astrocytic CXCL 10 expression in response to excitotoxicity in vivo remains to be 
established. 







Moreover, astrocytes have also been shown to express CXCR3 both in vivo (Omari et 
al., 2005; Simpson et al., 2000; Tanuma et al., 2006; Goldberg et al., 2001; Van der 
Meer et al., 2001) as in vitro (Biber et al., 2002; Croitoru-Lamoury et al., 2003; Flynn et 
al., 2003), suggesting that CXCL 10 could have an auto-regulatory effect on these cells. 
However, we did not detect any abnormalities or differences in astrocyte activation in 
CXCR3_,_ and CXCL 10-1- slice cultures when compared to wild type conditions (data not 
shown), indicating that CXCR3 in astrocytes is not required for the activation of these 
cells under conditions of neuronal excitotoxicity. 
Effects of CXCL 10 on neuronal survival are most likely mediated through microglia 
Microglia are considered to play a prominent role in excitotoxic-related injuries (Kohl et 
al., 2003; Lalancette-Hebert et al., 2007; Dehghani et al., 2003; Tikka and Koistinaho, 
2001 ). Here, we demonstrated that selective ablation of microglia in hippocampal slice 
cultures prior to NMDA-treatment resulted in severely enhanced neuronal degeneration, 
supporting the notion that microglia have a basal neuroprotective role in excitotoxic­
related injuries (Imai et al., 2007; Kitamura et al., 2004; Lalancette-Hebert et al., 2007; 
Turrin and Rivest, 2006; Xapelli et al., 2008). However, there are several lines of 
evidence that inhibition of microglia function is beneficial after acute CNS injury, 
supporting a neurotoxic role for microglia in this paradigm (Hailer et al., 2005; Hailer, 
2008; Tikka and Koistinaho, 2001; Yrjanheikki et al . ,  1998). Indeed, it has been 
demonstrated that upon excitotoxicity activated microglia express pro-inflammatory 
factors, such as TNFa, IL-1, nitric oxide (NO), inducible nitric oxide synthase (iNOS) and 
cycloxygenase-2 (COX2), which are all toxic to neurons when expressed in large 
quantities (Aloisi, 2001; Barone and Feuerstein, 1999; Campuzano et al., 2008). Thus, 
microglia are not inevitably neuroprotective as certain conditions might trigger a (pro­
)inflammatory phenotype in these cells that is detrimental for neuronal survival under 
excitotoxic conditions, showing the urgent need to identify the factors that control 
microglia activity. 
The data presented here demonstrate that CXCL 1 0/CXCR3 signaling might be one of 
the factors that affect microglia activity under excitotoxic conditions, leading to region­
dependent effects on the survival of CA and DG neurons. Previously, it has been 
demonstrated that microglia functionally express CXCR3 in vitro (Biber et al., 2001; Biber 
et al., 2002; Dijkstra et al., 2004; Rappert et al., 2002). We confirmed these findings by 
flow cytometry as acutely isolated microglia from wild type hippocampal slice cultures 
1 0  
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expressed CXCR3. The observation that the accumulation of microglia at sites of 
neuronal cell death was not impaired in CXCR3·'· slice cultures suggests that 
CXCL 10/CXCR3 signaling is not a prerequisite for microglia recruitment in response to 
excitotoxicity. In line with this evidence, it has been described recently that the migration 
of microglia towards injured neurons in the hippocampus depends on purinergic 
signaling, as induced degradation of extracellular ATP/ADP inhibited directed migration 
of microglia towards sites of neurodegeneration (Kurpius et al., 2007). However, since 
differences in neuronal cell death observed between wild type and CXCR3+ slice 
cultures were fully abrogated in the absence of microglia, it suggests that neuronal 
survival under excitotoxic conditions is affected through microglial CXCR3, which is in 
agreement with earlier studies from our group (Rappert et al., 2004). Why 
CXCL 1 0/CXCR3 signaling is detrimental in the CA regions of the hippocampus and 
protective in the DG region is not understood. Regional differences in the response of 
microglia to CXCR3-stimulation might be instrumental here. Alternatively, the differential 
effects of CXCL 1 0/CXCR3 signaling on DG and CA neurons might depend on regional 
differences in co-expression of local factors that modulate the pro-inflammatory activity 
of CXCL 10-stimulated microglia. More experiments are necessary to address these 
concepts. 
In summary, our results identify a region-specific role for CXCL 10/CXCR3 signaling in 
neuron-glia and glia-glia interactions under pathological conditions. Since ablation of 
microglia abrogated the differences in neuronal cell death between wild type and 
CXCR3-/- slices, an important role for microglial CXCR3 in neuronal excitotoxicity in the 
hippocampus is suggested. 
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Neuronal injury in the CNS inevitably results in the local accumulation of activated 
microglia, indicating that damaged neurons release signals that activate and/or attract 
microglia. Recently, it has been demonstrated that neurons rapidly express and release 
the chemokine CCL21 upon injury. Moreover, it has been demonstrated that CCL21  
activates microglia in vitro, a process dependent on the presence of  chemokine receptor 
CXCR3. It is therefore suggested that CCL21/CXCR3 might provide a signaling system 
between neurons and local glia cells that is associated with a neuroimmune response 
under pathological conditions. However, the effect of CCL21/CXCR3-signaling in the 
CNS has not been investigated yet. Therefore, we have determined the effect of CCL21-
signaling i n  an ex vivo model for N-methyl-D-aspartic acid (NMDA)-induced excitotoxicity 
using mouse organotypic hippocampal slice cultures. Treatment of wild type slice 
cultures with 1 0, 1 5, 25 and 50 µM NMDA for 4 hours and subsequent culturing for 24 
hours in standard culture medium resulted in region-selective loss of neurons in the 
hippocampal regions CA 1 ,  CA3 and DG. To determine the role of CCL21 and its 
receptor CXCR3 in this process, we prepared slice cultures from pit (CCL21/CCL 1 9-
deficient) and CXCR3-deficient (CXCR3+) mice and subsequently exposed these slice 
cultures to NM DA-induced excitotoxicity. Our findings demonstrate that in the absence of 
CCL2 1 ,  NMDA-induced neuronal cell death was significantly attenuated in the CA 
regions when compared to wild type conditions. while concomitant application of 1 0-a M 
recombinant CCL21 for 24 hours rescued this phenotype. Similar results were obtained 
in CXCR3_,_ slice cultures, although application of CCL21 had no effect on the rate of 
NMDA-induced neuronal loss in these slice cultures. Taken together, our data 
demonstrate that CCL21 -signaling in response to excitotoxic injury is associated with a 
neurotoxic response, a process most likely mediated through CXCR3. 
1 0& 
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INTRODUCTION 
Chemokines and their receptors have been implicated as important mediators in cell-to­
cell signaling both in the periphery (Campbell et al., 2003; Rot and von Andrian, 2004) as 
in the central nervous system (CNS) (Ambrosini and Aloisi, 2004; Cartier et al., 2005; de 
Haas et al., 2007). Chemokines are small chemotactic cytokines (8-14 kDa) and are 
classified into four distinct subclasses (CXC, CC, XC and CX3C) based on their 
conserved cysteine residue structure in the N-terminus (Bacon et al., 2002; Murphy et 
al., 2000). In general, members of these subclasses mediate their actions through their 
respective CXC-, CC-, XC- and CX3C receptors. One exception so far is chemokine C-C 
motif ligand 21 or CCL21 (formerly known as TCA-4, Exodus-2, 6CKine, Secondary 
Lymphoid-organ Chemokine (SLC)), which not only binds its primary receptor CCR7, but 
also binds and activates a member of the CXC-chemokine receptor family, namely 
CXCR3 (Soto et al., 1 998). 
In the periphery, CCL21 is constitutively expressed in secondary lymphoid organs and 
controls the homing of mature dendritic cells and of naive T- and 8-cells (Dieu et al., 
1 998; Sallusto et al., 1998; Stein et al., 2000; Yanagihara et al., 1 998). Accordingly, it 
has been demonstrated that mice lacking CCL21 (and CCL 19) show aberrations in the 
recruitment of naive T cells and activated dendritic cells to secondary lymphoid organs 
(Mori et al., 2001 ). However, recent findings suggest that CCL21 is also implicated in the 
development of several CNS pathologies. Elevated levels of CCL21 have been found in 
the cerebrospinal fluid (CSF) of patients suffering from multiple sclerosis (MS), an auto­
immune disease characterized by infiltration of auto-reactive T cells into the CNS 
(Pashenkov et al., 2003). In line with this, increased expression of CCL21 has been 
demonstrated in an animal model for MS, known as experimental autoimmune 
encephalomyelitis (EAE) (Alt et al., 2002; Columba-Cabezas et al., 2003). CCL21 
expression has been shown in the endothelium of inflamed blood vessels (Columba­
Cabezas et al., 2003) and venules of inflammatory cuffs surrounded by CCR7-positive 
cell-infiltrates (Alt et al., 2002). As desensitization with CCL21 or blocking of CCL21 with 
specific antibodies strongly reduced adhesion strengthening of T-cells to inflamed 
vessels in EAE, it was proposed that CCL21 facilitates the infiltration of T-cells into the 
CNS under pathological conditions (Alt et al., 2002). However, this suggestion is not 
without argument as transgenic over-expression of CCL21 in mouse brain was not 
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developed a strong neuropathology characterized by neurobehavioral deficits and 
reactive gliosis, leukocytic infiltrates into the CNS consisted primarily of neutrophils and 
eosinophils (Chen et al., 2002). 
Recent findings suggest an intrinsic role for CCL21 in the CNS as a communication 
signal between damaged neurons and surrounding glia cells under neuropathological 
conditions (Biber et al., 2001; de Jong et al., 2005; Dijkstra et al., 2004; Rappert et al., 
2002; Zhao et al., 2007). Generally, any type of neuronal injury induces activation and 
recruitment of microglia towards the site of injury, suggesting that endangered neurons 
emit signals that attract/activate local microglia (Biber et al. ,  2008; de Haas et al., 2007; 
Hanisch and Kettenmann, 2007). One of these signals might be CCL21 as it is 
expressed by damaged neurons in vivo early after onset of ischemia and in response to 
spinal cord injury (Biber et al., 2001; Zhao et al., 2007). In addition, neuronal expression 
of CCL21 has been reported in hippocampal slice cultures and primary neuronal cultures 
in response to toxic levels of glutamate (de Jong et al., 2005). Interestingly, CCL21 has 
been shown to induce activation and migration of human and mouse microglia in vitro 
(Biber et al., 2001; Dijkstra et al., 2004; Rappert et al., 2002). These findings are 
corroborated in vivo as injection of recombinant CCL21 into the thalamus of intact mice 
resulted in transient activation of microglia in this region (Zhao et al., 2007). An 
interesting feature here is that the activation of microglia in response to CCL21 in vitro 
has been shown not to be dependent on its native receptor CCR7, but on the presence 
of CXCR3 (Biber et al., 2001; Dijkstra et al., 2004; Rappert et al., 2002). 
Taken together, these results suggest that the chemokine CCL21 and its receptor 
CXCR3 could provide a signaling system between neurons and local glia cells that is 
associated with a neuroimmune response under pathological conditions. However, the 
role of CCL21/CXCR3-signaling between neurons and glia cells under neuropathological 
conditions has not been investigated yet. Therefore, we have investigated the implication 
of CCL21-signaling in an ex vivo excitotoxicity model for neurodegeneration using mouse 
organotypic hippocampal slice cultures. 
EXPERIMENTAL PROCEDURES 
Animals 
All experiments have been approved by the Dutch animal experimental committee. The 
C57BU6J (wild type, Harlan), CXCR3-deficient (CXCR3'1") and CCL21/CCL 19-deficient 
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(pit) mice were housed and handled in accordance with the guidelines of the central 
animal laboratory (CDL) facility of Groningen. The CXCR3_,_ mice were kindly provided 
by B. Lu and C. Gerard (Children's Hospital, Harvard Medical School, Boston, MA). 
Chemicals 
Culture media and supplements were all obtained from GIBCO® (lnvitrogen Corporation; 
Breda, The Netherlands), unless mentioned otherwise. Recombinant murine CCL21 and 
CCL 19 were obtained from PeproTech® (London, United Kingdom). 
Preparation of organotypic hippocampal slice cultures 
Organotypic hippocampal slice cultures (OHSCs) were prepared as described with minor 
modifications (Stoppini et al. , 1991). In brief, OHSCs were prepared from 2-3 day old 
C57BU6J, pit and CXCR3_1_ mouse pups under sterile conditions. After decapitation, the 
brains were rapidly removed and the hippocampi from both hemispheres were acutely 
isolated in ice cold serum-free Hank's Balanced Salt Solution (HBSS), supplemented 
with 0.5% glucose (Sigma) and 15 mM HEPES. Isolated hippocampi were cut into 350-
375 µm thick slices using a tissue chopper (Mcilwain) and were transferred to 0.4 µM 
culture plate inserts (Millipore, PICM03050). These culture plate inserts, containing four 
to six slices, were placed in six-well plates containing 1.2 ml of culture medium per well. 
Culture medium (pH 7.2) consisted of 0.5x minimum essential medium containing 25% 
heat-inactivated horse serum, 25% BME basal medium without L-glutamine, 2 mM 
glutamax and 0.65% glucose (Sigma). The slice cultures were kept at 35°C in a 
humidified atmosphere (5% CO2) and the culture medium was refreshed the first day 
after preparation and every consecutive two days. 
Induction of excitotoxicity in OHSCs 
After 6 days in culture, OHSCs were placed in culture medium containing 0, 10, 15, 25 or 
50 µM N-methyl-D-aspartic acid (NMDA; Sigma) for 4 hours to induce excitotoxicity and 
subsequently the medium was replaced with standard culture medium. NMDA-treated 
OHSCs were kept in culture for 24 hours after the NMDA challenge. 
lmmunohistochemistry 
For immunohistochemical analysis, control and NMDA-challenged OHSCs were shortly 
rinsed in phosphate-buffered saline (PBS, 35°C) and fixated with 4% paraformaldehyde 








overnight at 4°C. After fixation, the slice cultures were rinsed in PBS and pre-incubated 
with 5% normal goat serum (NGS; Vector) in PBS containing 0.3% Triton X-100 (PBS+) 
for at least one hour. Subsequently, the slice cultures were incubated with the 
appropriate primary antibody overnight in 1% NGS/PBS+ at 4°C. For detection of 
neuronal nuclei, mouse-anti-NeuN (1: 1000; Chemicon MAB377) was used with donkey­
anti-mouse-Alexa488 (Molecular Probes) as a secondary antibody. Analysis of the slice 
cultures was done by confocal imaging using a Leica SP2 AOBS system (Leica 
Microsystems). 
Quantification of neuronal cell death 
To determine neuronal cell death in response to NMDA-induced excitotoxicity, OHSCs 
were incubated with 5 µg/ml propidium iodide (Pl) during and after the NMDA-challenge 
(Pozzo Miller et al., 1994; Vornov et al., 1991). Confocal images of the neuronal layers 
were taken mid-section at 40x magnification and both NeuN• and NeuN•/p( cells were 
quantified using lmageJ software. The percentage of neuronal cell death was determined 
by the number of NeuN•Ip1• cells divided by the total number of NeuN-positive cells per 
neuronal layer. 
Quantative polymerase chain reaction (QPCR) 
For RNA analysis, OHSCs (6 slice cultures per condition) were lysed in guanidinium 
isothiocyanate/ monopthiolglycerol buffer (both from Sigma) and total RNA was extracted 
and precipitated with a one-chloroform-phenol step (Chomczynski and Sacchi, 1987). 
The quality and quantity of the total RNA were determined with the Agilent 2100 
bioanalyzer and the NanoDrop® ND-1000. RNA integrity number (RIN) values were 
between 9.9 and 8.8 and the 260/280 nm ratios around 1.9. 1 µg of total RNA was 
transcribed into cDNA as described previously (Biber et al., 1997). Amplification 
reactions were performed in a total volume of 10 µI containing 0.8 µI cDNA solution, 5.0 
µI TaqMan® universal PCR master mix, 0.5 µI TaqMan® primer-probe (Applied 
biosystems: !3-actin, Mm006 07939_s1; CXCR3, Mm00438259_m1; CCR?, 
Mm01301785_m1; CCL21, assay by design: intron-spanning, lot. 439860) and 3.7 µI 
pure water (Sigma). Reactions were run in triplets on the ABI Prism® 7900 HT real time 
PCR instrument. After 15 minutes at 95°C, the cDNA samples were run for 40 cycles, 
consisting of 15 seconds at 95°C for denaturation and 1 min at 60°C for annealing and 
elongation. Threshold cycles were determined manually by setting thresholds for 
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fluorescence intensity. Relative gene expression levels were analysed by the 2-titiCT 
method, using 11-actin as a reference gene (Livak and Schmittgen, 2001 ). The 
amplification efficiency was verified by linear regression with the fluorescence per cycle 
number (Ramakers et al., 2003). 
Statistical Analysis 
Data are represented as the mean ± standard error of the mean (SEM). In the neuronal 
cell death experiments statistical comparison between groups was performed using one­
way analysis of variance (ANOVA) with Gabriel's posthoc test. In the real-time PCR 
experiments statistical comparison between groups was performed using the two-tailed 
Students· t-test. In both tests, p-values smaller than 0.05 were considered significant. All 
statistical tests were performed in SPSS version 14.0.2 (SPSS Inc., Chicago). 
RESULTS 
NMDA-induced neuronal cell death is attenuated in the absence of CCL21/CCL 19 (pit) 
In order to determine the effects of CCL21 on NMDA-induced neuronal cell death we 
prepared hippocampal slice cultures from wild type and pit (paucity of lymph node T 
cells) mice, which carry a natural mutation resulting in CCL21/CCL 19-expression 
deficiency (Luther et al., 2000; Nakano and Gunn, 2001; Vassileva et al. ,  1999), and 
exposed these slice cultures to O (control), 10, 15, 25 and 50 µM NMDA to induce 
excitotoxicity. After six days in culture, the basal rate of neuronal cell death in (control) pit 
slice cultures (Fig. 4.1; open bars) was equal to control wild type conditions (CA 1; 0.7 ± 
0.1%, CA3; 1.7 ± 0.4%, DG; 1.4 ± 0.3%, all p=1.000). However, in response to NMDA­
treatment clear differences in neuronal cell death were observed between pit- and wild 
type slice cultures in the CA 1 (Fig. 4.1A) and CA3 regions (Fig. 4.18). Neuronal cell 
death in response to 10 µM NMDA was significantly lower in the CA1 (Fig. 4.1A) of pit 
slice cultures (22.4 ± 6.1 %) when compared to wild type conditions (67.1 ± 16.3%, 
p<0.001). Treatment with 15 µM NMDA or higher resulted in maximum levels of neuronal 
cell death (between 95-100%) in the CA1 region in both pit and wild type slice cultures. 
Similar decreases in neuronal cell death were observed in the CA3 region (Fig. 4.1 B) as 
neuronal cell death was markedly lower in pit slice cultures in response to 15 µM NMDA 
(10.4 ± 3.3% compared to 41.7 ± 11.3% in wild types, p<0.001) and in response to 25 
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Figure 4.1 (right). CCL21, but not CCL 19, negatively affects neuronal survival upon NMDA­
induced excitotoxicity. Graphs represent the percentages of neuronal cell death per hippocampal 
region (A; CA 1, B; CA3, C; DG) in response to O (CNTR), 10, 15, 25 and 50 µM NMDA in wild type 
(closed bars) and pit slice cultures (open bars) and in pit slice cultures treated with 10-8 M CCL21 
(light-grey bars) or 10-a M CCL 19 (dark-grey bars). Top: microscopic image of a hippocampal slice 
culture showing the localization of the neuronal subregions of interest (CA1, CA3 and DG). In pit 
slice cultures, neuronal cell death induced by NMDA-treatment was significantly lower in the CA1 
region (A) at 10 µM NMDA (p<0.001) and in the CA3 region (B) at 15 µM (p<0.001) and 25 µM 
NMDA (p<0.001) when compared to wild type conditions. In the DG region (C), no differences in 
neuronal cell death were observed between pit- and wild type slice cultures at any NMDA­
concentration. Application of 10-8 M CCL21 directly after NMDA-treatment for 24 hours partly 
"rescued" the effects observed in pit slice cultures as neuronal cell death in the CA 1 region (A) at 10 
µM (p<0.001) and in the CA3 region (B) at 25 µM (p<0.001) was significantly enhanced in the 
presence of recombinant CCL21. This enhanced NMDA-induced neuronal cell death in the 
presence of recombinant CCL21 equalled wild type conditions (all p=1.000). Moreover, neuronal cell 
death in the DG region in the presence of recombinant CCL21 was not only significantly higher in pit 
slice cultures at 25 µM (p<0.001) and at 50 µM NMD (p=0.019), but also higher when compared to 
wild type conditions (p=0.042 and p<0.001, respectively). Application 10-a M CCL 19 directly after 
NMDA-treatment had no effect on the number of dying neurons in pit slice cultures at any NMDA­
concentration. Data are a summary of three separate experiments with at least five slice cultures 
per condition. Bars indicate mean ± SEM. 
0
p<0.05, ··p<0.01, ... p<0.001, ANOVA. 
In contrast, in the DG region no significant differences in neuronal cell death were 
observed between pit and wild type slice cultures at any NMDA concentration (Fig. 
4.1C). 
CCL21, but not CCL 19, enhances NMDA-induced cell death in pit-derived OHSCs 
As a clear decrease in neuronal cell death was observed in the CA regions of NMDA­
treated pit slice cultures when compared to wild type conditions, we determined whether 
this effect was due to a lack of CCL21 and/or CCL 19. For this purpose we treated pit­
derived slice cultures with 0 (control), 10, 15, 25 or 50 µM NMDA for 4 hours to induce 
excitotoxicity and subsequently exposed these slice cultures to either 10-8 M recombinant 
mouse CCL21 or 10-8 M CCL 19 for 24 hours. After 24 hours the slice cultures were 
fixated and the percentages of neuronal cell death per hippocampal region were 
determined. 
Application of 10-a M CCL21 alone to pit-derived slice cultures did not result in significant 
changes in the basal rate of neuronal cell death in the three hippocampal regions, when 
compared to control pit conditions (CA 1; 1.4 ± 0.6%, CA3; 2.4 ± 0.9%, DG; 0. 7 ± 0.2%, 
all p=1.000). In contrast, application of CCL21 directly after NMDA-treatment clearly 
enhanced neuronal cell death in these slices cultures. 
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In the CA 1 region, application of 10-8 M CCL21 directly after treatment with 10 µM NMDA 
(Fig. 4.1A; light-grey bars) resulted in a significant increase in neuronal cell death in pit­
derived slice cultures (62.0 ± 14.5%, p<0.001), which was equivalent to the percentage 
of cell death observed in wild types (67.1 ± 16.3%, p=1.000). In the CA3 region, no 
significant effect of CCL21 application was observed after treatment with 15 µM NMDA 
in pit-derived slice cultures (4.0 ± 1.0% compared to 10.4 ± 3.3%, p=0.999). However, 
application of CCL21 directly after treatment with 25 µM NMDA resulted in a significant 
increase in neuronal cell death (72.3 ± 7.5%, p<0.001) in the CA3 region when 
compared to non-treated pit slice cultures (39.0 ± 4.5%), which was again equivalent to 
wild type conditions (79.9 ± 8.6%, p=1.000) 
Moreover, an effect of CCL21 after NMDA treatment was observed in the DG region 
(Fig. 4.1 C) as application of CCL21 significantly enhanced neuronal cell death after 
treatment with 25 µM NMDA (36.6 ± 4.3% compared to 14.9 ± 4.8% in pit slice cultures, 
p<0.001) and after treatment with 50 µM NMDA (51.9 ± 5.4% compared to 33.1 ± 6.0% 
in pit slice cultures, p=0.019). Enhanced neuronal cell death in the DG in the presence of 
CCL21 in pit slice cultures even exceeded percentages of cell death found in wild type 
slice cultures in response to 25 µM NMDA (p=0.042) and 50 µM NMDA (p<0.001). 
Application of 10-a M CCL 19 alone to pit-derived slice cultures did not induce neuronal 
cell death in the various hippocampal regions (CA 1; 0. 7 ± 0.3%, CA3; 0.3 ± 0.1 %, DG; 
0.7 ± 0.2%), nor did application of CCL 19 influence the percentage of neuronal cell death 
after treatment with 10-50 µM in these regions (Fig. 4.1; dark-grey bars), indicating that 
the decreased neuronal cell death observed in pit-derived slice cultures is solely due to a 
lack of CCL21 expression, but not of CCL 19. 
CXCR3, but not CCR?, is expressed in hippocampal slice cultures 
In order to determine which chemokine receptor might be involved here, we analyzed the 
expression of chemokine receptors CCR? and CXCR3, which are both known to bind 
CCL21, in the slice cultures. For this purpose, we analyzed the presence of CXCR3 and 
CCR7 mRNA by means of real-time PCR in total slice culture RNA lysates of control wild 
type slice cultures and of NMDA-treated slice cultures at set time-points (0, 4, 8, 24 and 
48 hours after induction). CXCR3 mRNA was readily detected in control conditions (Fig. 
4.2A) and was present up to 48 hours after the NMDA-treatment. CXCR3 mRNA 
expression levels did not change significantly at 4 (p=0.084), 8 (p=0.308), 24 (p=0.192) 
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Figure 4.2. Constitutive expression of CXCR3, but not CCR7, in OHSCs. Graphs represent the 
relative mRNA expression levels of CXCR3 (A) and CCR7 (B), as determined by QPCR analysis, in 
whole slice culture lysates of control (c) wild type slice cultures and of slice cultures at 4, 8, 24, and 
48 hours after excitotoxicity induction with 50 µM NMDA. Real-time PCR analysis revealed CXCR3 
mRNA expression in both control and NMDA-treated slice cultures (A). Levels of CXCR3 mRNA did 
not change significantly at 4 (p=0.084), 8 (p=0.308), 24 (p=0.192) or 48 hours (p=0.172) after 
excitotoxicity-induction when compared to control levels. In contrast, CCR? mRNA was below 
detection levels in control slice cultures (B), and could also not be detected in response to NMDA­
treatment at any time-point. Relative mRNA expression levels were determined as the expression of 
CXCR3 or CCR? normalized to j3-actin and related to non-treated control conditions. Data are a 
summary of four separate experiments. Bars indicate mean ± SEM. 
or 48 hours (p=0.172) after the start of the NMDA-treatment. In contrast, CCR? mRNA 
could not be detected in control slice cultures (Fig. 4.28). Neither did we observe CCR? 
mRNA in NMDA-treated slice cultures at 4, 8, 24 or 48 hours after induction (Fig. 4.28), 
while CCR? mRNA could be readily detected in thymus tissue, which served as a 
positive control (data not shown). These results show that CXCR3, but not CCR?, is 
expressed in our slice culture system. 
CCL21-induced effects mediated through CXCR3? 
Based on the real-time PCR findings we hypothesized that the observed effects of 
CCL21 on NMDA-induced neuronal degeneration are mediated through CXCR3 as 
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Figure 4.3 (left). Application of CCL21 directly after NMDA-treatment has n o  effect on 
excitotoxicity-induced neuronal cell death in CXCR3-1- OHSCs. Graphs represent the 
percentages of neuronal cell death per hippocampal region (CA 1, CA3, DG) in response to 0 
(CNTR), 10, 15, 25 and 50 µM NMDA in wild type (closed bars) and CXCR3�- slice cultures (open 
bars) and in CXCR3·'· slice cultures treated with 10·9 M recombinant CCL21 directly after NMDA­
treatment (grey bars). Similar to pit slice cultures, neuronal cell death in CXCR3·'· slice cultures was 
significantly lower in the CA 1 region at 10 µM NMDA and in the CA3 region at 15 µM and 25 µM 
NMDA when compared to wild type conditions. In contrast, neuronal cell death in the DG region was 
higher in response to 50 µM NMDA in CXCR3.,. slice cultures. Application of CCL21 directly after 
NMDA-treatment had no significant effect on the percentage of dying neurons observed in CXCR3.,
. 
slice cultures in any hippocampal region. Data are a summary of three separate experiments with at 
least five slice cultures per condition. Bars indicate mean ± SEM. 'p<0.05, '"p<0.01, ""p<0.001, 
ANOVA. 
CXCR3 in NMDA-induced excitotoxicity using slice cultures derived from CXCR3-
deficient (CXCR3·'·) mice (Van Weering et al. ,  manuscript in press). Interestingly, we 
observed differences in NMDA-induced neuronal cell death in the absence of CXCR3 in 
all three hippocampal regions when compared to wild type conditions, which are similar 
to the differences we observed in the pit slice cultures (Fig. 4.3). Like pit-derived slice 
cultures, CXCR3_,_ slice cultures showed significantly lower percentages in neuronal cell 
death in the CA 1 region in response to 10 µM NMDA (p<0.001 ), and in the CA3 region in 
response to 15 µM NMDA (p<0.001) and 25 µM NMDA (p=0.038) when compared to 
wild type conditions (Fig. 4.3). Additionally, a significant increase in neuronal cell death 
was observed at 50 µM NMDA in the DG region of CXCR3·'· slice cultures (p<0.001), an 
effect we did not observe in pit slice cultures (see Fig. 4.1 C). 
Interestingly, in CXCR3+ slice cultures application of 10·8 M CCL21 directly after NMDA­
treatment had no effect on neuronal cell death in the CA 1 and CA3 regions, nor in the 
DG region (Fig. 4.3; grey bars), whereas in pit slice cultures a clear increase in neuronal 
cell death was observed in the presence of recombinant CCL21 (see Fig. 4.1 ). 
CCL21 mRNA levels are significantly lower in CXCR3_,_ OHSCs 
Next, we determined the expression of CCL21 mRNA in both wild type- and CXCR3·1• 
slice cultures by means of QPCR analysis. CCL21 mRNA was clearly detected in total 
RNA lysates from untreated (control) wild type slice cultures (Fig. 4.4, closed bars). No 
changes in CCL21 mRNA levels were observed in response to treatment with 50 µM 
NMDA at 4 (p=0.147), 8 (p=0.292), 24 (p=0.655) or 48 hours (p=3.94) after induction 
when compared to control conditions. Similar results were observed in CXCR3-1- slice 
cultures as CCL21 mRNA was detected in untreated control slice cultures (Fig. 4.4, open 
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bars). Also here, levels of CCL21 mRNA did not change in response to NMDA-treatment 
at the time-points measured (Fig. 4.4). However, we observed a discrepancy in relative 
CCL21 mRNA expression levels between CXCR3·'· and wild type slice cultures. Although 
CCL21 mRNA could be detected in both wild type- and CXCR3.J. slice cultures, the 
relative expression levels of CCL21 mRNA in CXCR3.J. slice cultures were 50 times 
lower than observed in wild type slice cultures (Fig. 4.4). Also after NMDA-treatment, 
levels of CCL21 mRNA remained 50-100 times lower in CXCR3·'· slice cultures than in 
wild types. These unexpected findings suggest that the expression of CCL21 in these 
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Figure 4.4. CCL21 mRNA expression levels are downregulated in CXCR3_,_ OHSCs. Graph 
represents the relative mRNA expression levels of CCL21, as determined by QPCR analysis, In wild 
type (closed bars) and CXCR3-1. slice cultures (open bars) before (control, c) and 4, 8, 24, 48 hours 
after excitotoxicity-induction with 50 µM NMDA. CCL21 mRNA was detected in both control wild 
type- and CXCR3-1- slice cultures. Relative levels of CCL21 mRNA did not change in response to 
NMDA treatment at any time-point measured. However, relative CCL21 mRNA levels in CXCR3-1-
slice cultures were 50 times lower when compared to wild type conditions (1<0.02 respectively), 
which remained constant at all time-points measured after NMDA-treatment. Relative mRNA 
expression levels were determined as the expression of CCL21 normalized to J3-actin and related to 
non-treated control conditions. Data are a summary of four separate experiments. Bars indicate 
mean ± SEM. 
DISCUSSION 
CCL21-signaling in the CNS is associated with a neurotoxic response 
Among all chemokines expressed in the CNS, CCL21 displays a unique feature as it is 
exclusively expressed in damaged neurons (Ambrosini et al., 2005; Biber et al., 2001; 
Columba-Cabezas et al., 2003; de Jong et al., 2005; Zhao et al., 2007). Moreover, 
CCL21 has been reported to activate glia cells in vitro and in vivo, in particular microglia 
and astrocytes, and it is therefore suggested that CCL21 could function as a neuronal 
stress signal that activates and/or attracts surrounding glia cells (Biber et al., 2001; de 
Jong et al., 2005; Dijkstra et al., 2004; Rappert et al., 2002; Van Weering et al., 2009; 
Zhao et al., 2007). Despite this knowledge, little is yet known about the consequences of 
CCL21 expression in the injured CNS. 
Here, we have investigated the impact of CCL21-signaling in a model for excitotoxicity­
induced neuronal cell death using mouse hippocampal slice cultures . Our data 
demonstrate that, in the absence of a peripheral immune response, CCL21 negatively 
affects neuronal survival under excitotoxic conditions, suggesting an endogenous, 
neurotoxic role for CCL21 in the hippocampus. Accordingly, we show that hippocampal 
slice cultures derived from pit mice are less susceptible to a neurotoxic insult, as the 
levels of neuronal cell death in the CA regions in response to NMDA-induced 
excitotoxicity were markedly lower when compared to wild-type conditions. Furthermore, 
we could rescue this phenotype by exposure of pit-derived slice cultures to 10"8 M 
recombinant CCL21, which significantly enhanced neuronal cell death in response to 
NMDA-treatment. No effects were observed in response to 10-a M recombinant CCL 19. 
These observations are in line with previous findings, where it was demonstrated that 
transgenic over-expression of CCL21 in the CNS of intact mice (MBPCCL21 mice) 
resulted in reactive gliosis and severe neuropathology, while mice transgenic for CCL 19 
(MBPCCL 19 mice) did not show any apparent physiological abnormalities (Chen et al., 
2002). Moreover, these results suggest that expression of CCL21 within the CNS is 
associated with a neurotoxic response, which strongly corroborates our findings. 
Involvement of CXCR3 
Although the actions of CCL21 in the periphery are well described and have been shown 
to be induced through its corresponding receptor CCR7 (Forster et al., 1999; Forster et 
al., 2008; Lira, 2005), there is strong evidence that CCL21-induced signaling in the CNS 
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is mediated through another receptor (Biber et al., 2001; de Jong et al., 2005; Dijkstra et 
al., 2004; Rappert et al., 2002). Several lines of evidence point towards CXCR3 as a 
likely candidate for CCL21 -induced effects in the CNS (Biber et al., 2001; Chen et al., 
2002; Dijkstra et al., 2004; Jenh et al., 1 999; Rappert et al., 2002; Soto et al., 1 998; Van 
Weering et al., 2009). In line with this, it has been demonstrated in vitro that CCL21-
induced activation of both microglia and astrocytes is not mediated through CCR?, but 
depends on the presence of CXCR3 (Biber et al., 2001; Dijkstra et al., 2004; Rappert et 
al., 2002; Weering et al., 2009). Our results corroborate these findings. First of all, we did 
not detect CCR? mRNA expression in our slice cultures, while CXCR3 mRNA was 
readily detected both under control- and NMDA-treated conditions. Secondly, slice 
cultures derived from CXCR3+ showed a similar decrease in NMDA-induced neuronal 
cell death as in pit-derived slice cultures when compared to wild type conditions. 
Moreover, whereas in pit-derived slice cultures a clear increase in NMDA-induced 
neuronal cell death was observed in the presence of recombinant CCL21, exposure of 
CXCR3_,_ slice cultures to CCL21 had no such effect. Taken together, our results suggest 
that the neurotoxic effect of CCL21 in CNS-excitotoxicity is not mediated through CCR?, 
but through another receptor, most likely through CXCR3. Additional studies in pit­
derived slice cultures with selective CXCR3 antagonists could prove this assumption. 
Involvement of microg/ia 
Various lines of evidence show that CCL21 activates glia cells, in particular microglia 
(Biber et al., 2001; Dijkstra et al. ,  2004; Rappert et al., 2002; Zhao et al., 2007). 
Moreover, recent evidence suggests that CCL21-induced activation of microglia in the 
CNS might also be involved in the modulation of pain sensation. Injection of recombinant 
CCL21 in intact mice directly into the ventral posterolateral nucleus of the thalamus 
resulted in transient activation of local microglia and induced pain-related behaviour 
(Zhao et al., 2007). This effect could be blocked by co-injection with minocycline, which 
is known to inhibit microglia activation, suggesting that CCL21-induced pain behaviour is 
dependent on the activation of microglia (Zhao et al., 2007). 
Although direct evidence is lacking in our paradigm, it is likely that the neurotoxic effect 
of CCL21 in our slice cultures is mediated through microglia too. In line with this, several 
publications have shown that suppression of microglia function in excitotoxicity might be 
beneficial for the survival of neurons in this process (Hailer, 2008). Blocking of CCL21-
signaling in the injured CNS might therefore be of therapeutic value. 
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In summary, we propose that CCL21 is a neuron-derived factor that is part of a signaling­
cascade (most likely through CXCR3-mediated activity of microglia) leading to increased 
neuronal cell death in excitotoxicity. 
Remaining questions 
Several questions remain open in this study. First of all, it is yet unclear why we did not 
observe a significant induction of CCL21 mRNA in our slice cultures after N DMA­
treatment. Here, only a slight increase (p=0.147) was found at 4 hours after NMDA­
treatment. Since neuronal CCL21 expression in vivo is only demonstrated in injury 
models, the basic levels of CCL21 mRNA expression in our system may be due to 
cellular stress and thus may reflect the culture situation (de Jong et al., 2005). Therefore, 
the CCL21 mRNA expression levels present in control slice cultures might be sufficient 
for the degree of neuronal damage in response to NMDA-treatment. In this way, a further 
increase in CCL21 expression might not reach significant levels. The second question 
concerns the difference in CCL21 mRNA expression levels between wild type- and 
CXCR3_,_ slice cultures, indicating a role of CXCR3 in the regulation of CCL21 mRNA 
expression. How neuronal CCL21 expression is regulated on the molecular level and 
whether CXCR3 signaling is required here is at the moment not clear. Further 
experiments are needed to address this question. 
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ABSTRACT 
CCL21 is a homeostatic chemokine that is expressed constitutively in secondary lymph 
nodes and attracts immune cells via chemokine receptor CCR7. In the brain however, 
CCL21 is inducibly expressed in damaged neurons both in vitro and in vivo and has 
been shown to activate microglia in vitro, albeit not through CCR7 but through 
chemokine receptor CXCR3. Therefore, a role for CCL21 in CXCR3-mediated neuron­
microglia signalling has been proposed. It is well established that human and mouse 
astrocytes, like microglia, express CXCR3. However, effects of CCL21 on astrocytes 
have not been investigated yet. In this study, we have examined the effects of CCL21 on 
calcium transients and proliferation in primary mouse astrocytes. We show that similar to 
CXCR3-ligand CXCL 10, CCL21 (10-9 M and 10-a M) induced calcium transients in 
astrocytes, which were mediated through CXCR3. However, in response to high 
concentrations of CCL21 (10-7 M) calcium transients persisted in CXCR3-deficient 
astrocytes, whereas CXCL 10 did not have any effect in these cells. Furthermore, 
prolonged exposure to CXCL 10 or CCL21 promoted proliferation of wild type astrocytes. 
Although CXCL 10-induced proliferation was absent in CXCR3-deficient astrocytes, 
CCL21-induced proliferation of these cells did not significantly differ from wild type 
conditions. It is therefore suggested that primary mouse astrocytes express an additional 
(chemokine-) receptor, which is activated at high CCL21 concentrations. 
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INTRODUCTION 
Chemokines are small chemotactic cytokines of approximately 8-14 kDa and are 
classified into four distinct groups (CXC, CC, XC and CX3C) based on the position of 
their conserved cysteine residues in the N-terminus (Bacon et al., 2002; Murphy et al. ,  
2000). Chemokines are produced locally and exert their actions on seven­
transmembrane, G-protein coupled chemokine receptors (Allen et al., 2007; Murphy et 
al., 2000). In general, activation of chemokine receptor-induced signaling pathways 
results in an increase in intracellular calcium and is in most cases pertussis toxin 
sensitive, suggesting that most of these receptors are G;-protein linked (Murphy, 1996). 
In recent years approximately twenty chemokine receptors and over forty chemokines 
have been identified (Bacon et al., 2002; Murphy et al., 2000; Murphy, 2002). 
CXC-, CC-, XC- and CX3C-chemokines predominantly induce their actions through their 
respective CXC-, CC-, XC- and CX3C receptors. One exception is chemokine C-C motif 
ligand 21 (CCL21, formerly known as TCA-4, Secondary Lymphoid-organ Chemokine 
(SLC), Exodus-2, 6CKine), which not only binds its primary receptor CCR?, but also 
functionally binds to CXCR3, a member of the CXC-chemokine receptor family (Soto et 
al., 1998). In the periphery, CCL21 is constitutively expressed in secondary lymphoid 
organs and controls the homing of mature dendritic cells and of naive T- and B-cells 
(Dieu et al., 1998; Sallusto et al., 1998; Yanagihara et al., 1998; Stein et al., 2000). In the 
CNS however, CCL21 is rapidly expressed by endangered neurons during an ischemic 
insult or spinal cord injury (Biber et al., 2001; Zhao et al., 2007). CCL21 expression was 
detected in damaged neurons but not in other brain-resident cells (Biber et al., 2001). In 
addition, CCL21 is inducibly expressed in neuronal cultures and neurons in hippocampal 
slice cultures after exposure to high levels of glutamate (de Jong et al., 2005). 
Interestingly, it has been demonstrated that CCL21 induces activation of human and 
mouse microglia as measured by chemotaxis, calcium signaling and induction of er 
currents (Biber et al., 2001; Dijkstra et al., 2004; Rappert et al., 2002). Moreover, the 
activation of mouse microglia by CCL21 was shown to be dependent on the presence of 
CXCR3, but not CCR? (Rappert et al., 2002), as microglia derived from CCR?-deficient 
mice migrated towards CCL21, while microglia derived from CXCR3-deficient mice did 
not. In line with this evidence it has been proposed that CCL21/CXCR3 functions as an 
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during the development of various diseases in the CNS (Biber et al., 2001; de Jong et 
al., 2005; Rappert et al., 2002). 
Next to microglia, astrocytes are an integrative component of the neuron-glia support 
system both under healthy and pathological conditions. Astrocytes not only have been 
shown to be involved in neuronal information processing and synaptic transmission 
(Volterra and Meldolesi, 2005), but also seem to be important mediators in the activation 
of microglia under pathological conditions (Davalos et al., 2005). Interestingly, astrocytes 
express various chemokine receptors (Ambrosini and Aloisi, 2004) and respond to a 
variety of chemokines such as CXCL 10, CXCL1 2, CCL2 and CX3CL 1 in vitro 
(Andjelkovic et al., 2002; Bajetto et al., 2001; Biber et al., 2002; Maciejewski-Lenoir et 
al., 1999; Rezaie et al., 2002). Therefore it would be of interest to determine whether 
astrocytes, like microglia, have the capacity to respond to CCL21. 
Although the presence of CCR? has not been detected on astrocytes (Biber et al., 2002; 
Columba-Cabezas et al., 2003), it has been shown that both human and mouse 
astrocytes functionally express CXCR3 protein (Biber et al., 2002; Flynn et al., 2003). 
Astrocytes clearly respond to the CXCR3-ligand CXCL 10, as measured by calcium 
transients, chemotaxis and cell proliferation (Biber et al., 2002; Flynn et al., 2003). 
Whereas the response of microglia to CCL21 is known and depends on the presence of 
CXCR3, possible effects of CCL21 on astrocytes have not yet been investigated. In this 
study, we have examined the effects of CCL21 and CXCL 10 on primary mouse 
astrocytes by means of single-cell calcium imaging and proliferation and determined 
whether these effects were mediated through CXCR3 or another receptor. Additionally, 
we characterized the calcium responses to both chemokines with respect to calcium 
mobilization and involvement of G,-proteins. 
EXPERIMENTAL PROCEDURES 
Animals 
All experiments have been approved by the Dutch animal experimental committee. 
C57BU6J (Harlan) and CXCR3_,_ mice with C57BU6J background were housed and 
handled in accordance with the guidelines of the central animal laboratory (CDL) facility 
of Groningen, the Netherlands. The CXCR3_,_ mice were kindly provided by B. Lu and C. 
Gerard (Children's Hospital, Harvard Medical School, Boston, MA). 
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Materials 
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Cell culture media and supplements were all obtained from GIBCO® (lnvitrogen 
Corporation; Breda, The Netherlands), unless mentioned otherwise. Recombinant 
murine CCL21 and CXCL 10 were obtained from PeproTech® (London, United 
Kingdom). Pertussis toxin and thapsigargin were purchased from Sigma-Aldrich 
(Bornhem, Belgium). 
Primary mouse astrocyte cultures 
For primary mouse astrocyte cultures brains from postnatal C57BU6J and CXCR3_,_ 
mice (< 1 day) were rapidly isolated and, after removal of the meninges, the cortices 
were dissected in ice-cold medium-A (Hank's Balanced Salt Solution (HBSS) 
supplemented with 0.5% glucose and 1.5 mM HEPES). Cortices were carefully 
dissociated by trituration in medium-A using a 1 ml pipette and subsequent trypsinisation 
for 20 minutes at 37°C in medium-A, supplemented with 0.25% trypsin and 1000 U/ml 
Dnase I (Roche). After a trypsin inhibition step with medium-A, containing 0.1 mg/ml 
trypsin inhibitor (Sigma-Aldrich), 20% fetal calf serum (FCS) and 1000 U/ml Dnase I, the 
cells were centrifuged for 10 minutes at 150 RCF. Single cell suspensions were seeded 
in 75 cm2 culture flasks (Greiner), containing 10 ml Dulbecco's Modified Eagle's Medium 
(DMEM) with 10% FCS, 1 % L-Glutamine, 1 % sodium pyruvate, 100 µg/ml streptomycin 
and 100 U/ml penicillin. These mixed glial cell cultures were kept in a humidified 
incubator (5% CO2) at 37°C. Culture medium was refreshed one day after the isolation. 
After 7-10 days in vitro, the mixed glial cultures were placed overnight on a cell-shaker 
(240 rpm) at 37°C and the following day the non-adherent glial cells were removed . Next, 
astrocytic mono-layers were carefully separated from the underlying adherent microglia 
by a mild trypsinisation step (5 ml HBSS with 0.05% trypsin-EDTA) and plated in new 75 
cm2 culture flasks. In consecutive weeks, overnight shaking and trypsinisation steps 
were repeated until pure astrocyte cultures (>98%) were obtained. The astrocyte 
cultures were passaged every week by mild trypsinisation and culture medium was 
refreshed one day after passaging. 
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) 
For RNA analysis, astrocyte cultures were lysed in guanidinium isothiocyanate/ 
monopthiolglycerol buffer (both from Sigma) and total RNA was extracted and 
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total RNA was transcribed into cDNA, as described previously (Biber et al., 1997). 
Subsequently, 2 µI of cDNA was amplified by polymerase chain reaction (PCR) and its 
products were visualized as bands on a 1.5% agarose gel with ethidiumbromide. The 
quality of RNA was checked using primers for house keeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH; accession number AF1 0680), with the following 
sequences; forward primer 5'- CATCCTGCACCACCAACTGCTTAG-3' and backward 
primer 5'-GCCTGCTTCACCACCTT CTTGATG-3' (product size 346 base pairs). 
Contamination of RNA isolates by genomic DNA was checked for by running the 
reactions without reverse transcriptase, followed by PCR amplification with GAPDH 
primers. The following primer sequences for mouse CXCR3 (accession number 
AF045146) were used; forward primer 5'-AGAATCATCCTGGTCTGAGACAA-3' and 
backward primer 5'-AAGATAGGGCATGGCAGCTA-3' (product size 288 base pairs). 
Primer sequences used for mouse CCR? (accession number L31 580) were; forward 
primer 5'-ACAGCGGCCTCCAGAAGAACAGCGG-3' and backward primer 5·_ 
TGACGTCATAGGCAATGTTGAGCTG-3' (product size 345 base pairs). The PCR­
products have been verified by cloning and subsequent sequencing. 
Flow Cytometry 
For analysis of chemokine receptor-expression astrocyte cultures were collected by mild 
trypsinisation, then pelleted by centrifugation for 10 minutes at 150 RCF (4 °C) and 
resuspended in ice-cold, sterile phosphate-buffered saline (PBS) at a concentration of 
100,000 cells per vial. Next, the astrocytes were stained for phycoerythyrin-coupled 
monoclonal anti-mouse CXCR3 (R&D, FAB1685P), CCR? (eBioscience, 12-1971)  or 
concentration-matched isotype lgG2A controls (eBioscience, 12-4321) for 20 minutes at 
4 °C in PBS containing 1 % FCS. Cell-size, granularity and fluorescence intensity were 
analyzed by flow cytometry using a 488-nm laser FACSCalibur (Becton Dickinson), 
supported by CellQuest software (Becton Dickinson) and the acquired data (minimal 
10,000 events per sample) was analyzed using WinMDI version 2.9 (Joseph Trotter). 
Intracellular calcium measurements 
For single-cell calcium imaging, astrocytes were cultured on glass cover-slips (30 mm 0) 
for at least two days in culture medium, as described above. Next, the cover-slips were 
rinsed shortly in standard loading buffer, containing 150 mM NaCl, 2 mM KCI, 2 mM 
CaCl2, 1 mM MgCl2, 10 mM HEPES/NaOH and 10 mM glucose (pH - 7.35) and loaded 
' 2' · )u•, • [J  t f f [ (  TS •. \,..; lCJl.V � 
with 5 µM Fura-2(AM) (Teflabs.com) together with 0.4% pluronic© F-127 (Molecular 
Probes) in 1 ml loading buffer for 30-45 minutes at 37°C. After an additional washing 
step of 30 minutes in plain loading buffer, the cover-slips were fixed in a perfusion 
chamber (37°C) and attached to an inverted microscope (Axiovert 35M, Zeiss) equipped 
with a 12 bit Sensicam CCD camera (PCO) supported by Imaging Workbench 5.0 
software (INDEC systems, Inc.). Using a 16x plan-neofluar objective digital images were 
taken at an emission wavelength of 510 nm using paired exposure at 340 nm and 380 
nm excitation wavelengths at a frequency of 1 Hz. Changes in intracellular calcium levels 
were expressed as the ratio of the 340 and 380 nm excitation wavelengths (0340/380) in 
time (seconds). 
During recording experiments, compounds were administered directly to the loading 
buffer using a pipette. Recombinant chemokines CCL21 and CXCL 10 were administered 
at end-concentrations of 10-9 M, 10-8 M and 10-7 M (in PBS). Administration of 10-5 M 
(end-concentration) ATP served as a positive control and PBS as a negative control. The 
percentage of chemokine-responsive cells was related to the total number of ATP­
responsive cells per experiment. Astrocytes non-responsive to ATP were excluded from 
the experiments. 
For pertussis toxin experiments, astrocytes were pre-incubated with 200 ng/ml pertussis 
toxin 24 hours before calcium measurements. In addition, experiments were done in 
calcium-free loading buffer, containing 150 mM NaCl, 2 mM KCI, 2 mM MgCl2, 0.5 mM 
EGTA, 2 mM MgCl2, 10 mM HEPES/NaOH and 10 mM glucose (pH - 7.35). Cells were 
loaded with Fura-2(AM) and washed as described above. During recording experiments, 
standard loading buffer was replaced by calcium-free loading buffer. 
For intracellular calcium-depletion experiments, cells were loaded with Fura-2(AM) as 
described above, followed by incubation with 2 µM thapsigargin in standard loading 
buffer for 45 minutes. Also here, intracellular calcium measurements were done in 
calcium-free buffer. 
Astrocyte proliferation assay 
Astrocyte proliferation in response to CXCL 10 and CCL21 was assessed by conversion 
of 3-(4,5-dimethylthiazol)-2,5-diphenyltetrazolium bromide (MTT) into formazan. Freshly 
prepared astrocyte cultures were plated in 24-wells plates at a density of 10,000 cells per 
well in standard culture medium (10% FCS). After attachment (3 to 4 hours) the cells 
were rinsed once in PBS and incubated with serum-free culture medium (0% FCS), 
supplemented with either CCL21 or CXCL 10 at concentrations of 10-9 M and 10-a M for 
72 hours at 37°C. Medium was refreshed every 24 hours. After 72 hours, MTT (Sigma) 
was added to the medium at an end-concentration of 0.5 mg/ml for an additional 4 hours. 
Subsequently, the medium was carefully aspirated and the formazan crystal residues 
were solved in 700 µI DMSO. The optical density was measured by spectrophotometry 
at a wavelength of 570 nm with background subtraction at 690 nm. Serum-free culture 
medium served as a negative control for proliferation and standard culture medium with 
10% FCS served as a positive control. 
Statistical analysis 
Data are represented as the mean ± standard error of the mean (SEM). For calcium 
imaging experiments, n is the total number of cells measured. For proliferation 
experiments, n is the total number of experiments performed. Statistical comparison 
between groups was performed using the two-tailed Students· t-test and p-values 
smaller than 0.05 were considered significant. All statistical tests were performed in 
SPSS version 14.0.2 (SPSS Inc., Chicago). 
RESULTS 
Primary mouse astrocytes express CXCR3, but not CCR7 
Since CCL21 has been reported to signal through CXCR3 as well as CCR?, we 
performed RT-PCR analysis for both receptors in primary mouse astrocytes, using 
spleen tissue as a positive control. Presence of CXCR3 mRNA was detected in both 
astrocyte cultures and spleen control tissue, as indicated by clear bands at 288 base­
pairs (Fig. 5.1A). In contrast, whereas in spleen the presence of CCR7 mRNA (345 
base-pairs) was found, this message was absent in the astrocyte cultures (Fig. 5.1 A). 
Subsequently, surface expression of CXCR3 and CCR? protein was analyzed by flow 
cytometry. Astrocytes showed substantial surface expression of CXCR3 protein, 
whereas no expression of CCR7 protein was detected, corroborating the RT-PCR results 
(Fig. 5.1 B and C). 
Both CXCL10 and CCL21 induce calcium transients in primary mouse astrocytes 
In order to determine whether primary mouse astrocytes respond to CCL21 and whether 
this response is mediated through CXCR3, single-cell calcium imaging was performed. 
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CXCR3-ligand CXCL 10 was used as a reference, since this chemokine has been shown 
to induce calcium transients in primary murine astrocytes (Biber et al, 2002). 
Here, the percentage of CXCL 10-responsive astrocytes was dependent on the 
concentration as 10·9 M CXCL 10 induced calcium transients in 23% (out of n=47), 10·5 M 
CXCL 10 in 25% (out of n=145) and 10·7 M CXCL 10 in 68% (out of n=40) of the 
astrocytes (Fig. 5.2A). The amplitude of the calcium transients induced by CXCL 10 was 
highly variable and did not show any concentration-dependency (p=0.659). 
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Figure 5.1 .  Primary mouse astrocytes express CXCR3, but not CCR7. (A) RT-PCR analysis 
revealed CXCR3 mRNA positivity (288 bp) in cultured mouse astrocytes (astro), while CCR? m RNA 
was not detected. Spleen tissue (spl), which served as a positive control, was positive for both 
markers. To check for comparable RNA qual ity, amplification of the housekeeping gene GAPDH 
was used. MM; molecular marker, - ; control without reverse transcription. (B,C) Flow cytometric 
analysis confirms these findings as CXCR3 protein expression (B, solid black line) was found on a 
subpopulation of astrocytes, while CCR? protein expression (C, solid black line) was not detected. 





Figure 5.2 (right). Both CXCL 10 and CCL21 induce calcium transients in primary mouse 
astrocytes, which are (partly for CCL21) mediated by CXCR3. (A) The percentage of responsive 
astrocytes in wild type (•) and CXCR3·'· (o) induced by 10·9, 10"8 and 1 0·1 M recombinant mouse 
CXCL10 as calculated to the percentage of ATP-responsive cells (=100%). Bars indicate the mean 
± SEM. 10·9 M and 10·1 M CXCL 10 induced calcium transients in 23% (out of n=47) and 25% (out of 
n=145) of the astrocytes, respectively, while 1 0·1 M CXCL10 induced responses in 68% (out of 
n=40) of the astrocytes. CXCR3.,_ astrocytes showed hardly any responses to the various CXCL 10 
concentrations. Bottom calcium traces represent typical CXCL 10-induced calcium responses in both 
wild type and CXCR3.,_ astrocytes, expressed as the change in the 340/380 nm ratio (a340/380) in 
time (sec). Arrows indicate time-point of chemokine application. The amplitude and duration of the 
calcium responses were highly variable and showed no concentration-dependency (data not 
shown). (B) The percentage of responsive astrocytes in wild type (•) and CXCR3.,_ (a) induced by 
10·9 , 10 .. and 10·7 M recombinant mouse CCL21 as calculated to the percentage of ATP-responsive 
cells (=100%). Similar to CXCL 10, 10·9 M and 10·• M CCL21 induced calcium transients in 22% (out 
of n=41) and 26% (out of n=157) of the astrocytes respectively, while 10·7 M CCL21 induced 
responses in 70% (out of n=56) of the astrocytes. Although hardly any responses were detected in 
CXCR3·1• astrocytes in response to 10"9 and 10·• M CCL21 , 10·1 M CCL21 induced calcium transients 
in 70% (out of n=33) of these cells, suggesting involvement of another (chemokine) receptor. 
Bottom traces represent typical CCL21-induced calcium responses in both wild type and CXCR3·1· 
astrocytes, expressed as the change in the 340/380 nm ratio (a340/380) in time (sec). Also here, 
the amplitude and duration of the calcium responses did not show concentration-dependency (data 
not shown). Arrows indicate time-point of chemokine application. Student's t-test. * p<0.05; 
p<0.01; *** p<0.001. 
Wild type astrocytes clearly responded to CCL21 with an increase in intracellular calcium 
and also here the number of responsive astrocytes depended on the concentration of 
CCL21 (Fig. 5.28). The percentages of C CL21 -responsive astrocytes were similar to that 
of CXCL 10 as 1 0·9 M and 1 0-a M CCL2 1  induced calcium transients in approximately 
22% (out of n=4 1 )  and 26% (out of n=1 57) of the astrocytes. Also here, application of 1 0" 
7 M CCL21 g ave the highest percentage of responsive astrocytes (70% out of n=56). 
Similar to CXCL 1 0-induced calcium responses, the amplitude of the transient calcium 
responses induced by CCL21 varied considerably and did not show any concentration­
dependency (p = 0.276). 
Unlike CXCL 10, CCL21-induced calcium transients are just partly dependent on CXCR3 
In order to determine the involvement of CXCR3, single-cell calcium experiments were 
performed in astrocytes derived from CXCR3_,_ mice. CXCR3_,_ astrocytes did not 
respond to application of either 10"9 M (4% out of n=53), 1 0-a M (5% out of n=1 47) or 1 0·7 
M (6% out o f  n=35) CXCL 1 0, confirming that CXCL 1 0-induced calcium transients are 
mediated entirely through CXCR3 in primary mouse astrocytes (Fig. 5.2A). 
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Figure 5.3 (right). CXCL 10 and CCL21-induced calcium transients in primary mouse 
astrocytes originate from intracellular calcium stores and are partly inhibited by pertussis 
toxin. Effects of calcium-free buffer (-[Ca2·1 •• ), thapsigargin (thap) and pertussis toxin (PTX) on 
intracellular calcium transients in primary mouse astrocytes induced by 10·5 M CXCL 10 (A), 10·5 M 
CCL21 (B) and 10·1 M CCL21 (C). The percentage of CXCL 10-responsive astrocytes (A) was not 
significantly affected when experiments were performed in calcium-free buffer (21% out of n=42; 
p=0.650). Pre-treatment with 2 µM thapsigargln, blocking calcium mobilization from intracellular 
stores, completely inhibited the response to 10·5 M CXCL 10 (0% out of n=40; p<0.001). Pre­
treatment with PTX resulted in a slight reduction in the percentage of CXCL 10-responsive 
astrocytes from 25% (out of n=145) to 17% (out of n=79), which was not significant (p=0.277). Top 
graphs show representative calcium traces, expressed as the change in the 340/380 nm ratio 
(6340/380) in time (sec), showing the effects of calcium-free buffer, thapsigargin and PTX on 
CXCL 10-induced calcium transients (A). Similar results were found for 10·8 M CCL21 (B) as 
depletion of extracellular calcium had no significant effect on the number of responsive astrocytes 
(20% out of n=137, p=0.099) nor on the amplitude and duration of the transients. Thapsigargin 
completely abolished CCL21-induced transients (0% out of n=76, p<0.001). Also here, pre­
treatment with pertussis toxin resulted in a slight reduction in the percentage of astrocytes 
responsive to 10·8 M CCL21 from 27% (out of n=157) to 15% (out of n=92), which was not 
significant (p=0.059). In response to 10·1 M CCL21 (C), omission of extracellular calcium had no 
effect on the percentage of responsive wild type (closed bars, 71% out of n=42, p=0.834) and 
CXCR3_,_ (open bars, 72% out of n=43, p=0.960) astrocytes and treatment with thapsigargin fully 
inhibited these responses in both cell-types (0% out of n=47 and n=53, respectively, p<0.001). Pre­
treatment with PTX had no effect on the percentage of wild type (72% out of n=42, p=0.685) and 
CXCR3_,_ astrocytes (65% out of n=37, p=0.554) responsive to 10·1 M CCL21. The percentage of 
chemokine-responsive astrocytes was calculated to the percentage of ATP-responsive cells (= 
100%). Bars indicate mean ± SEM. Student's t-test, *** p<0.001, 'p=0.059. 
Like CXCL 1 0, 1 0·9 M (2% out of n=48) and 1 0"8 M CCL21 (6% out of n=82) failed to 
induce calcium transients in CXCR3+ astrocytes. Surprisingly, whereas application of 1 0· 
7 M CXCL 1 0  had no effect on CXCR3+ astrocytes, clear responses were detected in 
response to 1 f
f7 M CCL21 with similar percentages (70% out of n=33) as detected in 
wild type astrocytes (fig .  5.28). Interestingly, the latency (time between application and 
the start of the response) of 1 0·7 M C CL21 -induced calcium responses in CXCR3-t­
astrocytes (3.1  ± 1 .9 sec) was clearly shorter then in astrocytes derived from wild types 
(23.2 ± 5.3 sec, p<0.001 ) .  
Intracellular elements involved in CXCL 10- and CCL21- induced calcium transients 
To determine whether CXCL 1 0  and CCL21 -induced calcium transients originate from 
intracellular calcium stores or are caused by extracellular calcium influx, measurements 
were performed in calcium-free buffer while intracellular calcium stores were depleted 
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Thapsigargin inhibits sarco/endoplasmic reticulum Ca2+ ATPases (SERCA), resulting in 
an incapability of a cell to pump calcium into the sarco/endoplasmic reticulum which 
causes these stores to become depleted. Omission of extracellular calcium did not 
significantly affect the number of astrocytes responding to 10-a M CXCL 1 0  (21 %  out of 
n=42, p=0.650; Fig. 5.3A). The calcium responses to CXCL 10  in calcium-free buffer had 
similar amplitudes and kinetics as observed in control experiments . Pre-treatment with 
thapsigargin (2 µM) completely abolished the response to 1 0-a M CXCL 1 0  (0% out of 
n=40, Fig. 5.3A). These results show that CXCL 10-induced calcium responses in 
astrocytes derive from intracellular calcium stores. 
To determine involvement of G,- and Go-coupled proteins in CXCL 1 0-induced calcium 
transients, astrocytes were pre-treated with the G;- and G0-inactivating agent pertussis 
toxin. Treatment with pertussis toxin reduced the number of responsive astrocytes 
induced by 1 0-a M CXCL 1 0  from 25% (out of n=145) to 1 7% (out of n=79), although this 
reduction was not significant (p=0.277; Fig. 5.3A), suggesting involvement of other G­
proteins than G; and Go. 
Like in response to CXCL 1 0, the percentage of astrocytes responding to 1 0-a M CCL21 
(Fig. 5.38) was not significantly affected after omission of extracellular calcium (20% out 
of n=1 37, p=0.099; Fig. 5.38) and the average response amplitude (80. 1 8  ± 0.03) was 
similar to that observed in control experiments (80.25 ± 0.03). Also here responses to 
1 0-a M CCL21 were completely abolished after pre-treatment with 2 µM thapsigargin (0% 
out of n=76; Fig. 5.38). Pre-treatment with pertussis toxin reduced the number of 
responsive astrocytes induced by 1 0-a M CCL21 from 27% (out of n=1 57) to 1 5% (out of 
n=92), although also here this reduction was not significant (p=0.059; Fig. 5.38). Further 
analysis showed that treatment with pertussis toxin did not significantly affect the 
amplitude, latency or duration of CCL21 -induced calcium responses. 
As a high ( 1 0-7 M) CCL21 -concentration induced calcium transients in both wild type and 
CXCR3+ astrocytes, we determined also here the effects of pertussis toxin, extracellular 
calcium omission and thapsigargin on these responses. Like the calcium transients 
induced by 1 0-a M CCL21 in wild type astrocytes, 1 0-7 M CCL21 induced calcium release 
from intracellular stores in both wild type and CXCR3./- astrocytes (Fig. 5.3C). Omission 
of extracellular calcium did not influence the percentages of responsive cells in wild type 
(71 %  out of n=42, p=0.833) or CXCR3_,_ astrocytes (72% out of n=43, p=0.960) and 
treatment with thapsigargin fully blocked these responses in both cell-types (0% out of 
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Figure 5.4. Both CXCL 1 O and CCL21 promote proliferation in primary mouse astrocytes, 
albeit through different receptors. Effects of CXCL 10 (A) and CCL21 (B) on wild type and 
CXCR3·1• astrocyte proliferation as measured by MTT conversion. Prolonged exposure (72 hrs) to 
10·9 M CXCL 10 (p=0.016) and 10·5 M CXCL 10 (p<0.001) promoted proliferation in wild type 
astrocytes (A, black bars), while this effect was significantly reduced in CXCR3-1- astrocytes (A, 
open bars with p=0.007 for 10·9 M and p=0.005 for 10·5 M CXCL 10 compared to wild type 
conditions). Prolonged exposure to 10·5 M CCL21 (p<0.001) also induced proliferation of wild type 
astrocytes (B, black bars), while 10·9 M CCL21 showed no significant effects (p=0.271) on these 
cells. However, unlike CXCL 10, CCL21-induced proliferation in wild type astrocytes did not 
significantly differ from the effects observed in CXCR3·1· astrocytes, suggesting involvement of 
another receptor than CXCR3. Culture medium without FCS (0%) served as a negative control 
(=100%) for proliferation and medium with 10% FCS served as a positive control. Exposure to 10% 
FCS induced equal amounts of proliferation in wild type and CXCR3·1• astrocytes (p=0.149). Bars 
indicate mean ± SEM. Data are a summary of four individual experiments performed in quadruplets. 
Student's t-test, * p<0.05; ** p<0.01; *** p<0.001. 
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n=47 and n=53, respectively, p<0.001). In addition, pre-treatment with pertussis toxin 
prior to application of 10-7 M CCL21 had no significant effect on the percentages of 
responsive wild type (72% out of n=42, p=0.685) and CXCR3_,_ astrocytes (65% out of 
n=37, p=0.554), corroborating our findings in response to 10-e M CCL21. 
Both CXCL 10 and CCL21 promote primary mouse astrocyte proliferation, albeit through 
different receptors 
Finally, we determined the effects of CXCL 10 and CCL21 on astrocyte proliferation. 
Prolonged exposure (72 hours) to either 10-9 M (p=0.01 6) or 10-8 M CXCL 10 (p<0.001 )  
promoted proliferation of  wild type astrocytes (Fig. 5.4A). I n  addition, long-term exposure 
of both 10-9 M (p=0.096) and 10-e M CXCL10 (p=0.124) had no effect on CXCR3_,_ 
astrocyte proliferation and was significantly inhibited compared to wild type conditions 
(Fig. 5.4A, p=0.007 and p=0.005 respectively). These results confirm again that CXCL 10 
mediates its effects through CXCR3 in primary mouse astrocytes. 
Interestingly, exposure to 1 o-s M CCL21 (p<0.001 ), but not 10-9 M CCL21 (p=0.271 ), also 
clearly promoted proliferation of wild type astrocytes with values comparable to that of 
CXCL 10  (Fig. 5.48). However, in contrast to the effects of CXCL 10, we did not find any 
difference (p=0.440) for the effects of 10-e M CCL21 on wild type- and CXCR3·1-
astrocytes (Fig. 5.4B), suggesting also here that another receptor than CXCR3 might be 
involved. 
DISCUSSION 
In this study we have addressed the effects of chemokine CCL21 (and CXCL 10) on 
intracellular calcium mobilization and proliferation of primary mouse astrocytes, and 
determined to what extent CXCR3 and CCR7 were involved. 
Here, pronounced expression of CXCR3 both at mRNA and protein level was found in 
primary mouse astrocyte cultures, whereas no expression of CCR7 mRNA or protein 
could be detected in these cells. These results are in line with previous findings in both 
human and mouse astrocytes in vitro (Biber et al. ,  2002; Croitoru-Lamoury et al., 2003; 
Flynn et al. , 2003). Moreover, expression of CXCR3, but not CCR7, has been 
demonstrated in human and mouse astrocytes in vivo (Simpson et al., 2000; Goldberg et 
al., 2001;  Van der Meer et al., 200 1 ;  Columba-Cabezas et al., 2003; Omari et al., 2005; 
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Tanuma et al . ,  2006), indicating that the chemokine receptor expression pattern 
observed in this study resembles the one observed in astrocytes in vivo. 
In order to determine CXCR3 functionality in our primary astrocyte cultures, CXCL 1 0  
was used as a reference chemokine. Previous work in our lab showed that mouse 
astrocytes respond to CXCL 10 with intracellular calcium mobilization (Biber et al., 2002). 
Here, the astrocytes responded to CXCL 10 with intracellular calcium transients in a 
concentration-dependent manner. In addition, we confirmed that this CXCL 1 0-response 
was mediated through CXCR3, as astrocytes derived from CXCR3·'· did not respond to 
this ligand. 
Secondly, we showed that CXCL 1 0  promoted proliferation of primary mouse astrocytes 
in a CXCR3-dependent manner. This phenomenon of CXCL 1 0-enhanced proliferation 
has been described previously in human astrocytes (Flynn et al. , 2003), where it was 
shown that similar concentrations (5 ng/ml) of recombinant human CXCL 1 0  promoted 
astrocyte growth. Interestingly, chemokine-induced proliferation of astrocytes in vitro has 
been described for other chemokines such as CCL2, CCL3 and CXCL 12 (Bajetto et al. , 
2001 ; Rezaie et a l . ,  2002). Although it is currently unknown whether chemokines have 
the capacity to induce/enhance astrocyte prol iferation in vivo, it is tempting to speculate 
that chemokines could be involved in the regulation of astrogliosis, a process which is 
characterized by astrocyte proliferation in response to CNS injury. 
Similar results were found for CCL21 demonstrating not only that this chemokine acts on 
astrocytes, but confirming also that CCL21 , like CXCL 10 ,  mediates its action at least 
partly through CXCR3 in these cells. Experiments with primary cultured astrocytes 
derived from CXCR3-1. mice clearly showed no calcium transients in response to lower 
concentrations of CCL21 ( 10.9M and 1 0-aM) suggesting that CXCR3 is the primary 
receptor for this ligand. However, in contrast to CXCL 10 ,  a high concentration of CCL21 
( 10.7M) induced clear calcium transients in CXCR3·'· astrocytes, with similar percentages 
of responding cells as observed in wild types. Moreover, we showed that prolonged 
CCL21 stimulation promoted astrocyte proliferation, albeit that this response seemed not 
to depend on the presence of CXCR3 as we observed no significant differences between 
CXCR3·'· and wild type astrocytes. 
Taken together, these responses to CCL21 in CXCR3·'· astrocytes, in absence of CCR?, 
suggest the involvement of another receptor apart from CXCR3 and CCR?. Given the 
unknown binding properties of CCL21 to most of the other chemokine receptors it is 
unknown at the moment which alternative (chemokine-) receptor might be involved here. 
Currently, the only chemokine-receptor like protein that is known to bind CCL21 with high 
affinity is CCX-CKR (Gosling et al., 2000; Townson and Nibbs, 2002). Interestingly, RT­
PCR analysis showed that both wild type and CXCR3_,_ astrocytes express CCX-CKR 
mRNA (supplementary figure 5.5). However, so far no signalling properties have been 
published for this protein and CCX-CKR is discussed to function as a chemokine 
scavenger (Comerford et al., 2006; Comerford and Nibbs, 2005; Haraldsen and Rot, 
2006). Whether high CCL21-concentrations activate CCX-CKR and induce calcium 
transients or proliferation through this chemokine receptor-like protein in mouse 
astrocytes remains to be established. Alternatively, a chemokine receptor heterodimer­
system with other (non)-chemokine receptors may be involved in the CCL21-induced 
effects seen in both CXCR3_,_ and wild type astrocytes. Examples of altered 
pharmacology of chemokine receptors after heterodimerization with either chemokine- or 
non-chemokine receptors have been described (Chakera et al. ,  2008; El-Asmar et al., 
2005; Mellado et al., 2001 : Pello et al., 2008; Sohy et al., 2007). 
+ MM 
primary astrocyte cultures 
WT1 WT2 K01 K02 
mCCX-CKR 
349 bp 
Supplementary figure 5.5. Primary mouse astrocytes express CCX-CKR. RT-PCR analysis 
revealed CCX-CKR mRNA expression (349 bp) in wild type astrocytes (WT1. WT2) and CXCR3.i­
astrocytes (K01, K02). Primers used for CCX-CKR (accession number AY072938): forward 5'­
AGGACCAAGACCGATGTGTA-3', backward 5'-GAAAGATGGGAGTGCACCTA-3'. +; positive 
control (mouse heart tissue), MM; molecular marker, WT; wild type, KO; CXCR3+ , -; control without 
reverse transcription. 
CCL • [ L CE ' E C c,  "c A ,•ricit,rTE , 
Finally, involvement of a not yet characterised chemokine receptor could explain the 
response to CCL21 in astrocytes derived from CXCR3·'· mice. 
Further analysis of the CXCL 10- and CCL21-evoked calcium transients in astrocytes 
shows that the primary source of the calcium response to CXCL 10 and CCL21 comes, 
like in microglia, from the intracellular calcium stores. This is further corroborated by 
application of thapsigargin, which fully blocked calcium responses to CXCL 1 0  and 
CCL21. However, differences in CXCL 10- and CCL21-induced calcium responses 
between astrocytes and microglia are evident. One difference between astrocytes and 
microglia concerns the concentration-dependency of the parameters involved. In case of 
astrocytes the number of cells responding to CXCL 10 and CCL21 showed concentration­
dependency, whereas in microglia the concentration-dependency involved the amplitude 
of the transient calcium responses (Biber et al., 2001). Most likely, the concentration­
dependency of the amplitude of the calcium response in astrocytes is very steep, 
resembling an all-or-none response. Secondly, it seems that CCL21 induces recruitment 
of other sets of G-proteins in astrocytes than in microglia. Treatment of astrocytes with 
the G;- and Go-inactivating agent pertussis toxin did not significantly affect the transient 
calcium response to CXCL 10 and CCL21, whereas in human microglia the response to 
CCL21 could be fully blocked by pre-treatment with pertussis toxin (Dijkstra et al., 2004). 
Whether or not CCL21 directly binds to CXCR3 in an expression system is a matter of 
debate (Soto et al., 1998; Jenh et al., 1999). However, in both human and mouse 
microglia CXCR3 is the primary receptor for CCL21-induced migration and calcium 
transients (Biber et al., 2001 ;  Dijkstra et al., 2004; Rappert et al., 2002). Microglia 
derived from CXCR3-deficient mice did not migrate towards a CCL21-gradient and 
cross-desensitization experiments between CCL21 and CXCL 10 in both human and 
mouse microglia suggest that these chemokines activate the same chemokine receptor, 
namely CXCR3 (Biber et al., 2001 ; Dijkstra et al., 2004; Rappert et al., 2002). It has 
therefore been suggested that the pharmacology of CXCR3-signalling depends on the 
cellular background in which CXCR3 is expressed (Dijkstra et al., 2004) and the data 
presented here in astrocytes further corroborate this assumption. 
In conclusion, we report for the first time that CCL21 induces calcium responses and 
proliferation in primary mouse astrocytes with similar dynamics as seen in response to 
CXCR3-ligand CXCL 10. However, in absence of CXCR3, high concentrations of CCL21 








prolonged CCL21 exposure did not differ from wild type conditions, suggesting 
involvement of another or additional (chemokine-) receptor. Furthermore, these CCL21-
induced responses in mouse astrocytes seem to differ from microglia in dynamics and G­
protein- and receptor involvement, suggesting that CCL21 has specific separate 
functions in these two glia cell-types. The precise role of neuronal CCL21 expression in 
vivo remains to be determined, although it is clear that both microglia and astrocytes 
have the capacity to respond to CCL21 in vitro, suggesting that this chemokine plays a 
role in the communication between neurons and surrounding glia cells under 
pathological conditions. 
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SUMMARY & GENERAL DISCUSSION 
Glia cells rapidly respond to neuronal injury 
Next to their neuronal support functions in the healthy CNS, glia cells (in particular 
microglia and astrocytes) are intimately involved in the initiation and regulation of 
neuroinflammatory responses within the CNS. Any type of neuronal injury leads to rapid 
activation of these cells. Tight regulation of these glia responses is a prerequisite for 
neuronal survival under these conditions and therefore requires intimate interactions 
between neurons and glia cells through cell-cell contact and expression of soluble 
factors. However, glia reactions in the injured CNS are not inevitably neurosupportive as 
excessive or chronic activation may lead to the development of neurodegenerative 
responses. Identification of these mechanisms will give important insight in the role of 
glia cells in acute CNS injury and in the development of chronic CNS disease. 
Microglia activation in excitotoxicity: beneficial or detrimental? 
Excitotoxicity is a process associated with many CNS pathologies and is characterized 
by a progressive loss of neurons as a result of persistent activation of glutamate 
receptors, in particular NMDA receptors, by excessive levels of extracellular glutamate. 
Although the classical concept of excitotoxicity-induced neuronal cell death has been 
considered for a long time as a result of endogenous processes, recent data suggest a 
prominent role for microglia in this process. However, based on several contradictory 
observations it is still unclear whether microglia promote neuronal survival or exacerbate 
the original extent of neuronal damage in this paradigm. In Chapter 2 we have 
addressed the role of microglia in an ex vivo model for NMDA-induced excitotoxicity in 
mouse hippocampal slice cultures. In this paradigm, treatment with 10-50 µM NMDA 
resulted in region-selective neuronal cell death in the hippocampal regions CA 1, CA3 
and DG, with CA1 neurons being most vulnerable to NMDA-treatment, followed by CA3 
and DG neurons, respectively. Our data demonstrate that hippocampal microglia display 
a profound neuroprotective role in this paradigm as specific ablation of microglia prior to 
NMDA-treatment resulted in severely enhanced neuronal cell death in the hippocampal 
regions CA3 and DG. Moreover, our data suggest that morphological activation of 
microglia is not a prerequisite for their neuroprotective function. At lower concentrations 
of NMDA (10 µM) we did not observe neuronal cell death in the CA3 and DG regions 
and microglia in these regions retained their ramified phenotype. From a classical point 
' ,. 
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of view one would assume that these microglia are not active. However, neuronal loss 
was profound in these neuronal regions in the absence of ramified microglia when 
exposed to 10 µM NMDA. Therefore, it is proposed that ramified microglia should not be 
regarded as solely inactive "resting" cells, but as active contributors in the protection of 
neurons under excitotoxic conditions. 
Our results are in line with other reports describing neuroprotective properties for 
microglia upon excitotoxic or ischemic injury (Imai et al., 2007; Kitamura et al. ,  2004; 
Lalancette-Hebert et al., 2007; Turrin and Rivest, 2006) and it is therefore tempting to 
suggest that microglia activation in excitotoxicity-related disorders is primarily a 
beneficial process. However, this assumption may be presumptuous for the following 
reasons. Several lines of evidence have shown that inhibition of microglia activation by 
immunosuppression is beneficial after acute CNS damage (discussed in (Hailer, 2008)). 
In all cases treatment with immunosuppressive agents resulted in improved neuronal 
survival and function, which coincided with a decrease in microglia activation. Although 
most of these immunosuppressants have shown to directly inhibit the pro-inflammatory 
profile of isolated microglia (e.g. the secretion of pro-inflammatory cytokines and NO), 
there is an equal amount of evidence that these agents directly affect neurons and/or 
astrocytes as well. Therefore, a direct link between the beneficial effects of 
immunosuppression and the observed downregulation of microglia function in acute CNS 
injury remains to be elucidated. Nonetheless, it is likely that the basal protective function 
of microglia might be overshadowed by their pro-inflammatory profile in response to 
excitotoxic conditions (Hailer, 2008; Hanisch and Kettenmann, 2007; Ransohoff and 
Perry, 2009). It is therefore of importance to elucidate at what time-point microglia turn 
from "neuroprotective" into "neurotoxic" cells in this paradigm and which factors may be 
implicated here. 
Chapter 3 and Chapter 4 of this thesis provide evidence that the expression of 
chemokines, in particular of CXCL 10 and CCL21, within the CNS affects neuronal 
damage under excitotoxic conditions, possibly through modulation of glia function. 
CXCL1 0 
Expression of the chemokine CXCL 10 in the CNS has been associated with both acute 
and chronic CNS pathologies. Depending on the type of injury, in vivo expression of 
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lesions (Balashov et al., 1999; Omari et al., 2005; Simpson et al., 2000; Tanuma et al., 
2006; Wang et al., 1998; Xia et al., 2000), and to a lesser extent in neurons (Rappert et 
al. ,  2004; Wang et al. ,  1998). Interestingly, expression of its corresponding receptor 
CXCR3 has been demonstrated in microglia (Biber et al., 2001 ;  Biber et al., 2002a; 
Dijkstra et al., 2004; Rappert et al., 2002) and in astrocytes (Goldberg et al., 2001; Omari 
et al. ,  2005; Simpson et al., 2000; Tanuma et al., 2006). These findings suggest that 
CXCL 1 0 and CXCR3 might provide a signaling system between neurons and glial cells 
under pathological conditions. In line with this suggestion, it has been demonstrated in 
vitro that CXCL 10 induces CXCR3-mediated migration of microglia (Biber et al., 2001; 
Biber et al., 2002a; Rappert et al., 2002) and proliferation in primary astrocyte cultures 
(Flynn et al., 2003). However, the potential role for CXCL 10/CXCR3 signaling between 
neurons and/or glia cells under pathological conditions is far from understood. In 
Chapter 3 we have addressed this concept by examining the effect of CXCL 1 0/CXCR3-
signaling in hippocampal slice cultures in response to NMDA-induced excitotoxicity. 
Here, we show that NMDA-induced neuronal cell death coincided with a rapid 
upregulation (within 4 hours) of CXCL 1 0  expression in astrocytes. To examine the effect 
of CXCL 10 expression in our paradigm, we compared the levels of NM DA-induced 
neuronal cell death in wild type (control) slice cultures with those in slice cultures derived 
from CXCL 10-1- and CXCR3-1- mice. In the absence of CXCL 10 (CXCL 10-1-), neurons of 
the CA1 and CA3 regions displayed a decreased vulnerability to (10-25 µM) NMDA­
treatment, while the opposite effect was observed in the DG region when exposed to 
high (50 µM) NMDA-concentrations. These findings not only support a role for CXCL 10 
in excitotoxicity, but also show that CXCL 10 expression differentially affects CA and DG 
neurons in this paradigm. In addition, we could demonstrate that the phenotype 
observed in CXCL 10_,_-derived slice cultures was identical to that observed in CXCR3-1-_ 
derived slice cultures, indicating that CXCL 10 mediates its effects through CXCR3. We 
confirmed these findings by demonstrating that exposure to exogenous CXCL 10 ( 10-a M) 
directly after NM DA-treatment "rescued" the phenotype observed in CXCL 10-1--derived 
slice cultures, but not in slice cultures derived from CXCR3-1--mice. 
Finally, we demonstrated that microglia in slice cultures expressed CXCR3 and that 
ablation of these cells prior to NMDA-treatment fully abrogated the differences in 
neuronal cell death observed between wildtype- and CXCR3_,_-derived slice cultures. 
These findings suggest a prominent role for microglial CXCR3 in the degeneration of 
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neurons under excitotoxic conditions, which is in agreement with earlier studies from our 
group (Rappert et al., 2004). 
Taken together, the results presented in Chapter 3 identify a region-specific role for 
CXCL 1 0/CXCR3 signaling in the communication between damaged neurons and/or glia 
in hippocampus excitotoxicity. Why CXCL 10/CXCR3 signaling under excitotoxic 
conditions is detrimental in the CA regions of the hippocampus and protective in the DG 
region remains to be elucidated. This dual effect of CXCL 10/CXCR3 signaling may 
depend on regional differences in CXCR3 expression. For example, heterogeneity in 
CXCR3 expression has been demonstrated previously in distinct microglia 
subpopulations (Li et al., 2006), and it would therefore be of interest to determine 
whether the expression profile of CXCR3 in hippocampal microglia (and other 
hippocampal cell-types) in the various regions vary. Another possibility for the dual role 
of CXCL 10 in the hippocampus may be regional differences in the response of microglia 
to CXCR3-stimulation or regional differences in co-expression of local factors that, 
together with CXCL 10, direct microglia to either a pro-inflammatory or a neuroprotective 
phenotype. Additional experiments are necessary to address these questions. 
CCL21 
Another prominent candidate that might influence microglia function under excitotoxic 
conditions is the chemokine CCL21. The expression of CCL21 in vivo has been 
exclusively demonstrated in ischemic cortical neurons in the close vicinity ("penumbra" 
zone) of the ischemic lesion core and in dorsal horn neurons after spinal cord injury 
(Biber et al., 2001; Zhao et al., 2007). In addition, neuronal expression of CCL21 has 
been observed in vitro in hippocampal slice cultures and in cortical neuron cultures when 
exposed to toxic levels of glutamate, showing that this chemokine is also expressed 
under excitotoxic conditions (Biber et al., 2002b; de Jong et al., 2005). Previously, we 
have shown in vitro that CCL21 activates microglia as measured by directed migration, 
induction of calcium transients and changes in electrophysiological properties (Biber et 
al., 2001; Dijkstra et al., 2004; Rappert et al., 2002). Moreover, it was demonstrated that 
activation of microglia by CCL21 was not mediated through its cognate receptor CCR?, 
but depended on the presence of CXCR3 (Biber et al., 2001; Dijkstra et al., 2004; 
Rappert et al., 2002). Taken together, it was suggested that the expression of CCL21 by 
neurons might provide a signal that activates/recruits CXCR3-positive microglia under 
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between injured neurons and microglia remains elusive. In Chapter 4 we provide 
evidence that the presence of CCL21 in hippocampal slice cultures exacerbates 
neuronal damage under excitotoxic conditions. Accordingly, it was demonstrated that 
neuronal cell death in response to NMDA-treatment was attenuated in the CA regions of 
pit (CCL21/CCL 19-deficient)-derived hippocampal slice cultures when compared to wild 
type conditions, while application of exogenous CCL21 (10-8 M) directly after NMDA­
treatment aggravated neuronal cell death in these slice cultures in all three hippocampal 
regions. In addition, we provide evidence that this "neurotoxic" effect of CCL21 under 
excitotoxic conditions depends on the presence of CXCR3, and not CCR?. 
As we have shown previously that acutely isolated microglia from hippocampal slice 
cultures express CXCR3 (see Chapter 3) and that CCL21 activates microglia in vitro in a 
CXCR3-dependent manner, it is suggested that these cells might be implicated in the 
neurotoxic effect of CCL21-signaling we observed in our paradigm. Interestingly, a 
recent study has demonstrated that injection of CCL21 directly into the ventral 
posterolateral nucleus of the thalamus resulted in transient activation of local microglia 
and induced pain-related behavior (Zhao et al., 2007). This CCL21-induced pain 
behavior could be blocked by co-administration of minocycline, which is known to inhibit 
microglia function. In line with our own findings, it is therefore likely that CCL21 triggers a 
response in microglia that is associated with a pro-inflammatory phenotype. 
Taken together, we propose that CCL21 is a neuron-derived factor that is part of a 
signaling-cascade (most likely through CXCR3-mediated activity of microglia) that leads 
to neuronal cell death under excitotoxic conditions. Therefore, it would be of interest to 
determine whether specific blocking of CCL21 in vivo might be beneficial in animal 
models for excitotoxicity-related CNS pathologies. 
Two ligands, one receptor, distinct signaling events 
Summarizing Chapter 3 and Chapter 4, we demonstrated that the expression of 
CXCL 10 and CCL21 in the hippocampus both affected the degree of neuronal cell death 
in response to NMDA-induced excitotoxicity. Although we showed that the effects of 
these two ligands were mediated through the same receptor, namely CXCR3, various 
observations suggest that their expression and mode of action are not redundant but part 
of distinct signaling cascades. First of all, we demonstrated in our paradigm that CXCL 1 0  
was expressed in astrocytes, while CCL21 expression under excitotoxic conditions has 
been detected exclusively in damaged neurons (Biber et al., 2001; de Jong et al., 2005). 
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Secondly, if CXCL 10 and CCL21 were part of a redundant signaling system, the effects 
of abrogation of one ligand in our paradigm would have been compensated for by the 
other ligand, an event we did not observe in our studies. The third observation, and 
maybe the most evident one, is that the absence of CXCL 10- (CXCL 10-,_) or CCL21-
expression (pit) in our paradigm resulted in different effects on the survival of CA and DG 
neurons after treatment with NMDA. Some overlap in effects may exist as NMDA­
induced neuronal cell death in the CA regions was attenuated in the absence of either of 
these two ligands, however, their effects on neuronal cell death in the DG region were 
opposing. The observation that CXCL 10 and CCL21 may have different effects in the 
CNS has been corroborated recently in vivo as transgenic over-expression of CCL21 in 
the CNS of intact mice resulted in the development of severe neuropathologies and 
premature death (Chen et al., 2002), while transgenic over-expression of CXCL 10 in the 
CNS did not result in evident neuropathological signs under healthy conditions (Boztug 
et al. ,  2002). Although in these studies the involvement of CXCR3 in their paradigm was 
not investigated, it is likely that CXCL 10 and CCL21 induce different signaling events 
through the same receptor. This assumption is also reflected in the fact that the 
pharmacology of CXCR3-signaling depends on the cellular background in which CXCR3 
is expressed (Dijkstra et al., 2004). Accordingly, it has been demonstrated in vitro that 
CXCL10 induced CXCR3-mediated migration in cultured microglia (Biber et al., 2002a; 
Rappert et al., 2002), proliferation in astrocytes (Flynn et al., 2003) and changes in 
excitatory activity in neuronal cultures (Nelson and Gruol, 2004). Similarly, CCL21 
induced migration and electrophysical changes in cultured microglia (Biber et al., 2001; 
Dijkstra et al., 2004; Rappert et al., 2002), while this ligand induced proliferation in 
astrocytes (see Chapter 5). In line with these findings we provide evidence in Chapter 5 
that the effects of CCL21 (and CXCL 10) in cultured astrocytes may differ from those in 
microglia in dynamics, G-protein- and (partly) receptor involvement, emphasizing that 
indeed the pharmacology of CXCR3 signaling depends on the cell-type in which it is 
expressed. 
CXCL 10- and CCL21-induced responses in primary astrocytes: differences in 
receptor dependency 
Finally, we have demonstrated in Chapter 5 that CXCL 10 and CCL21 induce calcium 
transients and proliferation in primary mouse astrocytes, suggesting that these cells 























effects of CXCL 10 on astrocytes have been demonstrated previously (Biber et al . , 
2002a; Flynn et al., 2003), the involvement of its receptor CXCR3 needed to be 
confirmed. Pronounced expression of CXCR3 was found both at an mRNA and protein 
level. In addition, we demonstrated that, in contrast to wild type astrocytes, CXCL 10 had 
no effect on astrocytes derived from CXCR3_,_ mice in terms of intracellular calcium 
mobilization and proliferation, confirming the involvement of this receptor in these 
processes. 
Similar results were observed in response to CCL21 demonstrating not only that this 
chemokine acts on astrocytes, but confirming also that CCL21 mediates its effects 
through CXCR3 in these cells (CCR? expression was not detected in these cells). 
Indeed, lower concentrations of CCL21 (10"9 -10-s M) failed to induce calcium transients 
in astrocytes derived from CXCR3_,_ mice. However, exposure to higher concentrations of 
CCL21 (10-7 M) clearly induced calcium transients in CXCR3_,_ astrocytes. Moreover, we 
demonstrated that CCL21 promoted astrocyte proliferation, albeit that this response did 
not depend on the presence of CXCR3 as we observed no significant differences 
between wild type and CXCR3.,_ astrocytes in this respect. 
Taken together, the response of CXCR3_,_ astrocytes to CCL21, in the absence of CCR?, 
suggests the involvement of another (chemokine-) receptor apart from CXCR3 and 
CCR?. The only other candidate that is known to bind CCL21 with high affinity is the 
chemokine receptor-like protein CCX-CKR (Gosling et al., 2000; Townson and Nibbs, 
2002). Indeed, we did observe CCX-CKR mRN A  expression in both wild type- and 
CXCR3+ astrocytes. However, so far no signaling properties have been described for 
this protein and CCX-CKR is currently discussed to function as a scavenger protein for 
various chemokines (Comerford and Nibbs, 2005; Comerford et al., 2006; Haraldsen and 
Rot, 2006). Whether this chemokine receptor-like protein is involved in the CCL21-
induced effects in wild type- and CXCR3_,_ astrocytes remains to be established. 
Alternatively, a chemokine receptor heterodimer-system with other (non)-chemokine 
receptors may be involved here. Various examples of altered pharmacology after 
chemokine receptor-heterodimerization with other chemokine- or non-chemokine 
receptors have been described (Chakera et al., 2008; El-Asmar et al., 2005; Mellado et 
al., 2001; Pello et al., 2008; Sohy et al., 2007). Finally, involvement of a not yet 
characterized chemokine receptor might explain the response to CCL21 in CXCR3_,_ 
astrocytes. 
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De primaire functionele eenheid van het centrale zenuwstelsel (CZS) is de zenuwcel, 
oftewel het neuron. Neuronen verzorgen de communicatie tussen de verschillende 
hersengebieden en tussen het CZS en de rest van het lichaam via elektrochemische 
signaaloverdracht. Deze vorm van neuronale communicatie (neurotransmissie) maakt 
complexe processen zeals het aansturen van bewegingen, het vermogen tot waarnemen 
(zicht, reuk, smaak, gehoor en tast), bewustzijn, leren, denken en herinneren mogelijk. 
Neuronen zijn zeer kwetsbare cellen en om goed te functioneren warden deze cellen 
ondersteund door gespecialiseerde steuncellen, ook wel glia cellen (uit het Grieks, y>..1a = 
lijm) genoemd. Deze glia cellen warden onderverdeeld in drie groepen: 
oligodendrocyten, astrocyten en microglia, en hebben elk een specifieke functie in het 
CZS. Oligodendrocyten omwinden neuronale uitlopers (axonen) met myeline en 
versnellen zo de elektrische geleiding van neuronale signalen. Astrocyten hebben vele 
functies, maar zijn met name betrokken bij de handhaving van ion- en water­
homeostase, de regulatie van neurotransmitterconcentraties in het CZS, het verschaffen 
van voedingsstoffen aan neuronen en het verzorgen van de afbraak en afvoer van 
afvalstoffen naar de bloedcirculatie. Daarnaast spelen astrocyten een belangrijke rol bij 
het herstel van neuronen na schade in het CZS. Microglia daarentegen warden 
beschouwd als de immuuncompetente cellen van het CZS. Microglia manifesteren zich 
in het "gezonde" CZS als kleine cellen met vertakte uitlopers, waarmee ze continu hun 
directe omgeving aftasten. Staffen die normaal niet aanwezig zijn of in verhoogde mate 
tot expressie warden gebracht in het CZS kunnen herkend warden door middel van 
specifieke receptoren aan het celoppervlak. Voorbeelden van stoffen die herkend 
kunnen warden door microglia zijn niet alleen "lichaamsvreemde" stoffen zeals 
bacteriele- en virale componenten, maar ook celresten, bloedcomponenten en 
stressfactoren afkomstig van naburige cellen. Wanneer er sprake is van schade in het 
CZS trekken microglia (in bijna alle gevallen) hun uitlopers in en transformeren ze van 
vertakte cellen in ronde "geactiveerde" macrofaagcellen. Door deze transformatie zijn 
microglia in staat te migreren naar het schadegebied (chemotaxis) en, eenmaal 
aangekomen, afgestorven cellen en celresten op te nemen (fagocytose) en af te breken 
om zo het herstel na weefselschade te bevorderen. Daarnaast kunnen geactiveerde 
microglia zich vermeerden door celdeling (proliferatie). 
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Naast het hebben van een ondersteunende functie is tevens gebleken dat glia cellen 
(met name astrocyten en microglia) een belangrijke rol spelen bij de initiatie en regulatie 
van ontstekingsprocessen in het CZS. Elke vorm van weefselschade of verstoring leidt 
dan ook tot de activering van deze cellen. Deze activering manifesteert zich in de 
accumulatie van geactiveerde microglia rondom- en in het directe schadegebied en kan 
zich uiten in littekenweefselvorming door lokale astrocyten .  Daarnaast geven astrocyten 
en microglia stoffen af die het lokale schadeproces kunnen versnellen of vertragen. 
Omdat neuronen zeer kwetsbaar zijn ,  is het van belang dat de activering van glia cellen 
zeer gecontroleerd verloopt. Zowel in het gezonde- als het beschadigde CZS vindt dan 
ook een continue communicatie plaats tussen neuronen en glia cellen via directe eel-eel 
interacties en door afgifte van signaalstoffen over en weer. Langdurige verstoringen in 
deze interacties (b.v. wanneer er sprake is van grote schade of een infectie) kan 
resulteren in overmatige, chronische of inadequate activering van glia cellen wat weer 
kan leiden tot een verergering van het originele schadeproces. Het is daarom van belang 
om beter inzicht te krijgen in het proces van neuron-glia communicatie onder zowel 
fysiologische als neuropathologische omstandigheden. Met name de rot van microglia in 
dit proces is interessant, omdat in theorie zowel de neurotoxische als de 
neuroprotectieve eigenschappen van deze cellen een therapeutisch aangrijpingspunt 
kunnen zijn voor acute of progressieve hersenaandoeningen. 
Het doel van het onderzoek beschreven in dit proefschrift was 1. om meer inzicht te 
krijgen in de rol van microglia tijdens neuronale schade en 2. stoffen te identificeren die 
mogelijk een rot spelen in de communicatie tussen neuronen en geactiveerde glia cellen 
tijdens neuronale schade. 
Microglia en excitotoxiciteit 
Excitotoxiciteit speelt een rol in zowel acute- als chronische hersenaandoeningen en is 
een proces waarbij te hoge extracellulaire concentraties van de neurotransmitter 
glutamaat (veroorzaakt door een afname in beschikbare energie in neuronen) leidt tot 
overprikkeling van neuronen met als gevolg dat deze cellen afsterven. Eerder werd 
verondersteld dat dit proces van neuronale celdood geheel werd bepaald door 
intracellulaire cascades in het neuron zelf. In de laatste jaren is echter duidelijk 
geworden dat glia cellen in hoge mate bijdragen aan dit proces. De rol van microglia in 
excitotoxiciteit is echter nog onduidelijk, omdat uit onderzoek is gebleken dat, afhankelijk 
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van de methode, onderdrukking van geactiveerde microglia tijdens excitotoxiciteit tot 
zowel een versterking als een afzwakking van het schadeproces (= neuronale sterfte) 
kan leiden. In Hoofdstuk 2 hebben we de rol van microglia in het proces van 
excitotoxiciteit-gemedieerde neurodegeneratie nader onderzocht. Om het proces van 
excitotoxiciteit ex vivo na te bootsen hebben we gebruik gemaakt van hippocampale 
slice cultures (kleine hersenplakjes) afkomstig van muizen en deze vervolgens 
behandeld met de glutamaat receptor agonist N-methyl-0-aspartaat (NMDA). 
Behandeling met NMDA resulteert specifiek in het afsterven van neuronen in deze slice 
cultures. 
Onze resultaten laten zien dat na behandeling met NMDA zowel activering als 
accumulatie van microglia alleen plaatsvindt in gebieden waar neuronale celdood 
optreedt, terwijl microglia in ongeschonden gebieden hun vertakte vorm behouden. 
Vervolgens hebben we laten zien dat wanneer de gehele microglia populatie in de slice 
cultures van tevoren wordt verwijderd met behulp van clodronaat (specifiek toxisch voor 
microglia), het aantal neuronen dat afsterft na behandeling met NMDA zeer sterk 
toeneemt ten opzichte van de controle situatie. Dit effect van verhoogde neuronale 
celdood in de afwezigheid van microglia werd ook waargenomen in neuronale gebieden 
waar eerder geen celdood gedetecteerd was, wat suggereert dat vertakte microglia 
bijdragen in de bescherming van neuronen onder excitotoxische omstandigheden. 
Samengevat laten deze resultaten zien dat microglia een basale neuroprotectieve 
waarde hebben in het proces van excitotoxiciteit. 
Het is echter niet ondenkbaar dat bepaalde stoffen die warden afgegeven tijdens 
weefselschade in het CZS een negatieve invloed kunnen hebben op het 
activeringsproces van microglia. Men heeft bijvoorbeeld laten zien dat het herstel na 
neuronale schade kan warden bevorderd wanneer geactiveerde microglia (deels) 
warden onderdrukt in hun functie. In hoofdstuk 3 en 4 van dit proefschrift laten we zien 
dat de expressie van bepaalde chemotactische cytokines (chemokines, zie kader 1) in 
het CZS invloed kan hebben op de mate waarin neuronen afsterven, een proces dat 





















Chemoklnes zijn kleine chemotactische cytokines (8-12 kDa) en zijn met name betrokken 
blj de regulatie van cellulalre migratie in het lichaam. Een kenmerkend voorbeeld is de 
migratie van perifere immuuncellen van- en naar de lymfeknopen en naar doelorganen. 
Andere processen waar chemokines bij zijn betrokken zljn o.a. de ontwikkeling, 
wondheling, eel adhesie, bloedvatvorming en tumorgroei. 
Nomenclatuur 
De chemokine familie wordt onderverdeeld in vier subfamilies (CCL, CXCL, CX:iCL en CL), 
gebaseerd op de lokatle en het aantal hoog geconserveerde cysteine residuen in de amino 
terminus. Chemokines lnduceren hun effecten via G-eiwlt gekoppelde receptoren. Op dit 
moment zijn ongeveer 50 chemokines en 20 chemokine receptoren beschreven. De 
nomenclatuur van de chemokine receptoren volgt dat van de chemokines waar ze preferent 
aan binden, namelijk CCR, CXCR, XCR en CX:iCR. Let wel, de meeste chemokine 
receptoren kunnen meerdere chemokines binden, en een chemokine kan meerdere 
receptoren binden. 
Chemoklnes In het CZS 
In de laatste 10-20 jaren Is gebleken dat chemokines door endogene cellen van het CZS tot 
expressie worden gebracht en met name wanneer er sprake is van weefseischade. lnitieel 
ward gedacht dat dit enkel als doel had om perifere immuuncellen aan te trekken tijdens 
schade. Nu Is achter bekend dat ook neuronen en gila cellen chemokine receptoren tot 
expressie brengan en dat hat chemokine-receptor natwark in hat CZS een belangrijka 
plaats inneemt in de communicatie tussen neuronen en glia cellen zowel onder 
fysiologische- als ender pathologische condities. 
CXCL 1 0  in excitotoxiciteit 
Een van de chemokines die mogelijkerwijs een rol speelt in de communicatie tussen glia 
cellen en/of neuronen tijdens neuronale schade is CXCL 1 0. Verscheidene studies in 
zowel mensen als muizen hebben aangetoond dat CXCL 10 verhoogd tot expressie 
wordt gebracht in het CZS wanneer er sprake is van acute schade of een hersenziekte. 
Afhankelijk van het diermodel of het type hersenziekte heeft men laten zien dat zowel 
neuronen als astrocyten CXCL 1 0 tot expressie kunnen brengen, terwijl de receptor voor 
CXCL 1 0, te weten CXCR3, met name werd gevonden in microglia en astrocyten. In vitro 
experimenten hebben uitgewezen dat CXCL 1 0  zowel migratie van microglia als 
proliferatie van astrocyten kan induceren. Een interessant gegeven is dat wanneer men 
in muizen de expressie van CXCL 10 en/of CXCR3 in vivo tegengaat of blokkeert met 
antilichamen dit invloed heeft op het verloop van het ziekteproces in het CZS. Het is 
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echter tot nu toe niet bekend welke rel neuronen, astrocyten en microglia hebben in dit 
proces. 
In Hoofdstuk 3 hebben we de rel van CXCL 10 in het proces van excitotoxiciteit nader 
onderzocht. Dit hebben we wederom gedaan in het slice culture model beschreven in 
hoofdstuk 2. Onze bevindingen laten zien dat wanneer slice cultures behandeld warden 
met NMDA, astrocyten CXCL 10 tot expressie brengen. Met behulp van slice cultures 
afkomstig van CXCL 10- en CXCR3-knockout muizen hebben we vervolgens laten zien 
dat, in de afwezigheid van het ligand of de receptor, het aantal neuronen dat afsterft na 
NMDA behandeling in het ene neuronale gebied toeneemt maar in anderen afneemt. Dit 
effect in slice cultures afkomstig van CXCL 10-knockout muizen kon warden 
tegengegaan door recombinant CXCL 10 toe te voegen aan het medium na behandeling 
met NMDA. Toevoeging van recombinant CXCL 10 na NMDA behandeling had geen 
effect in slice cultures afkomstig van CXCR3-knockout muizen, wat in combinatie met 
bovengenoemde resultaten laat zien dat het effect van CXCL 10 op neuronale celdood 
gemedieerd is door CXCR3. 
Omdat microglia CXCR3 tot expressie brengen, hebben we gekeken naar het effect van 
microglia depletie (door middel van clodronaat-behandeling) in slice cultures van 
controle- en CXCR3-knockout muizen en deze met elkaar vergeleken. Onze resultaten 
laten zien dat in de afwezigheid van microglia de verschillen in neuronale celdood tussen 
controle en CXCR3-knockout slice cultures verdwenen zijn, wat suggereert dat het effect 
van CXCL 1 0/CXCR3 signalering op neuronale celdood door microglia gemedieerd 
wordt. Samengevat laten de resultaten in hoofdstuk 3 zien dat CXCL 10 een rol speelt in 
de communicatie tussen microglia en astrocyten tijdens excitototoxische schade en dat 
deze vorm van communicatie effect heeft op de mate van neuronale sterfte in dit proces. 
CCL21 in excitotoxiciteit 
Een ander chemokine dat mogelijk een rol speelt in de regulatie van geactiveerde 
microglia ender neuropathologische condities is CCL21. Onlangs heeft men in twee 
verschillende muismodellen voor acute schade in het CZS laten zien dat beschadigde of 
bedreigde neuronen CCL21 tot expressie brengen. Daarnaast heeft men in vitro 
aangetoond dat neuronen CCL21 tot expressie brengen ender excitotoxische 
omstandigheden. Deze observaties zijn zeer interessant, omdat men tevens in vitro heeft 
aangetoond dat microglia geactiveerd kunnen warden door CCL21. Ten tweede is 
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verloopt, maar via CXCR3. Op basis van deze data heeft men dan ook voorgesteld dat 
de expressie van CCL21 door beschadigde of bedreigde neuronen een rol zou kunnen 
spelen in de activering en recrutering van CXCR3-positieve microglia uit de directe 
omgeving. In Hoofdstuk 4 laten we met behulp van hippocampale slice cultures zien dat 
het aantal neuronen dat afsterft door NMDA behandeling sterk afneemt wanneer CCL21 
niet tot expressie wordt gebracht. Dit effect kon worden tenietgedaan door recombinant 
CCL21 toe te voegen aan het medium na NMDA behandeling. Deze resultaten 
suggereren dat CCL21 een negatief effect heeft op de overleving van neuronen onder 
excitotoxische omstandigheden. Daarnaast laten we zien dat het effect van CCL21 in 
deze slice cultures gemedieerd wordt door CXCR3. Of het negatieve effect van CCL21 
op neuronale celdood van directe aard is of dat dit effect via microglia wordt gemedieerd 
is op dit moment (nog) niet duidelijk. 
CCL21-gemedieerde effecten in astrocyten 
Zoals eerder genoemd heeft men aangetoond dat behandeling met CCL21 leidt tot de 
activering en migratie van microglia in vitro, een proces dat wordt bepaald door de 
aanwezigheid van CXCR3 in deze cellen. Een interessant gegeven is dat, naast 
microglia, astrocyten oak CXCR3 tot expressie brengen. Het is echter niet bekend of 
astrocyten in staat zijn te reageren op CCL21. In Hoofdstuk 5 hebben we daarom 
onderzocht of astrocyten in staat zijn te reageren op CCL21, en zo ja, welke receptor 
hierbij een rol speelt. Met behulp van live-imaging microscopie en proliferatie assays 
hebben we in vitro kunnen aantonen dat behandeling met CCL21 leidt tot zowel 
celdeling (proliferatie) als het vrijkomen van intracellulair calcium in deze cellen. 
Daarnaast laten we zien dat, in tegenstelling tot microglia, CCL21-gemedieerde 
responsen in astrocyten maar deels worden bepaald door de aanwezigheid van CXCR3. 
Sinds de expressie van CCR7 (= de conventionele receptor voor CCL21) zowel op 
mRNA- als op eiwit niveau niet werd gevonden in deze cellen, geven onze data aan dat 
de effecten van CCL21 op astrocyten (deels) gemedieerd worden door een andere 




Ha! Eindelijk is het dan zover. Het einde is nu daadwerkelijk in zicht. Aangekomen bij de 
laatste, edoch meest essentiele, pagina's besef ik me wederom dat een groot deel van 
dit proefschrift niet tot stand was gekomen zonder de inzet en steun van collega's, 
vrienden en (schoon)familie. Om te voorkomen dat ik iemand onverhoopt vergeet te 
vermelden, wil ik bij deze alvast IEDEREEN bedanken die op zijn/haar manier (in)direct 
heeft bijgedragen aan de totstandkoming van dit proefschrift. Graag wil ik een aantal 
mensen in het bijzonder noemen: 
Allereerst wil ik mijn promotoren, Erik Boddeke en Knut Biber, bedanken voor de 
mogelijkheid, financiele steun en ruimte die ze mij gegeven hebben om een 
promotietraject te volgen bij de sectie Medische Fysiologie. 
Beste Erik, het staat mij nog goed bij dat je me tijdens het afstuderen bestempelde als 
een "atypische" student. lk denk dat de afgelopen jaren hier maar weinig aan veranderd 
hebben. Toch heb ik verschrikkelijk veel van je opgestoken en wil ik je bij deze bedanken 
voor je geduld en inzet om het project tot een succesvol einde te brengen. Met name 
voor de laatste (extra) zes maanden ben ik je erg dankbaar. Zander deze (voor de 
afdeling ongebruikelijke) verlenging was het misschien anders afgelopen. 
Beste Knut, ik kan niet anders zeggen dat het een weest genoegen was met je samen te 
werken. Zeals je weet, twijfelde ik in het begin nogal aan je "komt-wel-goed" en "probeer­
nog-maar-een-keer" aanpak, maar uiteindelijk had je wederom gelijk en is het inderdaad 
toch weer allemaal goed gekomen. Met name je unieke (en soms onorthodoxe) 
gedachtekronkels, je relaxte werkhouding en je buitengewone tolerantie voor al mijn 
onophoudelijke (en vaak overhaaste) vragen heb ik enorm gewaardeerd. Bovendien ben 
ik blij dat je me geTntroduceerd hebt in de kleine wereld van het microglia onderzoek. lk 
denk niet dat ik nag zonder kan. Dank daarvoor! 
Bovendien gaat mijn dank uit naar: 
De leescommissie, bestaande uit Prof. dr. C.J. Heijnen, Prof. dr. P. G.M. Luiten en Prof. 








CHAP. :R r, 
De graduate school for Behavioral and Cognitive Neurosciences (BCN), niet alleen voor 
het financieel mogelijk maken van het project, maar oak voor de vele nuttige cursussen 
en bijeenkomsten. 
Binnen de afdeling Medische Fysiologie wil ik in het bijzonder bedanken: 
Nieske Brouwer, (TOP)analiste der Medische Fysiologie. Lieve Nieske, uit alle 
experimenten waar ik van dacht 'doar komt gain gebak oet', heb jij met uitzonderlijk veel 
geduld en behendigheid alsnog zinnige resultaten weten te halen en zelfs weten te 
reproduceren. Op momenten dat ik er zelf geen koek meer van kon bakken, heb je me 
meer dan een keer versteld doen staan met je praktische en vaak nuchtere oplossingen. 
Zander jou was dit boekje een verrekt stuk dunner geweest. Daarnaast wil ik je ook 
bedanken voor alle gesprekken, gezellige momenten, bemoedigende woorden en steun 
die ik van je heb mogen ontvangen. 
Marjolein Hensens (Bestelgoeroe en Celkweekspecialist). Hensens : p, zonder jouw 
strakke regime in de celkweek was het maar een dikke, vieze en tevens onaangevulde 
puinhoop geweest. Onderschat nooit de waarde van een schone flow en een goed 
gevulde pipette-koker! Tevens ben ik je menig schoonmaakbeurt verschuldigd en bied ik 
je bij deze, met het schaamrood op de kaken, mijn excuses aan voor het soms vertraagd 
dan wel niet doen van mijn "taak". Bedankt voor je inzet en steun en ik wens je heel veel 
sterkte met de huidige generatie smeerpoetsen en gistkwekers! 
Michel Meier (Chef-des-Microscopes en lmageJ Wizard) voor het nodige vertier zowel 
op de werkvloer (Lang leve het 3D-brilletje en IMARIS!) als in de Buuf (Lang leve het 
Belgische bier alsmede de kaas en worst die daarbij geserveerd wordt!), o ja, en 
uiteraard ook voor de hulp bij het uitvoeren van verscheidene cruciale experimenten! 
Jonathan Vinet, for the elaborate lessons in "essential-hand-movements-while-speaking­
Italian" and "thousand-and-one-Canadian-and-Italian-delicacies-you-should-try-before­
you-die". Jon, also a million tnx and IOU's for your contributions in the various projects 
and manuscripts. I am soooo sorry for the unfinished projects I left behind. However, you 
took them on without (audible) complaints and I can only say it is highly appreciated. 
Also the dinners and drinks together with you and Serena I will not forget (especially the 
1 t >I 
DANKWOORD 
irresistible, yet deadly, pepper/tuna appetizers). It would be a pleasure to collaborate 
with you again in the near future. Cheers. 
Arthur de Jong (toenmalig student, tegenwoordig AIO) voor de wederzijdse begeleiding 
;) en je bijdrage aan het CCL21-astrocyten manuscript. Succes en sterkte met je AIO­
schap in A'dam! 
Mijn koffiebroeders Sander en Reinhard. Sander, ik denk dat we ondertussen precies 
weten wat we aan elkaar hebben. Het zal je dan ook niet verbazen dat je naam meer 
dan een keer voorkomt in dit dankwoord. En terecht. Reinhard, als een van de weinigen 
zag jij ook de kracht van het twee tot drie maal daags nuttigen van een stomende kop 
koffie in de "frisse" buitenlucht. Daarnaast kijk ik met veel plezier terug op alle momenten 
die we gespendeerd hebben in de Buuf, de Pint, en elders waar maar bier geschonken 
werd. 
De bench-mates en partners-in-crime (de AIOs en 'bursalen· van de afdeling Medische 
fysiologie); Fabrizio Bianchi, Hiske van Duinen (PhD), Alexander de Haas (MD/PhD), 
Eiko de Jong (PhD), Vishnu Kannan, Ming San Ma (MD), Annebet van der Meu/en (MD), 
Shamsudheen Moidunny, Martha Olah, Marijn Post (PhD), Reinhard Ro/3/er, Divya Raj, 
Falak Sher en Anneke Steens. Sommigen hebben de eindstreep al gehaald, anderen 
zijn na een lange en moeizame klim bijna bij de finish en weer anderen zijn nog fris in de 
benen en net gestart. Thank you all for the inspirational and pleasant time at the section 
Medical Physiology. For the ones who are not (quite) finished yet; good luck, keep your 
fingers crossed and, most importantly , do not forget to have fun! 
Daarnaast wil ik alle (oud-)medewerkers van de sectie Medische Fysiologie bedanken 
voor de prettige werksfeer, de gezellige Sorrel- en Buuf-uurtjes, labuitjes en de 
competitieve bowling-sessies. In alfabetische volgorde: Rob Bake/s, Veerakumar Ba-la­
su-bra-ma-ni-yan, Sjef Copray, /neke Dijkstra, Martin Dokter, Michie/ Fokkens, Albert 
Gramsbergen, Gerrie Hoogenberg, Josje ljkema-Paassen, Fester Klok, /etje Mantingh­
Otter, Joke van der Mark-van der Wouden, Tjalling Nijboer, Wieb Patberg, Klaas 
Sjollema, Trix van der Sluis-Rozema, Vesna Stanulovic, Koen Vaartjes, Evelyn 
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Buiten de Medische fysiologie wil ik graag bedanken: 
---- - -----
Prof. Allan Randrup Thomsen (Experimental Virology, University of Copenhagen, 
Denmark), for the opportunity to perform part of the experiments in his laboratory. 
De medewerkers van het CDL (Sylvia en Yvonne) en het dierenverblijf van het 
Biologisch Centrum (Auke Meinema) voor de verzorging van de dieren. 
Dr. P. C. van Voorst Vader (afdeling dermatologie, UMCG) voor de relatief snelle 
diagnose en Dr. D.M. Busz (afdeling radiotherapie, UMCG) voor de effectieve 
behandeling. Dat was me even schrikken geblazen .  Uiteraard wil ik hier ook alle 
vrienden, familie, collega's en anderen bedanken voor de steun. Het heeft een hart 
ender de riem gestoken op een moment dat ik even letterlijk niet verder kon kijken dan 
mijn neus lang was. 
Alie kennissen, vrienden, (schoon)fam ilie , buren en aanhang voor de broodnodige 
afleiding en ontspanning buiten werktijden om. 
Mijn paranimfen Sander (das 3 keer) en Lars, voor de morele support in de meest 
spannende 45 minuten van het hele traject. 
Mijn lieve ouders, voor jullie onvoorwaardelijke steun in alles wat ik tot nu toe gedaan 
heb, gelaten heb en nog ga doen. 
Lieve Suus, ik vind dat we elkaar nu wel genoeg gepest hebben met al die nachtelijke 
uren achter de PC en/of MAC, het veel te laat thuiskomen na slopende werkdagen en 
het doorbrengen van menig weekend op het lab in plaats van op de bank achter de buis 
of bij vrienden en familie. Van alle mensen hier genoemd ben jij voor mij de meest 
belangrijke steunpilaar geweest in dit hele gebeuren. Zander jou was dit proefschrift er 
simpelweg niet geweest. Omdat woorden niet kunnen uitdrukken wat je voor me 
betekend heb kan ik enkel zeggen: tusind tak voor alles wat geweest is en wat nog 
komen gaat. 
Hi/mar 
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